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“Science is not a body of knowledge nor a belief system; it is just a term 
which describes humankind’s incremental acquisition of understanding 









Recent technical developments have increased the scope for cardiac MRI as 
a research tool. This work presents novel approaches to the assessment of 
patients with coronary disease and heart failure.   
The thesis explores coronary physiology and microarchitecture, ischaemia 
and perfusion CMR, and in particular the quantification of ischaemia. In 
addition, in-vivo cardiac diffusion tensor imaging is employed to characterize 
microarchitecture in heart failure.    
This work comes to a number of conclusions.  
We have been able to show, for the first time in patients with heart failure, that 
even in patients who have thinned and remodelled ventricles, quantitative 
assessment with high resolution quantitative CMR is feasible and 
reproducible.   
Our work is also the first to perform assessment of the prognostic use of 
quantitative perfusion CMR - in a large group of unselected patients 
presenting with suspected coronary disease, we have investigated the 
prognostic value of a quantitative approach. This observational study 
proposes that this performs at least as well as visual assessment by expert 
readers.  
Furthermore, the thesis explores the correlation between CMR and PET using 
a specialized cardiac phantom which simulates perfusion and a hybrid CMR-
PET scanner. In this setting, we have concluded that there is excellent 
correlation between MR, PET and known true perfusion values. 
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This thesis also presents work on the use of cardiac diffusion tensor imaging 
in dilated cardiomyopathy, the first study to do so using a dual-phase in-vivo 
approach.  We have been able to demonstrate significant differences in fibre 
and sheetlet orientation by comparison to controls.  Our study used 
biomechanical modelling and strain data from 3D tagging CMR. 
Overall this work adds to the body of knowledge of quantitative perfusion 
CMR analysis and cardiac DTI and merits further larger studies, particularly 
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1.1 Rationale  
The initial aim of this PhD was to investigate the interplay between cardiac 
energetics, perfusion and structure / function, particularly in the setting of 
heart failure and cardiac resynchronization therapy.   These factors are 
intertwined - weight for weight, the heart consumes more energy than any 
other organ in the body. In the normal heart, the heart beats around 100,000 
times over each 24-hour period and pumps around 10 tonnes of blood 
through the body. This considerable cellular activity is fuelled by ATP, of 
which some 6kg is produced in 24 hours, 20 – 30 times the weight of the 
heart1.  Around 65% of the ATP produced is used to power muscle 
contraction; the rest is used up in the production and degradation of proteins 
and other cellular functions2.  The heart is primarily an aerobic organ which 
produces ATP in the mitochondria and which relies on a steady, adequate 
supply of oxygen-rich blood provided by the coronary circulation and 
mircoarchitecture.  This enables the relentless and effective cardiac 
contraction of normal cardiac function. Each myocyte is particularly adapted to 
these high-energy demands – mitochondria make up 30% of cell volume. In 
addition, there is a close physical and functional coupling between the 
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subcellular components and a dense coronary artery tree. In essence, in the 
normal heart, a number of highly structured, tightly controlled systems 
interconnect to produce efficient continuous function.  
The scenario of the energy-starved heart is well established in the 
pathophysiology of heart failure, due both to defects in calcium handling and 
excitation contraction coupling and to mitochondrial abnormalities; an 
imbalance between metabolic needs and energy production drives and 
exacerbates pump failure.  The redress of the energy demand–supply 
balance animates therapies for heart failure; energy-sparing agents such as 
beta-blockers or ACE inhibitors as well as cardiac resynchronisation therapy 
yield long term benefit.   
 
This interest led to the development of two projects investigating these factors 
in the context of dyssynchronous heart failure and cardiac resynchronization 
therapy (CRT).  These would focus on myocardial energetics, using PET and 
histology, perfusion, using CMR and PET, and remodeling.  The first involved 
a preclinical study in Aarhus, Denmark and the second a clinical study at  St 
Thomas’ Hospital, London.  Both projects were extensively planned (Home 
Office small animal licence and granted Ethical approval) though neither came 
to fruition – Support was withdrawn by the Danish collaborators for the first, 
and there were substantial delays with tracer production for the second.  
 
The failure to get these projects started was obviously a huge disappointment 
given the considerable preliminary work.  The focus of the work presented is 
based on background work to develop an understanding, in particular of 
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perfusion CMR.  The body of this thesis focuses first on quantitative perfusion 
CMR in the setting of CAD and heart failure, and secondly on cardiac diffusion 
tensor imaging (DTI) and 3D tagging, used to explore the changes in cardiac 
fibre architecture in dilated cardiomyopathy.  This work aims to demonstrate 
feasibility of these advanced CMR approaches with a view to building on, and 
exploring, the interplay between the variables of cardiac energetics, perfusion 
and structure / function.     
 
1.2 Thesis overview  
The thesis has been divided into the following eight chapters:  
 
Chapter 1. 
Introduction and rationale for the thesis.   
 
Chapter 2.  
Summary of coronary physiology, describing normal coronary arterial system and the 
pathophysiology of ischaemia. Overview of the importance of the assessment of 
myocardial ischaemia and summary of the work done on the ischaemic cascade 
which has led to significant changes in practice for the management of patients with 
stable coronary disease.  Description of studies to date on non-invasive assessment 
of myocardial ischaemia, focusing on those involving CMR. 
 
Chapter 3. 
This chapter consists of an overview of quantitative perfusion CMR, detailing current 
understanding and previous studies to date, including data published as a review 
article.   
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Chapter 4.  
This chapter describes the use of high-resolution perfusion CMR in a group of 
patients with ischaemic and non-ischaemic cardiomyopathy and demonstrates 
feasibility in this cohort.  
 
Chapter 5.  
The fourth chapter details results of a large retrospective study examining the impact 
of quantification of perfusion results on adverse events and prognosis.   
 
Chapter 6. 
The fifth chapter describes the use of hybrid PET-MR imaging.  The chapter 
discusses a study comparing quantitative results from PET versus CMR using a 
specialised dynamic cardiac perfusion phantom and a hybrid PET-MR scanner. 
 
Chapter 7.  
This chapter reviews current knowledge of cardiac microstructure and the use of 
diffusion tensor CMR imaging in its evaluation. The chapter also describes the 
results of in-vivo dual phase diffusion tensor imaging in patients with dilated non-
ischaemic cardiomyopathy.  
 











This section includes an overview of coronary physiology and 
pathophysiology, the importance of myocardial ischaemia and non-invasive 
assessment of myocardial ischaemia.  
As an introduction to the topic, one must consider the normal coronary 
physiology in order to then understand adaptations to coronary stenoses.  An 
account is given of the sophisticated and specifically adapted physiology of 
the coronary system providing efficient delivery of oxygen to the myocardium. 
Alterations in blood flow through the coronary arteries due to a coronary 
stenosis triggers a cascade of responses to a reduced blood supply to the 
myocardium and to maintain the demand-supply balance. Once these 
adaptive processes are exhausted ischaemia and symptoms ensue. This 
process is exploited in stress perfusion imaging through either vasodilatation 
or increased oxygen demand.  
The ischaemic cascade is described next. This is crucial to the appreciation of 
the temporal sequence of events, and the importance of ischaemia, in the 
setting of coronary artery disease and outlines the logic of ischaemia testing 
now in routine use.  In early clinical practice, the application of percutaneous 
coronary intervention (PCI) was relatively indiscriminate, based solely on the 
anatomical appearance of a coronary stenosis - it took no account of the 
presence of ischaemia. Initial studies based on this indiscriminate application 
suggested that management of stable angina could as effectively be treated 
medically as by PCI. More recent studies have shown that PCI is beneficial in 
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cases of documented ischaemia. This remains a controversial and debated 
topic.  The limitations of visual assessment of the extent of an epicardial 
coronary stenosis in diagnosing ischaemia in the area of supplied 
myocardium and use of invasive measurements of coronary flow reserve are 
also discussed.  
Finally the strengths and limitations of the three main non-invasive modalities, 
CMR, PET and SPECT, are discussed, with a focus on CMR and key studies 
comparing SPECT or PET to CMR.  
 
2.2 Coronary physiology   
In order to be able fully to understand the pathophysiology of CAD, it is crucial 
to consider underlying normal cardiac physiology. The first part of this chapter 
will focus on the physiology of the coronary system, in particular on 
vasodilatory capacity and microvasculature resistance, and the adaptations to 
reduced coronary flow in response to coronary stenosis.   
 
2.2.1 Physiology and pathophysiology of ischaemia  
Coronary artery flow is a function of the combined factors of arterial pressure 
and the resistance in a given coronary artery.  The physiology of the coronary 
circulation is complex and depends on numerous regulatory elements 
including nervous and metabolic control, mechanical factors including aortic 
pressure and heart rate, and coronary autoregulation. The difference in flow 
between rest and maximal vasodilatation is known as the coronary flow 
reserve (CFR).   
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It should be noted here that the terms CFR and MPR (myocardial perfusion 
reserve) are often used interchangeably but have fundamental differences - 
indeed different normal values have been obtained when using these terms.  
This can in part be explained by the very nature of CFR and MPR 
measurements, which are obtained using different techniques and are likely to 
provide complementary but not identical information on myocardial perfusion 
status. CFR is the maximum increase in blood flow [ml of blood/min] through 
the coronary arteries above the normal resting values and is usually 
measured invasively at the level of the epicardial coronary arteries. MPR is 
the ratio of global myocardial blood perfusion [ml of blood/g of 
myocardium/min] at stress versus rest, measured by microspheres or non-
invasive imaging at the level of the tissue. CFR measurements represent 
average blood flow to the perfusion territory distal to the point where the 
measurements are performed, whereas MPR measurements represent the 
amount of blood normalized by the mass of tissue in the perfusion territory. 
Since CFR is obtained with measurements of blood flow in the epicardial 
coronary arteries, the spatial resolution of CFR measurements corresponds to 
the perfusion territory downstream the point where the measurements are 
performed. Invasive CFR measurements do not enable measurements of 
perfusion specifically in the subendocardium. MPR instead can be analysed 
with higher spatial resolution than allowed by CFR measurements, with an 
independent visualisation of multiple layers across the LV wall, which is a 
factor contributing to the elevated sensitivity of perfusion imaging modalities to 
the detection of ischaemia compared to invasive assessment. Given these 
fundamental differences between CFR and MPR, it should not surprise that 
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the optimal CFR cut-off is higher than the optimal MPR threshold, as CFR 
represents average perfusion in a larger volume of myocardium. 
 
2.2.2 Coronary arterial system  
An understanding of the anatomy and physiology of the coronary circulation is 
crucial to analysis of the mechanisms of ischaemia at play in CAD.  
Average myocardial blood flow is calculated as the perfusion pressure 
(pressure difference between the ostium of left main coronary artery and 
coronary sinus) divided by the total coronary resistance:  
 
  𝑀𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑎𝑙 𝑏𝑙𝑜𝑜𝑑 𝑓𝑙𝑜𝑤 =
𝑃𝑒𝑟𝑓𝑢𝑠𝑖𝑜𝑛 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑟𝑜𝑛𝑎𝑟𝑦 𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒
     
 
In exploring this relationship, one must first consider the three functional 
sequential elements of the coronary arterial system: the epicardial coronary 
vessels, pre-arterioles and intramural arterioles.  Of the three elements, only 
the epicardial vessels are of a calibre that can be imaged by coronary 
angiography.   
 
2.2.3 Components of coronary microvasculature 
      The pre-arterioles and arterioles together form the microvasculature 
(Figure 2.1).  Each section of the coronary vasculature has a specific 
role.There are no differing, identifying, histological features 3,4.  
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- The epicardial / conductive vessels (ranging in size from few 
millimetres to 500μm in diameter) form the largest and most proximal 
component.  They have a capacitance function and offer little 
resistance to coronary blood flow when the epicardial arteries are free 
of CAD. During systole, these vessels dilate and increase their blood 
content by up to 25%. In diastole, this elastic energy is released and 
blood is propelled on into the distal vessel.  They are responsive to 
flow-dependent dilatation – they respond to endothelial vasodilators 
released in response to changes in shear stress.   
- The pre-arterioles (diameter 500-100μm) form the intermediate 
component, characterised by being largely extra-myocardial with a 
measurable pressure drop along their length.  The distal pre-arterioles 
are the main performers of autoregulation – constricting and dilating to 
maintain stable blood flow despite fluctuations in perfusion pressure.  
Proximal pre-arterioles are responsive to flow-dependant dilatation; 
distal pre-arterioles are more responsive to changes in intravascular 
pressure. Their extra-myocardial course makes them not susceptible to 
diffusible metabolic metabolites.  
-   The intra-mural arterioles (diameter <100μm) comprise the distal 
component and are characterised by an even greater pressure drop 
along their length. Their function is to match myocardial blood supply to 
oxygen consumption. The arterioles play a fundamental role in the 
metabolic regulation of coronary blood flow. They have a high resting 
tone and dilate in response to the release of metabolites from the 




   Figure 2.1 – Functional subdivision of the coronary arterial system  
Schematic showing the three functional components of the coronary arterial 
system and their relative effects to blood flow, metabolites and pressure. 
         Adapted from Camici et al.4 
 
2.2.4 Coronary resistance  
Total myocardial blood flow is related to both the perfusion pressure and the 
total coronary resistance.   
Total coronary resistance is the sum of three components: R1, R2 and R3 
(see  Figure 2.2).  
- R1 – represents the resistance in the epicardial vessels. This 
contributes approximately 10% of total coronary resistance in normal 
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arteries. R1 may become the limiting resistance in the setting of 
significant CAD.   
- R2 – This refers to the main resistive component and occurs at the 
level of the microvasculature.  In basal healthy state, resistance in the 
pre-arterioles makes up approximately 30%, and in the arterioles 40% 
of total coronary resistance.  When R1 rises in the setting of significant 
CAD, R2 will compensate, increasing vasodilatation to maintain flow to 
the distal myocardium. 
- R3 – Unlike R1 and R2, R3 resistance is extravascular and is due to 
the compressive force from the myocardium during systole. During 
systole coronary artery flow is impeded or even reversed and venous 
outflow is segmented.  For this reason it will vary through the cardiac 
cycle, and will affect the intramural components of the left coronary 
arterial system more than it does the right (the RV has lower pressure 
than LV). Furthermore, the pressure is uneven through the myocardial 
wall.  It is highest in the subendocardium due to increased intra-cavity 
LV pressure and higher myocardial inotropic force at this site, causing 
higher intramyocardial compression, which in turn produces more 
severe vascular narrowing to the vessels in their course through the 




  Figure 2.2 - Schematic diagram showing coronary arterial system 
Left side showing the normal situation where a majority of resistance is found in 
the arterioles.  The right side illustrates the reduction in R2 in the presence of a 
significant epicardial stenosis causing a rise in R1.  Note the increase in R3 
resistance from subepicardium to subendocardium.   
         Adapted from Amedeo Chiribiri10. 
 
The third component of resistance, R3 deserves further mention. Although 
this site contributes the highest resistance, animal studies have shown that 
resting flow to the subendocardium is normally highest in this section. This is 
due to higher wall stress and greater oxygen demand.  These factors help to 
explain why the subendocardium is affected first, and more severely affected 
in CAD, when R1 resistance is increased and R2 is maximally vasodilated.    
Even in healthy hearts, there is a phasic coronary perfusion which rises in 
diastole and decreases in systole due to the variation of compressive forces. 
Despite the fluctuation, in the absence of significant CAD or small vessel 
disease, this does not cause subendocardial ischaemia.  Similarly, in cases of 
tachycardia, where the diastolic component of the cardiac cycle is shortened, 
R3 is a factor and the subendocardium will be most affected. In the healthy 
heart, other resistive components will compensate for this. In tachycardia on a 
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background of significant epicardial stenosis, where resistive forces are 
already at maximal compensation, regional myocardial ischaemia may 
result11,12.  
 
2.2.5 Coronary flow reserve and CAD stenosis severity 
Various studies have shown that it is not possible to use CFR at rest to 
assess the severity of a stenosis since compensatory vasodilation of the pre-
arteriolar and arteriolar compartments are sufficient to compensate for the 
increase in epicardial R1 resistance13,14. 
 
Gould et al. used a preclinical model to measure coronary flow responses to 
progressive coronary artery stenosis using surgically implanted 
electromagnetic flow meters and comparing this to fluoroscopic images of the 
degree of stenosis.  The group were able to demonstrate that with an increase 
in percentage diameter stenosis, there is a decrease in maximal coronary flow 
during vasodilatation14 but that even with severe stenosis, coronary flow was 
relatively maintained at rest.  Importantly, this group demonstrated that with 
moderate (50-70%) lesions, there was both a high individual variability and a 
relatively preserved CFR even with vasodilatation.  This work elegantly 
demonstrates that a visually moderate stenosis may not correlate with a 
haemodynamically significant lesion. With more severe stenosis the CFR is 





   Figure 2.3 – Coronary flow reserve related to angiographic narrowing in 
animals  
Coronary flow reserve in relation to angiographic percent narrowing of the LAD in 
an experimental dog model.  An increase in percentage stenosis leads to 
decreased CFR during maximal hyperaemia.  The grey region shows 95% 
confidence interval.  Note (dotted line) that the CFR is relatively preserved in 
moderate stenosis.   
         Adapted from Gould et al.14 
 
Although large animal models reflect human anatomy and physiology better 
than small animal experimental models, concerns have been raised with 
regard to differences in coronary physiology.  Later studies considered the 
degree of stenosis and CFR in patients with CAD using PET, using either 
percentage narrowing from angiography or quantitative angiography15-21.   
The largest of these studies included 193 patients with previous MI and 
compared quantitative coronary angiography versus visual assessment of 
perfusion defects using PET (see Figure 2.4)15. The study found good 
correlation between coronary angiography and PET to identify areas of 
myocardial infarction.  With increasing degrees of coronary stenosis, the PET 
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defect score increased with a high PET defect score being highly predictive of 
a severe stenosis.  They also noted that there was considerable scatter of 
correlation, particularly in the moderate coronary stenosis range. It was 
postulated that this may relate to serial stenoses, collateralization, anatomical 
variations, visual assessment of PET imaging, inter-observer variability, and 
differing physiological conditions between the studies.  
  
 
Figure 2.4 - Coronary flow reserve against percentage coronary stenosis in 
patients   
Progressive decline in CFR with increasing severity of stenosis.  Note the 
wide spread of data points in the moderate CAD range (dotted box).   
Adapted from Demer et al.15 
 
2.2.6 Myocardial energetics and the microvasculature  
The heart has to sustain relentless contractile function as well as basal 
metabolic processes and ionic homeostasis and every day produces 6kg ATP 
(more than 20-30 times its own weight).  There is a small ATP reserve in the 
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heart and due to the high turnover, the heart cycles through the entire 
myocardial ATP pool approximately six to eight times per minute.   
The healthy adult heart is essentially an aerobic organ which produces 95% of 
its ATP via the tricarboxylic (TCA) cycle through oxidative phosphorylation1.  It 
is consequently highly reliant on an efficient oxygen-rich blood supply – a 
number of adaptations help to achieve this.   
The heart is adapted for aerobic metabolism with an increased number of 
mitochondria and the ability to use various substrates in the TCA cycle.  
Since there is near maximal extraction of oxygen at rest, it is an increase in 
blood flow which is the variable in response to higher oxygen demand. At rest, 
oxygen extraction between the coronary artery and the coronary sinus is near 
maximal level (70-80% in contrast to 30-40% in skeletal muscle). During 
exercise, the myocardial oxygen consumption can increase fourfold11,12. 
  At rest, myocardial blood flow is already greater than exercising skeletal 
muscle, underlining the need for an efficient and specialised system.  The 
blood flow through the various components of the coronary system is closely 
coordinated with supply demands. In addition to the increased flow secondary 
to vasodilatation, cardiac muscle is endowed with a higher density of 
microvasculature than is skeletal muscle.  Histological studies confirm that 
while the density of capillaries per mm2 in peripheral muscle cells is 300-400, 
in the myocardium, there are 3000-4000 capillaries per mm2 surrounding 
muscle fibres of relatively smaller diameter22-24.  
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2.2.7 The microvasculature in ischaemia 
It follows from the above that the haemodynamic implications of epicardial 
coronary artery stenosis largely depend on the microvasculature. The 
arterioles distal to a stenosis will vasodilate at rest in order to match supply to 
demand – this may also involve an element of steal from neighbouring 
vessels via collaterals. In hyperaemic / stress conditions, the arterioles distal 
to vessels without a stenosis will vasodilate to increase blood flow, whereas 
those distal to a stenosed vessel will already be at near maximal dilatation.  
This produces a relative imbalance in coronary flow reserve, the difference 
between stress (hyperaemic) blood flow, and resting blood flow.  Increased 
oxygen demand leads to ischaemia in the area supplied by the stenosed 
vessel. In the presence of further increased oxygen demand the area supplied 
by the stenosed vessel will become more ischaemic.  In this situation the 
contribution of previous ‘steal’ is diverted back to origin i.e. is not available to 






Figure 2.5 - Schematic representation to describe steal phenomenon in the 
presence of coronary stenosis during hyperaemia.  
A - LAD artery has a stenosis, distal microvasculature vasodilates (see dotted 
line) and via collaterals draws blood from CX territory to maintain adequate 
perfusion at rest.  
B- Under hyperaemia, vasodilatation of the Cx microvasculature draws more 
blood into the Cx territory (see dotted line).  The LAD microvasculature is already 
at near- or maximal vasodilatation and therefore ischaemia likely to occur in this 
territory.   
(LAD- left anterior descending artery, LCx – circumflex artery) 
         Adapted from Demer, et al.15  
 
This sequence process explains the symptoms described by patients with 
stable angina. Typically this patient will report no symptoms at rest but 
exertion increases myocardial oxygen demand and produce symptoms of 




2.3 The clinical relevance of myocardial ischaemia 
Despite advances in the prevention, detection and treatment of coronary 
artery disease (CAD), myocardial infarction (MI) and ischaemic 
cardiomyopathy, coronary heart disease remains a leading cause of morbidity 
and mortality in developed countries. The death rate has declined due to 
improved treatments and an ageing population.  The number of patients living 
with stable angina and heart failure continues to increase.   
Myocardial ischaemia is at the centre of this cardiovascular mortality and has 
been the subject of investigation by numerous groups over several decades.  
 
2.3.1 The ischaemic cascade  
The concept of the ischaemic cascade refers to the sequence of events 
whereby ischaemia is triggered by an imbalance between oxygen supply and 
demand. This leads to impaired diastolic then systolic dysfunction, ECG 
changes and culminates in anginal chest pain and potentially myocardial 
infarction. This cascade is key to understanding the approach to stable 




Figure 2.6 – Schematic representation of the ischaemic cascade 
Figure demonstrating the temporal dispersion of events in the ischaemic cascade. 
         Adapted from Nesto et al. 27 
 
 
The majority of early studies investigated animal or human models of 
coronary occlusion, namely ‘supply ischaemia’ by means of invasive 
epicardial coronary artery balloon occlusion assessed in terms of the changes 
in cardiac compliance (diastolic function) and contractility (systolic function) 
using echocardiography, invasive haemodynamic measures and ECG tracing.  
These studies demonstrated the temporal distribution of events and showed 
that typical symptoms of angina did not occur universally. These observations 
proposed that identification of events before the onset of chest pain and 
appreciation of changes seen with ischaemia-reperfusion could relate to 
cardiac function25-28.  
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Later studies used atrial pacing tachycardia or exercise, where the myocardial 
demand for oxygen is increased, to demonstrate the same temporal sequence 
of events in ‘demand ischaemia’29-32.  Once again, the presence of anginal 
chest pain was found to be an insensitive and unreliable marker of the 
presence of ischaemia when correlated with the other events noted in the 
cascade.  
In subsequent years, and with the development of nuclear imaging techniques 
and the use of dobutamine echocardiography for perfusion, investigators were 
able to start to identify specific, discrete, regions of hypoperfusion and link 
these directly to the other changes described in the ischaemic cascade – 
previously only implied by other studies – and demonstrated that 
hypoperfusion occurred earlier in the cascade and was a more sensitive 
marker than the development of regional wall motion abnormalities29-37.  
 
2.3.2 STEMI and unstable coronary syndromes 
The term ‘coronary artery disease’ encompasses a group of conditions which 
include ST-elevation myocardial infarction (STEMI), unstable acute coronary 
syndromes (non-ST elevation myocardial infarction (NSTEMI) and unstable 
angina) and stable angina.  The use of revascularisation procedures and 
medical therapy varies, depending upon which condition predominates.   
In patients with STEMI, where there is acute complete occlusion of a coronary 
artery, timely reperfusion is key.  A number of studies have shown that timely 
percutaneous coronary intervention (PCI) provides management superior to 
that of the alternative strategy of thrombolysis and leads to reduced infarct 
size, preservation of left ventricular function and reduced incidence of 
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morbidity and death38-46.  Similarly, in acute coronary syndromes, an invasive 
approach is generally favoured over medical therapy.  This remains a debated 
topic47-53.  
2.3.3 Stable angina 
The use of early revascularisation in place of medical therapy has been 
clearly shown to be beneficial in cases of STEMI and in several studies 
looking at unstable coronary syndromes and angiography is embedded in 
current standard National Institute for Clinical Excellence (NICE), European 
Society of Cardiology (ESC) and American heart association (AHA) clinical 
care guidelines.  In the setting of stable angina, guidelines advocate 
revascularisation only in patients who remain symptomatic after optimisation 
of medical therapy, lifestyle intervention and risk factor modification. 
Nevertheless, percutaneous coronary intervention (PCI) continues to be 
frequently performed in patients with stable angina referred for coronary 
angiography.  This continues to be a heavily debated issue and one which 
has been controversial for some years with contradictory evidence for either 
revascularisation or optimised medical therapy in these patients.  The key 
studies will be presented here.     
2.3.4 Key studies demonstrating importance of the presence of 
ischaemia 
The Asymptomatic Cardiac Ischaemia Pilot Study randomised patients with 
stable angina and coronary anatomy suitable for revascularisation, into one of 
three treatment strategies: angina-guided drug therapy (183 patients), angina 
plus ischaemia-guided therapy (183 patients), or revascularisation by PCI or 
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CABG (192 patients)54.  It was demonstrated that the lowest mortality at two 
years was recorded in the revascularisation group (1.1%), followed by the 
ischaemia-guided group (4.4%) and the angina-guided group (6.6%), with 
corresponding proportions for death, MI or recurrent cardiac hospitalisation, 




      Figure 2.7 - Outcomes - ACIP study  
A – Two-year cumulative mortality rates for three treatment strategies 
B- Two year cumulative rates of death, MI or cardiac rehospitalisation for 
three treatment strategies 
The lowest mortality at two years was recorded in the revascularisation 
group, followed by the ischaemia-guided group and finally the angina-
guided group.   
Adapted from ACIP study54 
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It is important to note that the eligibility criteria for the ACIP study included 
only patients with evidence of inducible ischaemia during pharmacological or 
exercise stress and at least one episode of asymptomatic ischaemia on 
ambulatory ECG. Furthermore, during the study period medication was 
uptitrated according to clinical evidence of ischaemia suggesting that the 
benefit of revascularisation could be linked to the presence of ischaemia, a 
theme which will become more apparent as further studies are described.   
 
A meta-analysis conducted around the same time by Katritis et al. which 
included the work by Davies et al, pooled the results of 11 randomised 
studies, comprising 1476 patients who received PCI and 1474 patients who 
received medical therapy for CAD55.  This, in contrast, concluded that overall 
there was no significant difference between the treatment strategies with 
regard to mortality, cardiac death, myocardial infarction (MI) or 
revascularisation rates during follow up. A possible survival benefit was seen 
only in patients who had recently had an MI.  However, it must be noted that 
the studies included were heterogenous with regard to inclusion and exclusion 
criteria and methodology and therefore it may be difficult to draw a reliable 
conclusion from this data.   
 
The SWISS-II trial prospectively studied patients with recent STEMI or 
NSTEMI, one- or two-vessel CAD and ischaemia on stress imaging and 
investigated the merits of revascularisation (with balloon angioplasty) versus 
medical therapy56.  This concluded that at 10 years post follow-up, 
revascularisation (96 patients versus 105 patients on optimal medical therapy) 
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resulted in a reduction of death, non-fatal MI and symptom-driven 
revascularisation, as well as long term preservation of cardiac function.  The 
benefit was apparent at the 2-year point and survival curves were seen to 
diverge continuously during follow up.  Once again, this supported the use of 
revascularisation where there was objective evidence of ischaemia.   
 
The Clinical Outcomes Utilitizing Revascularisation and Aggressive Drug 
Evaluation (COURAGE) trial was the first large multi-centre study specifically 
designed to compare optimal medical therapy plus PCI with optimal medical 
therapy alone in patients with stable coronary artery disease57.  2287 patients 
were randomly assigned to undergo either PCI and medical therapy or 
medical therapy alone with a median follow up of 4.6 years.  The primary 
finding of this study was that the cumulative primary event rate was similar in 
the two groups with no clear benefit conferred by PCI (p=0.62).  Specifically, 
there were no significant differences for the composite endpoint of death, 
myocardial infarction and stroke, and for hospitalisation due to acute coronary 
syndromes or MI (see Figure 2.8). Furthermore, sub-analysis of even the 
more severely narrowed coronary stenoses, showed that PCI was still not 




Figure 2.8 – Outcomes - COURAGE sub study 
A- Estimated 4.6 year rate of composite primary outcome of death from any cause 
and non-fatal MI (19.0% PCI group, 18.5% medical therapy group),  
B- Estimated 4.6 year rate of death from any cause (7.6% PCI group, 8.3% 
medical therapy group),  
C- Estimated 4.6 year rate of hospitalisation for acute coronary syndrome (ACS) 
(12.4% PCI group, 11.8% in medical therapy group),  
D- Estimated 4.6 year rate of acute myocardial infarction (13.2% PCI group, 
12.3% medical therapy group). 
No survival difference was observed between medical or revascularisation 
therapy.  
Adapted from COURAGE study57 
 
There was a substantial reduction in the prevalence of angina in both groups 
during follow up.  Rates of freedom from angina were in favour of the PCI 
group throughout most of the study period but at 5 years this difference was 
non-significant.    
This was an important study whose outcome was somewhat surprising. 
Interpretation must take into account the exclusion of patients with severe 
angina or marked ischaemic changes on initial screening exercise test. It 
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could therefore be argued that this may have excluded patients in whom the 
addition of PCI could have been beneficial.      
2.3.5 Ischaemic burden in stable coronary artery disease 
Over the same period the use of ischaemia testing was increasingly 
advocated on the basis of earlier studies facilitating a growing understanding 
of its impact on clinical outcomes. The simple presence or absence of a 
perfusion defect demonstrated by any imaging modality technique has been 
shown to be relevant to prognosis58-61.  However, in more recent years, this 
has been refined to consideration of the relevance of the ischaemic burden.  
This was considered in two important studies which will be discussed below.  
These demonstrated that, while the presence of significant ischaemia was 
relevant, severity and extent of ischaemic myocardium was also relevant.  
2.3.6 Key studies demonstrating the importance of ischaemic 
burden  
A study by Hachamovitch et al. set out to assess the relationship between the 
amount of inducible ischaemia and survival benefit achieved with medical 
therapy versus that achieved by revascularisation62.  This large retrospective 
observational study included 10,627 patients with no previous MI or 
revascularisation, who underwent exercise or adenosine single photon 
emission computed tomography (SPECT) to detect inducible ischaemia and 
then went on to be revascularised or receive medical therapy.  These patients 
were divided into two groups: those receiving either medical therapy (9956 
patients) or revascularisation (671 patients; CABG 325 patients, PCI 346 
patients). All included patients were within 60 days of the SPECT study with a 
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relatively short follow up period (1.9 +-0.6 years).  The study noted that 
patients sent for revascularisation had a greater burden of cardiovascular risk 
factors and this is a bias inherent to the observational nature of the study.   
The key finding was that, albeit with a relatively short term follow up, patients 
without inducible ischaemia treated medically had a very low risk of adverse 
events but that with increasing degrees of inducible ischaemia, the mortality 
rate increased in patients treated medically.  As shown in Figure 2.9 and 
Figure 2.10 below, this study demonstrated a survival advantage with 
revascularisation over medical therapy in those with an ischaemic burden of 
>12.5%, with medical therapy being favoured below this threshold.  There 
was significant benefit of revascularisation over medical therapy in those with 
>20% ischaemic myocardium. 
 
 
Figure 2.9 – Cardiac death according to ischaemic burden  
Observed cardiac death rates over the follow up period in patients undergoing 
revascularisation versus medical therapy as a function of the amount of inducible 
ischaemia.    
In those with ischaemic myocardium of 10% or more there was a significant 
benefit of revascularisation over medical therapy >20%. 




Figure 2.10 - Log hazard ratio according to ischaemic burden  
Log hazard ratio for revascularisation versus medical therapy as a function of 
percentage ischaemic myocardium based on a Cox proportional hazard model.  
There was a survival advantage of patients with no or little inducible ischaemia 
with medical treatment.  This was lost at a threshold of 10-12.5% ischaemic 
myocardium, above which the survival benefit favoured revascularisation. 
Adapted from Hachamovitch et al.62  
 
 
The relevance of ischaemic burden in guiding management of patients with 
stable CAD was further elaborated by the results of a substudy of the 
COURAGE trial63.  This reported data on a subset of 314 patients of the main 
COURAGE trial who underwent SPECT at baseline and at 6-18 months 
follow-up.  Substudy entry criteria included patients with at least one 
epicardial coronary artery stenosis of >70%. Importantly, on subanalysis of 
the patient characteristcs of the nuclear substudy population, the enrolled 
patients reported less severe angina than did the main cohort.  The pre-
treatment percentage of ischaemic myocardium was similar in those 
randomised to each group, with a similar number (about a third) of patients 
with moderate to severe baseline ischaemia burden assigned to either PCI or 
medical therapy alone. Patients who achieved a significant reduction of 
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ischaemia in response to medical therapy were less likely to crossover to PCI 
from the medical group (in contrast, 21% patients crossed over from the 
medical therapy group to have PCI and of these 80% had exhibited no 
significant reduction in ischaemic burden), or undergo repeated PCI from the 
PCI group (whereas 15% patients randomised to PCI had repeat 
revascularisation of whom 75% had exhibited no significant ischaemia 
reduction).  The addition of PCI to medical therapy was more effective in 
producing a measureable reduction of ischaemia at follow up scan (33% & 
19% respectively, p<0.0001).  The unadjusted rate of death or non-fatal MI for 
patients exhibiting significant reduction in ischaemia with either treatment 
strategy was 13.4% compared to 24.7% of patients for those without 
significant ischaemia reduction. The unadjusted event-free survival improved 
regardless of the original randomisation group or treatment received (see    
Figure 2.11).   This was measured by a reduction in the absolute amount of 
ischaemia by at least 5%, This clearly demonstrated that a reduction in 
ischaemia of  >5%, especially in those with more severe baseline ischaemia 
resulted in fewer adverse events - the 5% cut-off was identified on the basis of 




   Figure 2.11 – Survival curves (COURAGE substudy) 
Kaplan Meier curves for event free-survival according to reduction in ischaemic 
burden >5% at follow up for patients in either treatment group.  
   A – showing survival for patients with >5% reduction in ischaemia at 
         follow up  
   B - showing K-M survival for patients with >5% reduction in ischaemia 
         when baseline ischaemic burden was moderate or severe  
Survival was improved in those who demonstrated >5% reduction in ischaemia, 
particularly if moderate-severe ischaemia was present at baseline.  
         Adapted from COURAGE substudy63 
 
In summary, this reinforced the views of those proposing revascularisation as 
the superior treatment arm by demonstrating that PCI was more effective at 
reducing ischaemic burden and that a significant reduction in ischaemia with 
either treatment resulted in fewer adverse events.  Despite being 
underpowered to specifically investigate differences in clinical outcome 
according to change in ischaemic burden, the COURAGE substudy would for 
many years stimulate investigation into the importance of using ischaemia as 
a guide to revascularisation.  
 
Despite this, many have been critical of the COURAGE study design and 
findings and this has remained a debated topic.   
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The recent ORBITA trial, published in 2017, is also relevant to this same 
issue66.  The study aimed to evaluate whether there was a placebo effect of 
PCI and again compare PCI to medical therapy in stable CAD.  It identified 
230 patients with symptoms of stable angina and a single severe (>70%) 
coronary stenosis.  Patients were initially given several weeks of optimal 
medical therapy then randomized to either complete revascularistion with PCI 
(guided by FFR at the discretion of the operator) or a sham procedure where 
patients underwent FFR only and further medical therapy.  There was no 
demonstrable increase in exercise time increment or peak VO2 between 
groups, and no deaths in either group over the follow up period of 6 weeks.  
This study is particularly interesting as it is the first placebo controlled PCI 
trial, using contemporary medication and PCI techniques and again 
challenges the premise that PCI provides benefit over medical therapy. 
 
The ISCHEMIA trial67 is currently in recruitment stage and its findings eagerly 
awaited.  This is a large multi-centre study which will again compare PCI  and 
medical therapy.  In contrast to the COURAGE study, the ISCHEMIA patients 
will be enrolled on the entry criterion of moderate to severe ischaemia .  
 
2.3.7 Invasive assessment of myocardial ischaemia 
As studies drew attention to the importance of myocardial ischaemia as an 
index and other studies seemed to suggest that revascularisation in the 
absence of ischaemia may not be of benefit, it became clearer that visual 
assessment of angiography may be insufficient. It was postulated that some 
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lesions may not be haemodynamically significant nor flow-limiting despite 
appearing moderately to severely narrowed. Alternatively the simple 
explanation could be that angiography is a two-dimensional imaging modality 
and therefore difficult to judge visually.  It became apparent that even 
quantitative analysis of angiography in terms of percentage narrowing could 
be flawed as the result of collateralisation of vessels and changes in 
vasomotor tone, or by the absence of a reference diameter in those with 
diffuse disease which could make the use of luminal assessment alone 
potentially misleading.  In clinical practice, the issue is further complicated by 
the presence of complex CAD such as multi-vessel disease, previous 
coronary artery bypass grafting and reduced left ventricular function. In 
parallel there is a growing appreciation that, setting aside issues of cost, the 
risks inherent to PCI including stent thrombosis or peri-procedural MI and 
stroke which, despite the advent of newer drug-eluting stents, are not 
negligible68,69.  These factors discourage the use of unnecessary PCI.    
Although studies had suggested that intervention should be guided by the 
presence of myocardial ischaemia, the widespread availability of advanced 
non-invasive imaging techniques to assess myocardial ischaemia was limited 
until relatively recently. In consequence, interventional cardiologists 
developed more sophisticated invasive techniques and the ability to assess 
flow in each coronary artery directly during coronary angiography.  
 
Fractional flow reserve (FFR) is achieved with a microscopic transducer 
mounted on a wire which can be placed in a coronary artery and, under 
maximal hyperaemia, measures the relationship between the flow proximal 
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and distal to a narrowing.  The FFR compares the pressure distal and 
proximal to a stenosis and is expressed as a fraction of the proximal pressure. 
A normal value is therefore 1.0, with lower values indicating a degrees of 
stenosis.  There is no absolute value that establishes a threshold for 
significance however most studies have used a cut-off of 0.75 to 0.80.  
Collateralisation of a vessel may mean that a visually severe lesion is non-
significant since adequate blood flow is delivered to the relevant portion of 
myocardium; FFR is able to take this into account.  It should be noted that 
small vessel disease, diffuse coronary artery disease, exercise induced 
vasospasm or left ventricular hypertrophy may underestimate FFR value70. 
 
A number of studies have investigated the use of FFR in comparison to other 
measures in guiding intervention71-74.  
One such study investigated 45 patients with moderate coronary artery 
lesions and atypical chest pain and compared results of exercise testing, 
thallium SPECT, dobutamine stress echocardiography and quantitative 
coronary angiography with FFR measurements75.  There was no significant 
difference in minimal luminal diameter or percentage of the stenosis in the 
FFR >0.75 and <0.75 groups.  In all 21 patients with an FFR <0.75, reversible 
myocardial ischaemia was demonstrated on at least one non-invasive test.  
All but one patient with an FFR <0.75 underwent revascularisation and repeat 
non-invasive tests were subsequently negative for reversible ischaemia.  In 
contrast, in 21 of the 24 patients with an FFR measurement of >0.75 or 
higher, all tests for reversible ischaemia were negative.  These patients did 
not undergo revascularisation and were followed for a period of 14±5 months 
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during which no ischaemic events were noted. This study was important in 
supporting the use of FFR in patients where chest pain was not typical and 
where angiographic findings could be considered equivocal.  
2.3.8 Key studies investigating FFR to guide revascularisation 
Two key studies, DEFER76 and Fractional Flow Reserve versus Angiography 
for Multi-vessel Evaluation (FAME) 77-79, assessed the use of FFR versus 
visual assessment alone to guide PCI in patients with single and multi-vessel 
coronary artery disease.   
  
DEFER was an international, multicentre prospective randomised study which 
enrolled 325 patients with stable angina and a visually measured stenosis of 
>50% in a native vessel measuring >2.5mm in diameter, with no evidence of 
reversible ischaemia documented by another test in the preceding two 
months76. Patients were either randomised to deferral (167 patients) or 
performance (158 patients) of PCI (see    Figure 2.12) and were followed up 




   Figure 2.12 – DEFER study flowchart 
Study design, randomisation and definition of the three groups (dotted 
orange line).   
          Adapted from DEFER study76 
 
In order to minimise bias, patients were randomised to deferral or 
performance of PCI once enrolled, and before any physiological 
measurement.  All patients then underwent FFR measurement.  If this was 
below 0.75, randomisation was ignored and patients received PCI to that 
vessel (Reference group, 144 patients).  Those remaining with an FFR above 
0.75 either received no PCI (Defer group, 91 patients) or PCI (Perform group, 
90 patients).  Baseline characteristics were similar between the two groups.  
Follow up was performed at 1, 3, 6, 12, 24 and 60 months.  
The average FFR measurement in the Reference group was 0.57+/-0.16, with 
a smaller average percentage diameter of stenosis but with too much overlap 
between groups to serve as a useful predictor.  The stenosis severity and 
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average FFR in the Defer and Perform groups were similar (0.86+-0.06 




   Figure 2.13 – Fractional flow reserve in three groups studied – DEFER study  
DEFER study cohort - stenosis severity at baseline in three groups assessed by 
coronary angiography 
         Adapted from DEFER study76 
 
None of the patients in the Defer group had an adverse event (death, MI, 
CABG or coronary angioplasty) during the follow up period.  By contrast, in 
the Perform group, 5 patients suffered an event.  In the Reference group, 
there were 12 patients with an adverse event. This was non-significant 
compared to the Perform group (p=0.61) but significantly different to the Defer 
group (p=0.004).  At 5 year follow up, despite PCI, survival of patients in the 
Reference group was significantly lower (see    Figure 2.14) than in the 
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combined Perform or Defer groups (61% versus 76% respectively, p=0.03).  
Importantly, there was no significant difference in survival over 5 years 
between the Perform and Defer groups (73% versus 79% respectively, 
p=0.52).   
 
 
   Figure 2.14 - Cardiac death and acute MI rate in the three groups – DEFER 
study   
In patients with a functionally significant stenosis, (i.e. - FFR <0.75) managed with 
PCI, the incidence of cardiac death or acute myocardial infarction at 5 year follow 
up was five times higher than in patients with a negative FFR who were managed 
medically (15.7% versus 3.3%, p=0.002)  
         Adapted from DEFER study76 
 
The patients in the Reference group recorded the most symptomatic 
improvement.  In those with a negative FFR, there was also a benefit in 
symptoms of angina but interestingly this was more pronounced in the Defer 
group, even at the two-year point.  In summary, the results demonstrated that 
PCI of a non-functionally significant stenosis is neither of prognostic nor of 
symptomatic benefit.  It is important to note that this was a relatively small 
study but that nonetheless provided important findings.   
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The authors of the DEFER study later published 15-year follow up data.  At 
this long follow up, the mortality rate was similar between the three groups.  
The rate of non-fatal MI was lowest in the Defer group.  This showed that 
even long term, no adverse event was associated with avoidance of PCI to a 
functionally non-significant stenosis80.   
 
The FAME study further advanced this work and was designed to evaluate 
the role of FFR in the management of patients with multi-vessel CAD77-79.  
This tackled the important issue of interventional cardiologists being faced 
with patients with multi-vessel CAD having to determine which vessel 
warranted treatment. Data was collected on 1005 patients with multi-vessel 
CAD (luminal stenosis >50% in more than one of the three main epicardial 
arteries) who underwent PCI, either by angiography alone or by angiography 
on the basis of FFR measurements.  Patients from the angiography alone 
group underwent PCI of all affected vessels on the basis of angiographic 
appearance, whereas patients in the FFR guided group underwent PCI only to 
stenoses with an FFR measurement <0.80.  
In total 496 patients assigned to the angiography-guided group, and 509 
patients were assigned to the FFR-guided group for final analysis.  At one 
year, the primary endpoint, a composite of death, MI and repeat 
revascularization, occurred in 91 patients in the angiography-guided group 
(18.3%) and 67 patients in the FFR-guided group (p=0.02).  The event-free 
survival is shown in (see Figure 2.15).  Significantly more stents were placed 
in the angiography group (2.7+-1.2 versus 1.9+-1.3, p<0.001) with 
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comparable procedural times and mean length of stay leading to a significant 
cost benefit in favour of the FFR guided group (p<0.001)78.   
At 5 year follow-up, the group reported a similar rate of major adverse cardiac 
events between the angiography-guided and FFR-guided groups.  Though the 
initial advantage of an FFR-guided strategy had been lost, the patients in this 
group underwent less PCI suggesting that an FFR-guided approach was both 
safe and resulted in fewer stenting procedures79.  
 
 
Figure 2.15 – Survival curves comparing angiography versus FFR-guided 
revascularisation (FAME     study) 
Kaplan Meier curves showing improvements in FFR-guided treatment group in 
terms of major adverse cardiac events (A), overall survival (B), survival free from 
MI (C) and survival free from repeat revascularisation (D) compared to 
angiography alone.  
         Adapted from FAME study81 
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2.4 Non-invasive imaging of myocardial ischaemia  
Most clinicians now accept that the assessment of CAD ideally takes into 
account both anatomical and functional information in guiding 
revascularisation decisions.  
In the management of non-invasive assessment of myocardial ischaemia, a 
number of options are available each with inherent merits and pitfalls.  The 
choice of test used will of course also be based on the clinical scenario, local 
expertise and availability.   
 
The four main non-invasive imaging modalities for the assessment of 
myocardial ischaemia are:  
CMR,  
Positron Emission Tomography (PET),  
Single Photon Emission Computed Tomography (SPECT), and  
   Echocardiography 
 
2.4.1 Use of stressor agents in imaging  
There are two ways in which ischaemia can be appreciated by non-invasive 
imaging – both target points of the ischaemic cascade – vasodilator stress, to 
identify areas of hypoperfusion, or inotropic stress, to identify regional wall 
motion abnormalities. As described previously, the use of vasodilator stress is 




2.4.1.1 Vasodilator stress 
The changes in blood flow in response to stress agents which cause 
vasodilatation can be visualised by means of SPECT, PET or perfusion CMR.   
 
2.4.1.1.1 Perfusion CMR 
Perfusion CMR perfusion imaging is based on the delivery of a contrast agent 
to the myocardium after intravenous injection under hyperaemic conditions, 
usually with adenosine.  The imaging sequence is started shortly after 
injection of the contrast agent peripherally. The scan captures simultaneous 
basal, mid and apical LV cross-sectional slices with dynamic beat-to-beat 
imaging. The term ‘first pass’ is used to identify the images obtained on first 
passage of contrast first in the ventricles and then in the myocardium. The 
contrast is Gadolinium-based, which passes readily from the blood to the 
interstitial space (it does not enter intact cells and is therefore termed 
‘extracellular’) at a rate proportional to blood flow. The acquired images show 
a delayed wash-in of contrast to the area of myocardium served by the 
narrowed vessel which is most severe in the endocardium82,83.  This yields a 
contrast between areas of stress-induced hyperaemic myocardium and areas 
of reduced coronary reserve and relatively reduced perfusion due to 




   Figure 2.16 - Schematic showing difference in normal and hypoperfused 
myocardium  
Left panel –  
A – normal vessel with green dots indicating Gadolinium contrast molecules readily 
passing into the blood vessels then into the extracellular space.  
B- stenotic epicardial vessel with fewer Gadolinium contrast molecules resulting in 
lower myocardial Gadolinium concentration.  
Right panel – shows the relative signal intensity curves whereby the hypoperfused 
region reaches a lower and later peak in Gadolinium concentration.  
         Adapted from Amedeo Chiribiri10 
 
The acquisition of rest images is obtained after an interval of approximately 
10-15 mins. This second acquisition is identical to the first but without the 
vasodilatory influence of adenosine.  This identifies rest perfusion defects 
likely to represent areas of scar (or artefact). Quantitative analysis of these 
images also enables calculation of myocardial perfusion reserve. The interval 
between the stress and rest acquisitions can be used for functional and flow 
imaging.  Following the rest acquisition an additional dose of contrast agent is 






   Figure 2.17 - Schematic diagram showing scan sequence for a stress 
perfusion CMR 
Taken from clinical scan protocols, St Thomas’ Hospital, King’s College London 
 
2.4.1.1.2 Perfusion CMR sequences 
The signal generated, and how it relates to the myocardial blood flow is also a 
function of the specific CMR sequence used.  Perfusion CMR images were 
previously acquired using an inversion recovery pulse sequence – this can be 
used to null the tissue signal not exposed to Gadolinium and therefore creates 
a difference between normal and hypoperfused myocardium – these 
sequences however unfortunately require long acquisition which limits the 
temporal resolution and the number of slices possible within one cardiac 
cycle.   
Newer sequences tend to use a saturation recovery sequence where a 
saturation pre-pulse is given to null the myocardium then images are taken as 
the tissue relaxation recovers. This type of sequence is faster and permits an 
increase in the acquired in-plane spatial resolution while allowing multi-slice 
acquisition, at some expense in loss of the contrast between normal and 
hypoperfused myocardium. The saturation pre-pulse is triggered by the QRS 
complex and nulls the longitudinal magnetisation of the tissues.  The tissue 
will then start to recover, at a speed which is proportional to the local T1 
values. During first-pass, the concentration of gadolinium increases at a 
speed proportional to blood flow, and this reflects in the T1 of the tissue. 
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Areas of normal tissue will have received more contrast agent and will have a 
shorter T1 than hypoperfused regions. These two regions will therefore 
recover at different speeds and the hypoperfused region will reach a lower 
peak than normal tissue.  After the saturation pre-pulse, 90-120 ms are 
allowed for the recovery of longitudinal magnetisation, before the first image is 
acquired. Image acquisition can start in any phase of the cardiac cycle, after 
the initial saturation-recovery time has elapsed. This is controlled by a 
different parameter, the trigger delay84.  
 
 
   Figure 2.18 - Schematic showing typical image sequence for 2D perfusion 
CMR  
Saturation recovery sequence where a saturation pre-pulse is given to null the 
myocardium then images are taken as the tissue relaxation recovers. The 
saturation pre-pulse is triggered by the QRS complex and nulls the longitudinal 
magnetisation of the tissues.  The tissue will then start to recover, at a speed 
which is proportional to the local T1 values. During first-pass, the concentration of 
gadolinium increases at a speed proportional to blood flow, and this reflects in the 
T1 of the tissue. After the saturation pre-pulse, 90-120 ms are allowed for the 
recovery of longitudinal magnetisation, before the first image is acquired. Image 
acquisition can start in any phase of the cardiac cycle, after the initial saturation-
recovery time has elapsed. This is controlled by a different parameter, the trigger 
delay. Stress and rest perfusion images are usually acquired using a 2D imaging 
technique, and 3 short axis slices are usually acquired in basal, mid and apical 
geometry. Each slice will be imaged at a different point in the cardiac cycle. 
         Adapted from Motwani et al.84  
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2.4.1.1.3 Visual assessment of perfusion CMR 
In the clinical setting, visual assessment of stress, rest and late gadolinium 
imaging are used in combination to report on the presence of ‘non-inducible’ 
perfusion defects. These are seen on stress and rest perfusion imaging and 
typically correspond to scar on late gadolinium imaging provided this is not 
related to artefact.  Likewise, ‘inducible’ perfusion defects - seen on stress but 
not rest perfusion imaging and not corresponding to, or extending beyond 
areas of scar on late gadolinium enhancement imaging – are also identifiable.  
Myocardial perfusion is seen to fill from subepicardium towards the 
subendocardial layer with successive heartbeats.  Perfusion defects are seen 
to be arising from the subendocardium or transmural and, in the case of CAD, 
are located in the distribution of a coronary territory, typically affecting more 
than one slice.   
2.4.1.1.4 Advantages of CMR for stress perfusion imaging 
One of the key features of CMR is its higher spatial resolution of CMR 
compared to other imaging modalities.  In the field of perfusion CMR this is a 
clear advantage as CMR lends itself to the identification of subendocardial 
perfusion defects, potentially invisible to other modalities. Newer CMR 
sequence protocols, utilising high-resolution sequences can also reveal 
transmural gradients in perfusion and identification of subendocardial defects. 
As will be discussed later, this is an advantage in particular in patients with 
heart failure, where the left ventricular wall is thinned and the ventricle 





   Figure 2.19 - Schematic showing the different spatial resolution of SPECT, 
PET and MRI  
Diagram demonstrating the improved spatial resolution of MRI, in particular of a 
high-resolution sequence, compared to SPECT and PET.  This is an important 
consideration in heart failure where the myocardial wall can be thinned.   
 
The images are acquired first under hyperaemic conditions then again at rest 
in order to be able to compare, visually or quantitatively, the difference.  If 
done quantitatively, the stress value is divided by the rest value to produce 
the myocardial perfusion reserve (MPR).  In SPECT or PET, blood flow is 
recorded by means of a radioactive tracer, and in CMR by Gadolinium 
contrast agent, both injected through a peripheral vein and recorded at first-
pass entering the myocardium dynamically.   
In practice, both in CMR and in nuclear imaging, the most commonly utilised 
stress vasodilator agent is adenosine, delivered as an infusion to produce 
hyperaemic responses. It has a short half-life of less than ten seconds, with 
peak hyperaemic effect within two minutes.   
 
Other potential agents include dipyridamole and regadenoson but these are 
less commonly used. Dipyridamole has been shown to be a less potent 
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vasodilator with a more variable response than adenosine85-87.  In a practical 
sense regadenoson is easier to use than adenosine as it is given as a single 
bolus injection and is safe but its vasodilator effects are longer-lasting than 
those of adenosine. The washout periods before acquisition of rest images 
and time constraints make it a less popular agent in some centres and it can 
impact on MPR measurements from stress and rest perfusion estimates 88,89.  
 
In hearts with normal coronary arteries, blood (and contrast agent) will rapidly 
pass from the aorta to each part of the myocardium in a uniform manner, 
washing in from the subepicardium to subendocardium. In contrast, areas 
served by epicardial coronary vessels with significant stenosis, show little or 
no effect from vasodilator. Comparison of such an area with a healthy territory 
provides visual evidence of the difference in perfusion. The more severe and 
proximal the stenosis, the more transmural and extensive the perfusion 
defect.   
 
2.4.1.2 SPECT versus CMR  
 
Until recently, when CMR became more widely available, SPECT was the 
most commonly employed technique for non-invasive assessment of 
ischaemia.   
The CE-MARC and MR-IMPACT I and II studies compared SPECT directly 
with CMR and will be summarised below.  
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The CE-MARC study was the first large prospective study using angiography 
as the reference method to compare CMR with SPECT with regard to ability 
to predict major adverse cardiovascular events90. Patients with stable angina 
underwent stress and rest adenosine CMR and Tc (technetium) SPECT as 
well as coronary angiography. The primary outcome of this study was to 
determine the ability of a multi-parametric CMR protocol (rest and stress 
perfusion, left ventricular function, coronary magnetic resonance angiography, 
late gadolinium enhancement) to detect clinically significant coronary heart 
disease as measured by angiography.  The secondary outcome was a 
comparison of multi-parametric CMR and SPECT (rest and stress perfusion, 
left ventricular function) using angiography as the reference. Perfusion CMR 
images were analysed visually.  Of 752 patients, 628 patients had analysable 
CMR, SPECT and angiography data. 39% patients had significant CAD 
(defined as >70% coronary stenosis of one of the main coronary arteries or 
>50% left main stem, measured by quantitative angiography).  The key finding 
of the study showed that, by comparison with SPECT, sensitivities and 
negative predictive values of the CMR protocol were significantly in favour of 
CMR (p<0.0001 for both), with no significant difference in specificity or 
positive predictive value (p=0.916 and 0.061 respectively).  For the receiver-
operating curve (ROC) analysis, stress perfusion CMR significantly 
outperformed SPECT (AUC 0.89, 95% CI 0.86-0.91), see    Figure 2.20. 
Stress perfusion CMR was better than SPECT even when the angiographic 
cut-off value for a clinically significant stenosis was adjusted to 50% or greater 
for any main epicardial vessel or when multi-vessel CAD was considered. 
This was a necessary and important study in direct comparison of these 
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techniques but has been criticised by some due to the single site design, 
which carries inherent limitations, and the reported under-performance of 
SPECT compared to other published studies91. 
  
 
   Figure 2.20 - Receiver operator curves – CE-MARC study 
Receiver operator curves from SPECT versus CMR for the whole cohort 
A- angiographic cut-off ≥50% LMS; ≥70% for LAD, Cx, & RCA 
B- angiographic cut-off ≥50% for LMS, LAD, Cx, and RCA 
C- patients with single-vessel disease 
D- patients with multi-vessel (two or three vessel) disease 
(LMS - left main stem, LAD - left anterior descending, Cx -  circumflex artery, RCA 
- right coronary artery) 
         Adapted from CE-MARC90 
 
Published a few years earlier, the MR-IMPACT trial also aimed to compare 
the two modalities using coronary angiography as the reference92.  Perfusion 
CMR was assessed visually by experts.  Patients who had recorded positive 
in a clinically indicated SPECT scan, or had undergone a clinically-indicated 
coronary angiogram were eligible.  As a result of the entry criteria, this study 
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recruited a highly selected and higher risk population, evidenced by the high 
prevalence of CAD (77% patients had CAD, 31% had history of PCI).  A total 
of 225 patients were considered suitable for analysis of SPECT versus CMR.  
The results suggested equal performance of gated SPECT versus CMR for 
the detection of significant CAD in this higher risk patient group, with CMR 
performing better when ungated SPECT studies were included.   
 
The MR-IMPACT II study built further on this data and again sought to 
evaluate the diagnostic performance of perfusion CMR versus SPECT using 
coronary angiography as the standard reference93.  This was a large multi-
centre, multi-vendor study with 515 patients recruited to 33 American and 
European sites.  This included patients who were scheduled for a clinically 
indicated SPECT scan or coronary angiogram and included patients with 
previous myocardial infarction.  Perfusion CMR was assessed visually.  The 
primary endpoint was non-inferiority of CMR compared to SPECT for the 
detection of CAD.  Unlike the MR-IMPACT study, patients were included 
irrespective of the result of the SPECT scan and therefore the population was 
more representative of a general cohort with 48.8% of patients having 
significant CAD with a coronary stenosis >75%, and 29% patients having had 
previous MI.  In total 465 patients underwent all three investigations and were 
included in final analysis.   
The findings echoed the findings of the CE-MARC study and concluded that 
CMR was non-inferior to SPECT for the detection of CAD in terms of 
sensitivity but that SPECT was more specific.  
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In summary, these studies showed that visually assessed stress perfusion 
CMR performed better than SPECT in terms of sensitivity with similar 
specificity (somewhat favouring SPECT). There was also the advantage of 
eliminating exposure to ionising radiation and the ability to assess the detailed 
morphology of cardiac structure. These factors supported more widespread 
use of CMR to assess myocardial ischaemia.   
 
2.4.1.3 PET versus CMR  
Perfusion CMR can be assessed by direct visualisation of first pass of 
Gadolinium contrast agent or, like PET, can be assessed semi- or fully-
quantitatively.  Quantification of perfusion CMR will be discussed in more 
detail in a later chapter but, in essence, can provide stress, rest and 
myocardial perfusion reserve (MPR) estimates, measured either semi- or fully 
quantitatively.   
In brief, PET is performed in combination with CT or MRI scanning for 
attenuation correction and, anatomical localisation and co-registration of 
images.  One of several suitable short-lived metabolically active, or freely 
diffusible radioactive tracers is injected to the patient to measure stress and 
rest myocardial perfusion blood flow and myocardial perfusion reserve (MPR).  
This exposes the patients to ionising radiation from the PET tracer, and the 
CT scan when performed, and requires an on-site cyclotron if tracers such as 
15O-water or 13N-ammonia are to be used.  Previous studies have 
demonstrated a sensitivity and specificity of PET for the detection of CAD of 
around 90% and in consequence, PET is considered the non-invasive 
reference method for perfusion measurements18-21.   
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Due to the lack of widespread use of PET in the clinical setting for myocardial 
ischaemia assessment, studies comparing the techniques have been limited.  
These studies have used semi- or fully quantitative CMR analysis and will be 
discussed in more detail in the next chapter.   
 
2.4.1.4 SPECT versus PET versus CMR 
In a meta-analysis, SPECT, PET and CMR were compared94.  This reviewed 
3635 studies and found 166 met the inclusion criteria- that the test was used 
as a diagnostic test for obstructive CAD with angiography as the standard 
reference.  This resulted in analysis of 17,901 patients and 114 SPECT, 37 
CMR, and 15 PET studies. Patient-based analysis per imaging modality 
demonstrated pooled sensitivities of 88 % for SPECT, 84 % for PET, and 
89 % for CMR; pooled specificities were 61 %, 81 %, and 76 %, respectively.  
This demonstrated a high sensitivity of all modalities with a broader range of 
specificity but emphasised that CMR has a role to play in this area. 
 
2.4.1.5 FFR versus CMR  
Lockie et al. studied 42 patients with suspected CAD82.  Visual and 
quantitative assessment of perfusion CMR was compared with invasive 
fractional flow reserve findings (FFR).  FFR was measured in all vessels 
where the stenosis was >50% narrowed visually.  The results demonstrated 
that visual assessment of perfusion with CMR performed well against FFR - 
the FFR in territories deemed to be normal by visual assessment of perfusion 
was 0.93±0.09 versus an FFR of 0.59±0.22 in vessels with visual evidence of 
a perfusion defect.  This produced a sensitivity of 0.82 and specificity of 0.94 
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for detection of an FFR <0.75 for visual analysis.  Similarly, quantitative 
analysis also performed well – the MPR for territories with an FFR <0.75 was 
1.35±0.5 versus an MPR of 2.2±0.5 for those with a normal FFR.  This 
produced a sensitivity and specificity of 0.80 and 0.89 respectively for 
quantitative analysis.  Linear regression analysis suggested that quantitative 
measurements correlated better with FFR measurements than visual analysis.  
The optimal MPR value to detect lesions with an FFR <0.75 was found to be 
1.58.   
 
The MR-INFORM (MR Perfusion Imaging to Guide Management of Patients 
with Stable Coronary Disease) study has compared outcomes between 
patients treated according to the result of either a perfusion CMR or an FFR 
result95. This study compared the revascularisation rates and outcome of 
patients randomised either to an FFR-guided approach or a CMR perfusion-
guided approach.  In total, 918 patients were enrolled and followed up for 1 
year.  Preliminary results show that both groups demonstrated a very low 
event rate with similar performance of both tests. This showed that patients 
can safely be managed by either approach.  Importantly, the CMR-guided 
group underwent significantly fewer revascularisation procedures suggesting 
that a CMR-guided approach will avoid unnecessary invasive intervention.  




2.4.1.6 Invasive angiography versus CMR 
Several studies have specifically tested perfusion CMR against invasive 
coronary angiography. While this is reasonable at judging severity at the 
extremes of mild or severe CAD, its use in the moderate range this is open to 
scrutiny, even if assessed quantitatively.  Many of these studies were 
performed at a time where this was either not appreciated or when additional 
means of assessing the severity of coronary lesion were not available - most 
would now argue that fractional flow reserve is the reference standard for 
invasive assessment of coronary artery stenosis.   
 
Ishida et al. studied 104 patients referred for coronary angiography with 
suspected CAD and no prior history of MI and reported a sensitivity of 0.90 
and specificity 0.85 for perfusion CMR96.  Pilz et al. presented similar 
sensitivity and specificity on a series of 176 patients with stable angina (0.96 
and 0.83 respectively) compared to angiography and concluded that perfusion 
CMR was highly accurate as a gatekeeper for patients with intermediate 
CAD97.  
 
Some groups have examined the use of adenosine for evaluation regional 
wall motion abnormalities.  In one of these studies, it was demonstrated that 
DSMR was superior in the induction of regional wall motion abnormalities 
compared to adenosine - adenosine stress CMR is capable of detecting 
regional wall motion abnormalities but only identifies high-grade coronary 
stenosis using coronary angiography as the reference98.  
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2.4.2 Inotropic stress  
The assessment of inducible ischaemia may also use dobutamine, an 
inotrope which increases myocardial oxygen demand and uses regional wall 
function as the endpoint to indicate ischaemia. It is only applicable to CMR 
and echocardiography.  
Dobutamine CMR can be performed at low dose for assessment of viability, 
alone or in combination with LGE imaging, or can be used at high-dose as 
alternative to stress perfusion CMR to assess for ischaemia.  
Though not routinely performed in combination, there is evidence of improved 
diagnostic accuracy when perfusion CMR is added to high dose DSMR for the 
evaluation of patients with intermediate coronary stenosis, especially when a 
high-spatial resolution sequence is used99-101.  
 
 
Figure 2.21- Schematic diagram showing scan sequence for a stress DSMR 
Taken from clinical scan protocols, St Thomas’ Hospital, King’s College London 
If viability is the main question, low dose DSMR is performed, if ischaemia is the 
concern and if clinically indicated, high-dose DSMR is performed. 
 
 
This is performed using either dobutamine at low dose (up to 10 mcg/kg/min) 
or high dose (up to 40 mcg/kg/min).  Low dose dobutamine stress by echo 
(DSE) or by CMR (DSMR) is used to simulate recruitment of hibernating 
regions by demonstrating areas improve under stress with increased wall 
motion and thickening – this can be used alone, or in the setting of CMR in 
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combination with LGE images102-104.  High dose DSMR is used as an 
alternative to perfusion CMR to look for regional wall motion abnormalities at 
peak stress.  The target for a high-dose DSMR is to achieve target heart rate 
and this can be promoted with the addition of atropine during the scan.  At low 
dose DSE or DSMR, a region can be seen to improve but at a higher dose of 
dobutamine the ischaemic region is seen to worsen in contractility – a so-
called biphasic response.   
Exercise can also be used to drive increase in oxygen demand but is not 
practically feasible in CMR due to patient positioning and movement within the 
MRI bore.  In echocardiography, patients can be asked to cycle while being 
scanned in place of pharmacological stress.   
 
2.4.3 The importance of a negative stress CMR 
In work by Jahnke et al. 513 patients underwent both adenosine and high-
dose dobutamine stress perfusion CMR with a median follow up of 2.3 
years59.  This team found that the three-year event free survival was 99.2% in 
patients with a normal adenosine and dobutamine stress CMR, and 83.5% in 
those with an abnormal test.   Ischaemia detected by CMR was found to be 
an independent predictor of cardiac events - multivariate analysis showed that 
an abnormal test carried significant incremental value over other recognised 
clinical risk factors.   
A meta-analysis of 19 studies including over 11,000 patients with a mean 
follow up of 32 months showed that patients with an abnormal stress 
(vasodilator or dobutamine) CMR test had a 7.7-fold increased incidence of 
MI and a 7-fold increased risk for cardiovascular death compared to those 
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without demonstrated ischaemia.  A negative CMR implied a very low risk of 
adverse events58.  
Similarly, a second meta-analysis performed the same year reported on 14 
studies including over 12,000 patients. This demonstrated a high negative 
predictive value for MI and cardiac death of a CMR showing no evidence of 
ischaemia on vasodilator or dobutamine CMR - 98.1% and an annualised 
event rate of only 1%105.   
Nandalur et al. also performed a meta-analysis which pooled results of 37 
studies (2191 patients) using visual, semi-quantitative and fully-quantitative 
perfusion CMR analysis and DSMR against angiography and concluded that 
perfusion CMR has a sensitivity and specificity of 91% and 81% respectively, 
and that DSMR has a sensitivity and specificity of 83% and 86% 
respectively106. 
 
The growing impact of CMR in the clinical setting was highlighted in the Euro-
CMR Registry which studied over 11,000 patients in Germany.  This showed 
that CMR is a safe test, with diagnostic image quality in 98% patients and has 
an impact on subsequent patient management in nearly two-thirds of 
patients107,108.   
 
2.5 Conclusion 
In summary, this chapter introduces the concepts and themes on which 
subsequent chapters are based.  The assessment of ischaemia is relevant 
and sensitive to early detection of coronary artery disease and appears to 
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have prognostic benefit in decisions regarding revascularisation.  The use of 
ischaemia testing is relevant also to the avoidance of unnecessary 
revascularization and appears superior to visual assessment of coronary 
stenosis, in particular in the moderate range.  The use of perfusion CMR is 
increasingly prevalent, largely due to the multi-parametric capability and the 
high spatial resolution of the technique. Visual assessment of ischaemia by 
perfusion CMR compares well with invasive and other non-invasive 
techniques, with corresponding prognostic benefit.  In addition perfusion CMR 
can be quantified, bringing the additional potential of absolute, objective 
measurements of perfusion – this will be discussed in the subsequent 
chapter.   
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The quantitative analysis of perfusion CMR was first described over 20 years 
ago but its use has been limited to research.  As discussed in the previous 
chapter, both semi and fully quantitative CMR have been shown to compare 
well with the reference method of non-invasive perfusion (PET) in healthy 
volunteers109 and patients110-113.  
This chapter will discuss the evidence supporting the use of quantitative 
perfusion CMR analysis, the different approaches to quantification of 
perfusion CMR data and finally will explore the barriers limiting its transition to 
routine clinical use.  This chapter includes a published review article - Eva 
Sammut is first author and was responsible for literature review and involved 
with manuscript drafting.    
 
3.2 Quantitative perfusion CMR  
The search for quantitative measures of perfusion by CMR is motivated by the 
desire to obtain observer-independent and reproducible measures of 
myocardial perfusion status.  The advantages of a quantitative approach 
include assessment of global disease.  In broad terms, there are two ways to 
quantitatively assess perfusion CMR – semi-quantitatively, and fully 
quantitatively.  Both have been shown to be reproducible from studies 
investigating intra- an inter-reader variability114-117.  
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3.3 Linearity of signal intensity and gadolinium contrast 
It is important to appreciate that, for semi-quantitative assessment to be even 
possible, signal intensity in both the blood (input) and myocardium (output) 
should be proportional to the concentration of the contrast agent.   
Unfortunately, as will be outlined, linear relationship is only observed at lower 
Gadolinium concentration levels. At higher levels, the signal intensity is seen 
to saturate and loses its relationship to contrast agent concentration.  
 
 
   Figure 3.1 – Figure showing relationship between signal intensity and 
Gadolinium concentration 
Demonstrates findings of an experiment on human blood samples using a 
saturation recovery MRI sequence showing blood signal intensity (SI) plotted 
against Gadolinium (Gd) concentration.  The measured relationship is shown on 
Ox line and shows the signal with is initially linear but saturates at high Gd 
concentration.  Nx shows the theoretical, projected linear relationship between the 
SI and Gd concentrations, extrapolated from the lower concentration data points 
on Ox.   
          Adapted from Ichihara et al.118  
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Since perfusion CMR is judged visually in the clinical setting, it is desirable to 
maximise the contrast to noise ratio (CNR) in the myocardium – this requires 
a large Gadolinium (Gd) dose.  A higher contrast to noise is preferable for 
visual assessment but the loss of relationship between signal intensity and Gd 
concentration at higher doses, precludes direct quantification of signal to 
calculate Gd concentration and in turn perfusion. The dosage regime of 
Gadolinium used in previous studies has ranged from 0.025 – 0.15mmol/kg 
which is adequate to identify areas of hypoperfusion by visual assessment119.  
Lower doses make visual assessment suboptimal120. 
 
3.4 Semi-quantitative analysis of perfusion CMR  
Semi-quantitative analysis, the simplest quantitative approach, plots the signal 
intensity (SI) against the time of the dynamic perfusion images.  This provides 
a number of indices – the maximal SI; contrast appearance time; time to 
maximal SI; area under the SI curve and steepness of the upslope of the SI 
curve.   
The most widely used index is the upslope of the SI curve which measures 
the speed of wash-in of contrast agent as an index for blood flow. In view of 
the saturation of signal at higher Gd doses, in semi-quantitative analysis, 
higher values are extrapolated from the start of the SI slope and a linear fit 
curve is created.  Upslope analysis has been compared against angiography, 
FFR, microspheres and PET – it has been shown to reproducible between 
sites and can accurately discriminate between normal and hypoperfused 
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regions but some studies suggested an underestimation of semi-quantitative 
CMR analysis against other modalities110,121-126.    
 
3.5 Key studies - semi-quantitative perfusion CMR 
Giang et al. compared angiography with upslope analysis in 94 patients and 
showed a sensitivity of 93% and specificity of 75%121.  Rieber et al. studied 43 
patients with known or suspected CAD and compared upslope analysis 
against angiography alone versus FFR angiography and concluded that CMR 
was capable of detecting haemodynamically significant lesions with a high 
sensitivity and specificity (88% and 90% respectively)122.  Nagel et al. 
described the accuracy of upslope analysis on 84 patients referred for 
angiography, with a high prevalence of CAD and reporting sensitivity of 0.88 
and specificity of 0.90123.  Schwitter et al. used PET and angiography to 
assess upslope analysis and found that CMR was able to identify patients 
with CAD even when hypoperfusion was limited to the subendocardial layer, 
with a sensitivity and specificity of 91% and 94% respectively compared to 
PET, and 87% and 85% respectively compared to quantitative 
angiography110.  Al-Saadi et al. used upslope analysis against angiography to 
define an optimal MPR threshold of 1.5 and then prospectively tested this 
threshold in a second group and reported a sensitivity, specificity and 
diagnostic accuracy of 90%, 83%, and 87% respectively124.  Ibrahim et al. 
studied a group of patients with angiographically-documented CAD with CMR 
and PET and found that upslope analysis underestimated MPR values 
compared to PET with a sensitivity, specificity and diagnostic accuracy of 
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86%, 84% and 85% respectively125.  Plein et al. reported on 92 patients and 
10 healthy volunteers and a high diagnostic accuracy of upslope analysis with 
AUC 0.908, sensitivity 88% and specificity 82% compared to angiography126.  
 
Lee et al. used an in-vivo dog model to compare semi-quantitative analysis of 
CMR and SPECT against the preclinical invasive reference standard of 
microspheres127.  At rest they demonstrated homogenous regional 
microsphere concentrations and, using upslope analysis, CMR and SPECT 
performed similarly.  When the circumflex artery flow was reduced by >85%, 
both CMR and SPECT showed marked perfusion abnormalities.  Importantly, 
when the circumflex was occluded by 50%, a perfusion defect was seen only 
on CMR. There was a linear relationship between the CMR signal intensity 
curves and microsphere flow rate over the range of flow limitation.  This 
highlights the ability of CMR to appreciate moderate as well severe degree of 
stenosis, visually apparent as a subendocardial rather than transmural defect.  
This result is somewhat surprising given one would not typically expect a 
perfusion abnormality for a 50% lesion.  Nevertheless, as described in the 
previous chapter, moderate lesions can be flow limiting underlining the 
importance of ischaemia assessment with CMR or FFR.   
 
Schwitter et al. prospectively studied a group of 41 patients with suspected 
stable angina, using MR perfusion, analysed semi-quantitatively, and 13N-
ammonia PET against coronary angiography110. 18 healthy volunteers also 
underwent perfusion CMR to generate reference values for transmural and 
subendocardial perfusion levels.  The group concluded that first pass CMR 
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perfusion reliably detects and quantifies CAD, and includes the ability to 
identify subendocardial perfusion abnormalities.  They reported a sensitivity 
and specificity for perfusion CMR of 91% and 94% respectively for patients 
with reduced CFR as defined by PET, and 87% and 85% respectively 
compared to coronary angiography. There was a linear relationship between 
PET and MR in detecting the number of hypoperfused segments when 
considering no, one-, two- and three-vessel disease, with a tendency to 
underestimation by CMR (see  Figure 3.2).  ROC analysis demonstrated that 
semi-quantitative CMR data are highly reliable in the detection of significant 
CAD (see    Figure 3.3).  
 
 
 Figure 3.2 – Bar chart comparing results of CMR versus PET  
Bar chart summarising number of positive segments identified by each technique.  
With progressive increase in extent of CAD, both techniques identify increasing 
extent of ischaemia, with slightly higher values seen with PET.   
1VD- one vessel disease, 2VD – two vessel disease, 3VD – three vessel disease 




   Figure 3.3 – Comparison of semi-quantitative CMR to PET or angiography  
A – MR detection of haemodynamically significant CAD by PET (>1 sector with 
CFR <1.65, n=51) 
B - diagnostic accuracy of MR and PET are similar compared to angiography (>1 
coronary artery >50% stenosis, n=57). 
         Adapted from Schwitter et al.110  
 
3.5.1 Transmural perfusion analysis 
A different approach to exploit and quantitate high-resolution perfusion CMR 
data has been proposed by Hautvast et al.128.  This is based on the 
measurement of perfusion imbalances between endocardial and epicardial 
myocardial layers. Following accurate motion correction and segmentation of 
the LV wall, an algorithm calculates the transmural perfusion gradient G(α,t) 
frame-by-frame during first-pass wash-in of contrast agent (t) and in every 
myocardial transmural sector α according to the following formula: 
 
where Iepi(α,t)  is the signal intensity curve in the LV endocardial layers, 











is the average transmural signal intensity curve in the LV. The transmural 
perfusion gradient is expressed as a percentage of transmural redistribution of 
myocardial blood flow between layers. The optimal diagnostic threshold has 
been identified in comparison with FFR and then validated in an independent 
cohort of patients.  A transmural perfusion gradient of 20% identifies the 
presence of haemodynamically significant CAD with a sensitivity of 0.78, 
specificity of 0.94, diagnostic accuracy of 0.86 for in a per-segment analysis 
and of 0.89, 0.83, and 0.86 in a per-patient analysis, respectively129.    
Transmural perfusion gradient analysis offers a series of advantages over 
other methods used for quantitative analysis. It does not require 
administration of a diluted pre-bolus or the acquisition of rest perfusion 
images.  Additionally, it is more robust to image homogeneity due to variations 
in the B1 field, different coil configurations, different schemes of contrast 
agent administration, field strength, and the acquisition pulse sequence128,129.  
 
3.6 Fully quantitative analysis  
Fully quantitative analysis permits absolute measurement of myocardial blood 
flow during stress and at rest for the calculation of myocardial perfusion 
reserve (MPR).  Once again, accurate quantification must overcome the loss 
of a linear relationship between signal intensity and higher blood Gadolinium 
concentration.  As only a small proportion of the injected Gadolinium will pass 
from the blood pool to the myocardium, the ideal situation is achievement of a 
high dose of Gd in the myocardium, to maximise contrast to noise in the 
myocardium, and a low dose in the blood pool in order to minimise saturation 
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effects. This is unobtainable with a single injection but has been addressed by 
two approaches:  
The dual bolus approach using administration of lower concentration pre-
bolus of Gadolinium to measure the blood pool (arterial input function), 
followed by a full strength main bolus from which the myocardial signal is then 
calculated130.  
 A more recent dual sequence approach involves a short saturation low 
resolution image acquired for each heart beat to measure the arterial input 
function. This is followed by a higher resolution long saturation recovery 
image for myocardial signal intensity131.  
These approaches will be discussed in more detail later.  
The analysis of quantification data requires complex mathematics, each with 
limitations and assumptions, and these will be discussed later in the chapter.  
 
3.6.1 Quantitative CMR versus PET  
The current reference method of choice for quantitative analysis of perfusion 
is PET. As discussed in previous chapters, the alternative of CMR is attractive 
in view of the ability to obtain quantitative perfusion measurements by CMR, 
with its higher spatial resolution, as well as detailed functional and viability 
data, within a single examination and without the use of ionising radiation.   
 
Only few studies have compared PET with fully quantitative CMR.  
A good correlation between MPR derived from PET and MRI was noted in a 
study by in which 10 healthy individuals underwent PET and MRI at rest and 
dipyridamole stress – a linear relationship was found between the two 
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methods with a correlation coefficient of 0.96 however MRI measurements 
under-estimated perfusion compared to PET109.   
 
A key study directly comparing PET and CMR was performed by Morton et 
al.111.  A cohort of 41 patients was studied comparing fully quantitative CMR 
and PET perfusion measurements, performed on independent scanners on 
the same day. This was the first study comparing a fully quantitative approach 
to CMR analysis with PET.  It was demonstrated that calculation of MPR by 
the two techniques produced similar values but that absolute stress and rest 
MPR values differed between the two methods. It has since been suggested 
that this can be ascribed to differences between approaches to assessing and 
quantifying perfusion by CMR and PET techniques including specific tracer 
properties, modelling assumptions, fitting methods and parameter 
constraints132. 
 
Miller et al. compared a number of methods described for full quantification of 
perfusion CMR against rubidium-82 PET in 18 patients, 9 of whom had 
significant CAD112.  The median time between studies was 7 days (IQR 4-25 
days).  The data was analysed on a voxel-wise basis.  They showed no 
significant difference between the methods in terms of myocardial blood flow 
calculation, though the Fermi method showed the closest correlation with PET 
values.  There was a linear relationship with PET values using all methods 
however each CMR method under-estimated stress and rest estimates 
compared to PET.  This was largely cancelled out when calculating MPR.   
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In a very recent study by Engblom et al. 21 patients with stable CAD 
underwent CMR and [13N]NH3 PET sequentially, on the same day113. 
Perfusion CMR was analysed quantitatively using methods which will be 
described in more detail later in the chapter.  There was good agreement 
between global and regional myocardial perfusion and MPR between the two 
modalities, as shown below in   Figure 3.4.  Importantly, due to recent 
technological post-processing advances, this was done using a highly 
automated CMR analysis pipeline – a factor which has previously limited 
translation to more widespread use and will be discussed.  
 
 
  Figure 3.4 – Correlation between fully quantitative CMR and PET  
Scatter plot demonstrating a good correlation between quantitative CMR versus 
PET  
A - global myocardial perfusion by CMR versus PET 
B - regional myocardial perfusion by CMR versus PET 




In summary, previous studies comparing fully quantitative CMR against PET 
have suggested that there is a linear relationship between values derived from 
either modality, with a suggestion that CMR appears to underestimate values 
by comparison with PET.  MPR values obtained by quantitative CMR correlate 
better than stress or rest values109-113.  The complex mathematics and tracer 
properties required in both modalities would appear to have inherent errors 
which cancel each other out. These aspects require further investigation, 
refinement and validation. 
 
3.7 Perfusion quantification – where are we now?  
The following section is taken from a review article summarising the principles 
and methods used to quantify perfusion CMR.  In the final section of the 
chapter, an important new approach is described.   
 
3.7.1 Principles of perfusion quantification by CMR 
Perfusion quantification is based on the indicator-dilution principle. “A known 
quantity of an indicator is injected into a fluid flowing at unknown rate through 
a system of unknown volume. Fluid is sampled or monitored at one or more 
points downstream from the plane of introduction and the concentration of 
indicator, diluted by the parent fluid, is measured as a function of time”133.  In 
perfusion CMR, the indicator is a gadolinium-based contrast agent injected via 
a peripheral vein. As the concentration of contrast at the ostium of the 
coronary arteries is not known, the quantity is estimated by measuring the 
arterial first-pass time-intensity curve (arterial input function, AIF) in the left 
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ventricle or ascending aorta. Myocardial blood flow is monitored as a function 
of the measured myocardial time-intensity curve. 
First-pass CMR perfusion series are usually acquired using a dynamic T1-
weighted sequence, designed to generate a contrast between areas of stress-
induced hyperemic myocardium and areas of relatively reduced perfusion, 
based on the different speed of inflow of blood and gadolinium over time, as 
described in the previous chapter.  
3.7.1.1 Quantification by signal deconvolution 
The relationship between the AIF and the myocardial time intensity curve is 
defined by the following convolution equation: 
Cmyo(t) = CAIF(t) ∗ h(t) 
where Cmyo  (t) is the myocardial time-intensity curve, CAIF  (t) is the arterial 
input function and h(t) is the myocardial tissue impulse response. 
In essence, the arterial input and myocardial input functions are convolved, a 
mathemetical process, to produce a curve.  Myocardial perfusion can be 
estimated from the above equation by model-based or model-independent 
signal deconvolution - this is done by producing a large number of curves 
which are then matched to the convolved signal curve - the best fit represents 
the h(t) - this is taken as the perfusion rate. 
 
3.7.1.2 Model-based deconvolution 
Model-based deconvolution is considerably complex and is based on tracer-
kinetic modelling. The circulatory system is divided in different compartments 
and a transfer constant (Ktrans) is defined which physiologically reflects the 
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combination of perfusion, blood volume and capillary permeability to the 
contrast agent134.  In most implementations, the intravascular and 
extracellular compartments are considered, although single-compartment 
models have also been described by the assumption of a fast exchange of 
contrast agent between the vessels and the interstitial space during first-pass. 
The Patlak method135 is a specific implementation of a single-compartment 
pharmacokinetic model which has been adapted to perfusion CMR 
quantification118.  
Model-based deconvolution methods rely on a correct estimate of Ktrans. This 
parameter is difficult to assess in-vivo including in animal models. Some 
preclinical studies have been conducted in canines136-138.  The different 
characteristics in microscopic anatomy between the human and canine 
coronary microcirculation and a number of different physiological factors 
preclude direct application of assumptions on Ktrans to human studies. 
 
3.7.1.3 Model-independent deconvolution 
Model-independent deconvolution was originally developed for intravascular 
contrast agents studying brain perfusion. It has gained popularity as an 
alternative to model dependent deconvolution for myocardial perfusion 
assessment in the last few years. Perfusion is estimated without considering 
the tracer-kinetic modelling, using a variety of different deconvolution methods 
(Fermi function modelling, B-spline basis, exponential basis and 
autoregressive moving average model – ARMA) to constrain the results. 
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3.7.1.4 Fermi function modelling  
Fermi function modelling appears to be the most favorable method for model-
independent deconvolution quantification139-141.  First proposed by Wilke et 
al.142 and Jerosch Herold et al.143, this method for perfusion quantification is 
based on the observed similarity between the impulse response, h(t), for an 
intra-vascular tracer and shape of the Fermi function (Figure 3.5). Fermi 
function modelling is robust in application to different scanning and modelling 
parameters. Moreover, this method has been shown to be precise and to 
have a consistent outcome independent of the spatial resolution level and of 
the level of noise141,144.  
 
 
Figure 3.5 – Schematic demonstrating the use of Fermi function deconvolution 
with a dual-bolus approach  
A- The prebolus is made up of 10% full dose according to bodyweight, this can then 
be multiplied to achieve the predicted peak of the arterial input function without the 
effect of saturation.   To minimize contrast to noise, the signal from the main bolus is 
used for the myocardial signal.   
B- The deconvolution process extracts the myocardial transfer function by iteratively 
convolving the scaled signal intensity of the LV cavity by using a three-parameter 
Fermi transfer function until the myocardial enhancement can be predicted 
C- The transfer function characterizes the myocardial circulation that transforms the 
delivery of contrast material into the LV cavity (input) into the observed myocardial 
enhancement (output).  
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3.7.1.5 B-spline basis deconvolution   
Jerosch-Herold et al.145 later developed a model-independent deconvolution 
method based on B-spline functions and stabilized the solution by using 
Tikhonov regularization. B-spline model-independent deconvolution has been 
compared with other analysis methods in a number of studies, both for 
segmental and high-resolution (voxel-wise) quantification141,144.  
 
3.7.1.6 Exponential basis deconvolution 
Exponential functions can be used as the base function for the model-
independent deconvolution. Keeling et al. initially used decaying exponential 
functions in order to estimate perfusion of the brain146.  This approach has 
also been validated against a hardware cardiac perfusion phantom, where 
perfusion values are known, and was demonstrated to provide accurate 
quantification of myocardial blood flow147.  
 
3.7.1.7 ARMA (Auto regressive moving average model) 
Autoregressive-moving-average (ARMA) modelling is a linear algebraic 
technique without any direct curve fitting and a limited number of parameters.  
ARMA approach achieves the required model accuracy with a lower order 
approximation than other modelling methods141,144,148.  As a result, ARMA is 
faster than other methods of analysis and avoids convergence issues. 
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An accurate comparison of Fermi function modelling with the other algorithms 
for model-independent deconvolution was made possible by the availability of 
a novel perfusion phantom, capable of a realistic simulation of myocardial 
perfusion and providing true validation for absolute perfusion 
measurements149.  Sensitivity of all these deconvolution methods to their 
order and modelling parameter has more recently been tested against 
simulated data and a blood-perfused explanted pig heart with 
microspheres141,150.  This demonstrated that the choice of method and its 
order depend on several factors including signal-to-noise ratio of the data, 
computational burden and desired accuracy of the results.  The Fermi model 
was found to be the most favourable as all of the modelling parameters are 
either fixed or they will be determined during deconvolution process. 
Moreover it has shown to have good correlation with the real perfusion values. 
The ARMA model with the correct choice of order was superior to other 
methods including Fermi with better accuracy and less computational burden.  
 
3.7.2 Saturation effects and contrast agent injection schemes  
A number of critical assumptions need to be made in order to enable 
quantitative perfusion analysis. The indicator-dilution principle can be applied 
to perfusion CMR quantification under the presumption of a linear dose-signal 
response for gadolinium during first pass. 
Dosages of gadolinium in the range of 0.05-0.1 mmol/kg of body weight are 
required to generate images with sufficient contrast-to-noise ratio for visual 
and quantitative analysis. Though single-bolus approaches in this 
concentration range were previously used with good diagnostic accuracy 
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compared with invasive coronary angiography and FFR82.  Ichihara et al. have 
shown that these can result in significant saturation effects in the AIF118.   
Saturation effects lead to elevated and non-physiological perfusion estimates. 
For this reason, this approach is not currently considered adequate for 
accurate quantitative analysis. 
Several approaches have been proposed in order to overcome the limitations 
of first-pass signal saturation effects. Some studies have used lower doses 
(0.025-0.05 mmol of gadolinium per kg of body weight) of contrast agent in 
combination with strongly T1 weighted sequences143,151.  Despite a reduction 
in saturation effects, this approach is limited by the low myocardial contrast-
to-noise ratio.  Others have proposed strategies to correct for signal saturation 
using magnetization modeling152,153.    
   
3.7.2.1 Dual-bolus 
Currently, the most commonly implemented approach is the dual-bolus 
method. This consists of a combination of the low and high dosage 
approaches, using two consecutive injections of contrast agent. The first low 
dosage injection enables the acquisition of a non- saturated AIF. The second 
high-dosage injection elicits a sufficient myocardial signal response for visual 
and quantitative assessment154-158.  This approach has been shown to permit 
accurate perfusion estimates155 but can potentially be limited by the need for a 
state-of-the-art gadolinium injector and more patient preparation time. In 
addition it is more prone to blurring by respiratory motion over the time taken 
to acquire the images.  Ishida et al.130 devised a universal dual-bolus injection 
scheme that resolves these issues and can be easily employed in a clinical 
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setting.  The dual-bolus approach is based on a combination of a bodyweight-
adjusted and high-dose main bolus of contrast agent preceded by the 
injection of a low dose pre-bolus having the same volume of the bolus and 
only 10% of the concentration of gadolinium. The injector is filled with saline 
solution. Both the pre-bolus and the main bolus are loaded using a 3-way tap 
in a large bore tube connected between the injector and the patient.  A 25-
second pause was found to be a near optimal delay between the first and the 
second injection, avoiding overlap between the first and the second bolus 
while minimizing the duration of the acquisition (see Figure 3.6).   
 
 
Figure 3.6 - Schematic showing the dual bolus approach 
Prebolus (10% concentration) is given at Point A.   
After a 25 second pause the main bolus (Point B) is given.    
 
3.7.2.2 Dual-sequence 
An alternative to the dual-bolus approach is the dual-sequence method.  The 
dual-sequence approach is simple to use since AIF saturation is avoided at 
the time of image acquisition and it allows optimization of parameters for 
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blood and myocardium. In each cardiac cycle a low-resolution image is 
acquired to measure the AIF with a short saturation-recovery time after the R-
wave. This is then followed by the acquisition of high-resolution images with 
longer saturation-recovery time to measure the myocardial signal with high 
contrast. In order to quantify perfusion, the signals must be converted to 
Gadolinium concentration units (using Bloch simulation look-up table 
correction, and for the arterial input function, also correction for T2* recovery) 
in order to have common scaling between AIF and myocardial signals.  The 
signals can then be convolved - from here, the same deconvolution process 
as described above can be used whereby many simulated curves are 
produced and the best fit curve represents perfusion.  The dual-sequence 
method has been shown to provide accurate measurement of the AIF when 
using high-dose and single-injection protocols and has the potential to 
become the preferred protocol of acquisition131,159,160. Dual-sequence 
protocols are not yet available from all vendors and this is likely to be the main 
factor limiting its application. 
 
3.7.3 High-resolution sequences and quantification 
Important physiological factors could limit the clinical application of 
quantitative perfusion. These factors are mainly related to the spatial 
resolution used for the acquisition and for the analysis of the data.  
Myocardial ischaemia affects the inner (endocardial) layers of the LV wall 
myocardium earlier and more severely than the outer (epicardial) layers161.  
Perfusion CMR has an intrinsically high spatial resolution - higher than 
SPECT and PET. This enables the independent visualization of multiple 
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transmural myocardial layers and therefore visualization of subendocardial 
ischaemia83,162.  Visual assessment enables a highly accurate diagnosis of 
haemodynamically significant CAD90,92,93,163.  Visual assessment exploits the 
high spatial resolution of CMR perfusion images, identifying areas of 
subendocardial delayed and reduced signal intensity relative to the epicardial 
layers and to normal neighbouring segments. Subendocardial localization of 
perfusion defects and the epicardial to endocardial wash-in of signal during 
first pass are features that help to identify true perfusion defects. 
A few studies have demonstrated the advantages of using high-resolution 
perfusion CMR sequences in comparison with standard sequences when 
visual assessment is used to make a diagnosis164,165.  
When segmental quantitative analysis is performed from these high-resolution 
images, the spatial resolution of the images is only partially exploited as the 
signal intensity is sampled from transmural areas of myocardium or from the 
inner (subendocardial) half of the LV myocardium. The time intensity curves 
from subendocardial ischaemic areas are averaged in variable proportions 
with signals originated in more superficial and likely less ischaemic layers, 
resulting in partial-volume effects and reduced sensitivity. 
In order to preserve the improved spatial resolution enabled by CMR when 
quantifying, high-resolution quantification has been proposed by Zarinabad 
and Chiribiri et al.166 and by Hsu et al.140.  High-resolution, voxel-wise 
myocardial perfusion quantification allows for the detection of subendocardial 
perfusion abnormalities and offers additional information on the heterogeneity 
of myocardial perfusion. Moreover, the combination of absolute quantification 
and preserved high-resolution has the potential to allow calculating the true 
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ischaemic burden (a combination of severity and extent of myocardial 
ischaemia), limiting partial volume effects or the influence of other factors 
such as the geometry of the LV wall.  This is particularly important in patients 
with LV hypertrophy or previous infarcts. Moreover, high-resolution, voxel-
wise quantification has the potential to enable quantitative perfusion 
assessment also in patients with heart failure, regardless of remodelling and 
thinning of the LV wall.  
A potential limitation of high-resolution, voxel-wise quantification is the low 
signal-to-noise ratio typical of high-resolution datasets. This could result in 
inaccuracies of myocardial blood flow quantification or make quantification 
impossible. Simulations performed on patients’ data however have shown that 
voxel-wise analysis offers the most accurate diagnostic results and that the 
potential loss of diagnostic information due to the decreasing signal-to-noise 
ratio is counterbalanced by preserving the spatial information regarding 
presence and distribution of ischaemia144. 
 
3.7.4 Factors limiting the clinical translation of quantitative 
perfusion 
Over recent decades perfusion CMR imaging sequences have become more 
sophisticated.  This has offered the ability to visually assess perfusion 
abnormalities more precisely.  In parallel, various dosing regimes, acquisition 
protocols and analysis algorithms focusing on quantitative analysis have been 
developed.  Despite validation of perfusion CMR quantitative analysis against 
invasive measures such as FFR82,152,167,168, against microspheres140,155 and 
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more recently against PET111-113 there remain very few patient studies in the 
literature. Quantitative perfusion analysis is superior to visual assessment in 
the evaluation of patients with advanced multi-vessel CAD120.  Further  study 
on other patient groups is warranted to establish further beneficial applications 
of quantification. More recently, Mordini et al. have shown that quantitative 
stress perfusion CMR outperforms semi-quantitative measures of perfusion 
and visual assessment in comparison with quantitative coronary angiography. 
These findings suggest a potential clinical role for quantitative stress perfusion 
CMR169. 
The main obstacle to more widespread implementation of quantitative 
perfusion CMR is the lack of standardisation.  There is heterogeneity in 
acquisition and dosing protocols, analysis methods and software available for 
post-processing across centres.  There is now a reasonable body of work to 
support a standardized approach to drive this forward. Table 1 summarises 
the evidence from the literature on quantitative perfusion CMR (shown at end 
of chapter).   
This table underlines the limited number of studies including human subjects 
assessed with quantitative analysis and the heterogeneity of reference 
standards and deconvolution algorithms. Most of these studies included 
healthy volunteers and appraised the technical feasibility of quantitative 
perfusion rather than the clinical usefulness. 
From the point of view of acquisition, dual-bolus protocols can already be 
used in most centers without the need to acquire new software or hardware, 
with the drawback of a slightly higher complexity in the preparation of the 
scan. Dual-sequence protocols are simpler to implement and have the 
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potential to become the preferred acquisition protocol for quantitative 
perfusion assessment but widespread use remains limited by availability of 
specialized hardware on cardiac scanners. 
While Fermi function modelling appears to be the most accurate method for 
model-independent deconvolution and the optimal analysis parameters have 
been validated141,144, each centre relies on a different implementation, custom 
filtering and modelling parameters. Moreover, the lack of commercial software 
is road-blocking for centres that do not have significant expertise in signal 
processing and the capability to build their own software tools. This is coupled 
with the need for expertise to implement a robust approach to quantitative 
analysis in a centre.  Arguably the development of a standardized approach 
would enable user-independent, and ultimately more reproducible analysis, 
which would be less reliant a clinician with years of experience.  
High-resolution, voxel-wise perfusion assessment enables the assessment of 
the true ischaemic burden and is soon likely to become the preferred method 
for quantitative CMR perfusion analysis, particularly if coupled with full LV 
coverage enabled by 3D perfusion sequences170-172.  The optimal diagnostic 
criteria to recognize prognostically relevant ischaemia using these novel 
methods will need to be explored further with clinical studies. 
 
3.7.5 In-line quantitative myocardial perfusion mapping 
Since publication of this review, Peter Kellman's group has reported an 
important development in perfusion quantification.  This uses a dual sequence 
approach and runs on the MRI scanner.  It is able to produce fully automated, 
high-resolution (voxel-wise), almost instantaneous (within 1.5 minutes) MBF 
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maps.  The process is implemented via the open-source Gagetron 
framework173 and integrated inline on the scanner with motion-corrected 
perfusion images to produce stress, rest and MBF maps without any user 
interaction.  
This method has been validated in an MRI phantom, small numbers of healthy 
volunteers and patients. It has been shown to be feasible and reliable with low 
variability of calculated perfusion estimates159.  One study used a phantom to 
validate signal correction159, and tested the method in healthy volunteers159. A 
second study (previously described above) by Engblom et al.113 compared 
perfusion measurements from PET to CMR.   
This analysis pipeline is currently only deployed on selected scanners and is 
currently only available via one scanner provider.  Nevertheless, this 
development has the potential to make perfusion quantification significantly 
simpler, faster and available to less expert centres and will be a major step in 
the more widespread use of quantitative perfusion CMR clinically.   
 
3.8 Conclusion 
Accurate quantification of perfusion has been the goal of many investigators 
for over two decades.  Over this period, numerous imaging protocols, contrast 
agent dosage schemes and analysis methods have been developed.  
Regrettably, this has resulted in a lack of standardization which has hindered 
more widespread application, including multi-centre collaboration and 
comparisons.  Quantification has been well validated against a number of 
invasive and non-invasive methods. The recent development of rapid, fully 
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automated quantification of perfusion represents a significant step towards 
translation to the clinical setting.   
 
Part of this chapter consists of work that has been published:   
Sammut, E., Zarinabad, N., Vianello, P., Chiribiri, A. 
‘Perfusion quantification – where are we now?’  
Current Cardiovascular Imaging Reports, 2014 (http://doi 10.1007/s12410-014-
9278). 
Eva Sammut is first author on the publication and was responsible for literature 





Table 1 - Summary of Pubmed results on quantitative perfusion CMR (2014) 
Author, Reference  Number of human subjects  Reference standard 
used  
Deconvolution method used  Key findings  
 
Miller et al.  
JCMR 2014112  
9 patients with significant 
CAD, 9 healthy volunteers 
Rubidium-PET (patients 
only) 
Fermi function deconvolution, 
TSVD, first-order Tikhonov 
regularisation with b-spline  
Complex quantification gives 
similar MBF estimation compared 
to simple factors such as AIF 
location and inter-observer 
variability. 
Under-estimation of estimated MBF 
with deconvolution compared to 
PET findings. 
 
Mordini et al.  
JACC Imaging 
2014169   
 
 
67 patients referred for 






Fermi function deconvolution 
 
Fully quantitative analysis has high 
diagnostic accuracy for detecting 
obstructive coronary artery disease 
and outperforms semi-quantitative 
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measures and qualitative methods.  
 
Chiribiri et al.  
JACC Imaging 
2013129  
67 patients referred for 
assessment of myocardial 
ischaemia, training group 
30 patients  
Invasive coronary 
angiography with FFR 
(in vessels with visual 
stenosis >50%) 
N/A  Transmural perfusion gradients 
threshold of 20% has similar 
accuracy to visual assessment 
Significant correlation with FFR 




Morton et al.  
JACC 2012111  
 
41 patients referred for 







Fermi function deconvolution 
 
Good correlation between 
myocardial perfusion reserve PET 
and CMR and similar accuracy in 
detecting significant stenosis. 
Weak correlation between absolute 





Zarinabad et al.  
MRM 2012141  
 
5 patients with suspected 
CAD, 2 healthy volunteers  
Invasive coronary 
angiography 
Fermi function, b-spline, 
exponential, ARMA deconvolution 
Voxel-wise quantitative analysis is 
feasible and can detect areas of 
abnormal myocardial perfusion.   
Highest error seen with B-spline 
method.  Fermi most robust 
method to noise.    
 
Hsu et al.  
JACC 2012140 
 
5 patients with confirmed 
CAD, 1 healthy volunteer 
Invasive coronary 
angiography 
Model-constrained deconvolution Myocardial blood flow can be 
quantified on a pixel-level.  





Patel et al.  
JACC 2010120  
 
 
41 patients with abnormal 







Fermi function deconvolution 
 
 
Quantitative analysis differentiates 
moderate from severe coronary 




Papers using quantitative perfusion CMR in human subjects from Pubmed. The list of studies was retrieved using the 
following query: “("heart"[MeSH Terms] OR "heart"[All Fields]) AND ("perfusion"[MeSH Terms] OR "perfusion"[All Fields]) AND 
“deconvolution”[All Fields]” – last interrogation 17 April 2014. 
 
 
Improved inter-observer agreement 
with quantitative compared to 
visual assessment. 
Cullen et al.  
JACC 1999174 
20 patients with 
angiographically proven 
CAD;  
5 normal volunteers 
Invasive coronary 
angiography 
Tracer kinetic model  Possible to differentiate normal 
subjects from patients with CAD 
and may help decide significance 











This chapter will consider the use of perfusion CMR in the setting of heart 
failure.  The evaluation of myocardial perfusion status in patients with HF can be 
challenging due to the LV remodelling and wall thinning, the presence of scar, 
and respiratory artefacts.  
In this chapter we present a study of the use of high-resolution quantitative 
perfusion CMR in patients with heart failure, who have thinned and remodeled 
ventricles.  We have put forward the hypothesis that, using higher spatial 
resolution sequences combined with higher resolution analysis, the assessment 
of quantitative perfusion is feasible – meaningful and reproducible - even in 
patients with heart failure with thin walled and remodeled ventricles. Eva 
Sammut is first author on the publication and contributed to the study design, 
experimental work and draft/review of the manuscript.  
 
4.2 Aetiology of heart failure  
Around 900,000 individuals in the UK currently have heart failure and almost as 
many patients have evidence of damaged hearts while not displaying the clinical 
features of heart failure.  The recorded incidence and prevalence of heart failure 
have been steadily increasing. This is due to a combination of improved 
diagnostic tests and better treatment, and survival, of patients with acute 
myocardial infarction as well as an ageing population generally.   
Heart failure is a complex clinical syndrome produced by impaired pumping or 
compliance of the heart.  This leads to failure in the form of either reduced 
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ejection fraction (HFrEF) or with preserved ejection fraction but reduced 
relaxation (HFpEF).  Either will produce the same collection of clinical signs and 
symptoms with evidence of fluid overload but the underlying pathophysiology is 
significantly different. HFpEF is attracting increasing interest, but the bulk of 
previous work has focused on HFrEF and this is most pertinent to the work of 
this thesis and will be considered here – henceforth, the term heart failure will be 
used to refer to HFrEF.   
 
4.2.1 Ischaemic cardiomyopathy 
The most common cause of heart failure is coronary artery disease – namely 
ischaemic cardiomyopathy. Occlusion of a coronary artery causes scarring of 
the ventricular wall and this region will not contract normally, resulting in 
reduced pumping action of the heart.  The concept of myocardial ‘stunning’ is 
worth mentioning – an area supplied by an occluded artery will, in the acute 
phase after revascularisation, be hypocontractile and when re-examined at a 
later stage will show signs of partial or complete improvement.  Myocardial 
‘hibernation’ is also recognised - an ischaemic region will downregulate its 
contraction in order to match its function to the reduced available oxygen.  As 
discussed previously, the subendocardium is most susceptible to ischaemic 
insult and the scar pattern seen in ischaemic cardiomyopathy reflects this with a 
pattern of late gadolinium enhancement extending from the subendocardium to 
transmural in regions supplied by a coronary artery.  The specific segments 
supplied by each coronary artery can vary from person to person but are fairly 




   Figure 4.1 - Schematic diagram showing the typical distribution of myocardial territories 
Schematic diagram showing the typical distribution of myocardial territories according to coronary artery 
in AHA 16-segment model.   




Late gadolinium enhancement imaging is used to identify the radial and 
transmural extent of scar. This allows assessment of viability if revacsularisation 
is performed i.e. the likelihood of recovery of a segment with impaired 
contractility.  The concept of viability is based principally on a paper by Kim et 
al.181.  This used an instrumented canine model to investigate the association 
between transmurality of scar and recovery after revscularisation.  They 
demonstrated that in those with <25% transmurality LGE there was good 
functional recovery, but that >75% transmurality there was poor recovery, with 
an almost 50:50% chance of recovery in those with around 50% transmurality as 





Figure 4.2 – Bar graph of relationship between LGE and improvement in 
contractility after revascularization 
Bar graph showing relationship between transmural extent of LGE before 
revascularisation and likelihood of improved contractility after 
revascularisation (804 dysfunctional segments, 462 segments with at least 
severe hypokinesia and 160 segments with dyskinesia or akinesia) 
         Adapted from Kim et al.181  
 
4.2.2 Non-ischaemic cardiomyopathy 
Non-ischaemic cardiomyopathies encompass a range of non-coronary related 
conditions which also cause impairment of systolic function.  This term 
encompasses: idiopathic dilated cardiomyopathy; alcohol or toxin related 
cardiomyopathy; or genetically induced dilated cardiomyopathies. The pattern of 
scar in non-ischaemic cardiomyopathies differs from that seen in ischaemic 
cardiomyopathy.  One may find no late gadolinium enhancement or there may 
be mid or epicardial scar or fibrosis at the superior and/or inferior LV-RV 
insertion points.  In addition, if scar is present it will not correspond to a coronary 
artery territory.   
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Morphologically, aside from scar, in both ischaemic and non-ischaemic 
cardiomyopathy there is progressive chamber dilatation which may lead to 
functional valvular regurgitation.  Typically, there is thinning of the ventricular 
wall thickness with overall increase in LV mass – a process known as eccentric 
remodelling.   
 
4.3 Perfusion CMR in heart failure 
4.3.1 Spatial resolution 
Within the field of perfusion CMR, several technical developments have refined 
the sequences. The use of an advanced sequence such as kt sensitivity 
encoding and a 3-Tesla scanner allows considerable improvement in spatial 
resolution with improved image quality, signal-to-noise, contrast-to-noise and 
reduction in the transmural extent of dark-rim artefacts compared to standard 





Figure 4.3 - Schematic showing importance of a high resolution technique 
in patients with heart failure 
Schematic showing importance of a high resolution technique in patients 
with heart failure with thinned ventricular walls - A – Shows a normal left 
ventricular thickness where both standard and high resolution CMR are able 
to differentiate the myocardial layers, B – Shows reduced left ventricular wall 
thickness to demonstrate that a higher resolution technique is better able to 
appreciate these layers.  
 
 
4.3.2 Voxel-wise analysis 
Furthermore, advances in the quantification methods have allowed analysis on a 
voxel, rather than segmental level.  This approach has the potential to capture 
more detailed information on the location, extent and transmurality of coronary 
perfusion with less impact from spatial averaging effects but comes with 
possible compromise of lower signal to noise.   
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A previous study by Schuster et al. used an explanted porcine model to evaluate 
a voxel-wise approach and high-resolution CMR sequence compared to 
microspheres, the invasive reference of coronary perfusion184.   It was shown 
that this was feasible and was able to distinguish between normal and 
hypoperfused myocardium.  The values obtained for segmental analysis 
compared well to microsphere data at both 1.5- and 3-Telsa The same group 
used an explanted pig heart model to investigate the different deconvolution 
quantification algorithms using a voxel-wise approach and found that all 
methods appear to correlate well with MBF by microspheres.  Others studied 
patients with voxel-wise perfusion and compared results to PET and found that 
all methods compared similarly though all underestimated MBF compared to 
PET111-113.  In a study by Hsu et al. an experimental canine model was used to 
evaluate voxel-wise perfusion maps and again showed correlation though a 
degree of under-estimation compared to microsphere data.  In the same study, 
a group of patients with significant CAD showed regional blood flow decreases 
and transmural perfusion gradients in territories served by stenotic coronary 
arteries140.  In a more recent study, Villa et al. used a high-resolution imaging 
sequence and analysed patients with hypertrophic cardiomyopathy using voxel-
wise perfusion assessment combined with voxel-wise scar correction and 
showed that this combined approach improves sensitivity of detection of 
quantitative perfusion analysis by reducing the under-estimation of MPR through 
scar-related hypoperfusion185.  
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4.3.3 Respiratory artefacts 
Perfusion assessment in patients with HF can be further complicated by a well-
recognised irregularity in respiratory motion and reduced tolerance to breath-
holding186-188.  These are also key components to obtaining diagnostic-quality 
images.  In a study by Morton et al.164 whilst showing that visual analysis was 
superior with a higher-resolution sequence with better image quality, signal to 
noise and contrast to noise, there was a non-significant trend towards more 
respiratory artefact with the high-resolution sequence.    
 
4.4 Feasibility of high-resolution quantitative perfusion 
analysis in patients with heart failure 
The combination of a high-resolution sequence with voxel-wise quantification 
has the potential to assess perfusion even in the context of reduced LV wall 
thickness however it has been raised as a concern that respiratory artefacts 
may limit the use of these sequences in heart failure patients.  We recognised 
the importance of a specific study into the use of perfusion quantification in this 
group of patients. Our aim, in the following study was to test the feasibility of 3T 
kt high-resolution and voxel-wise quantitative perfusion CMR in a group of 
patients with heart failure. 
 
4.4.1 Methods 
We identified a group of patients referred for perfusion CMR to assess HF 
aetiology. Consecutive patients from one scanner at our site were selected 
where a dual bolus contrast regime and stress and rest images were acquired.  
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Patients were then retrospectively classified on the basis of the aetiology of HF 
as ischaemic (LVEF<50% with scar arising from the subendocardium or 
transmural in a location corresponding to a coronary territory) or non-ischaemic 
(LVEF<50%, either no scar or mid-myocardial or epicardial scar 189. A group of 
patients with normal LV function (LVEF >50%) referred with suspected coronary 
artery disease were used as control subjects. Patients with normal LV function 
and ischaemic cardiomyopathy included underwent a coronary angiogram either 
before or after the CMR scan.   
All included patients provided written consent (09/H0802/78) and the study was 
conducted in accordance with the Declaration of Helsinki. 
4.4.1.1 Imaging parameters 
Images were acquired on a Philips Achieva 3T (TX) system, equipped with a 32-
channel cardiac phased array receiver coil (Philips, Best, the Netherlands). First 
pass perfusion imaging consisted of a high-resolution kt turbo-gradient echo 
sequence (imaging parameters: shortest echo time (range 1.35 to 1.54ms), 
shortest repetition time (range 2.64 to 3.12ms), 18° flip angle, 90° saturation 
prepulse, 120ms prepulse delay, typical TR 2.6ms, typical TE 0.9ms, typical 
spatial resolution 1.2x1.2x10mm.   
Three short-axis slices (basal, mid and apical) were acquired during each 
heartbeat, covering 16 of the standard myocardial segments (segment 17 was 
excluded). Stress imaging preceded rest imaging by 14±2min (range 10 to 19 
min). To acquire stress imaging, 140 g/kg/min of adenosine was administered 
intravenously for 4 min. Imaging commenced 3 min into the infusion and 
continued during the acquisition of the images. Perfusion data was acquired 
during first pass injection of 0.075mmol/kg Gadobutrol (Gadovist, Schering, 
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Germany) at 4ml/minute followed by a 20ml saline flush.  A dual bolus contrast 
agent scheme was used to correct for signal saturation of the arterial input 
function as previously described130.  The CMR scan protocol included late 
gadolinium enhancement imaging for all subjects after a top up dose of contrast 
agent to a total dose of 0.2 mmol of gadolinium/kg of body weight in accordance 
with SCMR guidelines190.  
4.4.1.2 Visual analysis  
The studies were analyzed visually by two independent experts blinded to all 
other data.  CMR scans were classified positive for ischaemia in the presence of 
a perfusion defect (>60 degrees in either the basal or mid-ventricular slices, or 
>90 degrees in the apical slice) which was transmural, or involving 2 adjacent 
myocardial segments according to the criteria set out by Hussain et al.95.  In 
cases of disagreement, the observers reviewed the images together and a 
consensus was reached.  Late gadolinium enhancement and rest perfusion 
scans were then used to differentiate between stress-induced perfusion 
abnormalities and scar-related perfusion defects.  
4.4.1.3 Quantitative analysis  
An experienced operator, blinded to visual assessment and other clinical data, 
performed quantitative analysis using software and methods developed and 
previously validated against phantom and PET data111,141.  The implementation 
of high-resolution signal intensity (SI) analysis required accurate respiratory 
motion correction and myocardial contour delineation. Respiratory motion was 
corrected using affine image registration by maximization of the joint correlation 
between consecutive dynamics within an automatically determined region of 
interest. A temporal maximum intensity projection was calculated to serve as a 
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feature image for automatic contour delineation. The operator then manually 
optimized the automatically generated contours to avoid partial volume effects at 
the endocardial and epicardial border, as previously described147.  Areas of 
subendocardial dark-rim artefact occurring at the point of arrival of the main 
bolus of contrast agent in the LV were carefully selected and excluded from the 
segmentation. 
 
Quantitative perfusion analysis was performed by Fermi deconvolution 
according to the methods described by Wilke et al.142 and Jerosch-Herold et 
al.143 where time curves for the tissue impulse response function,  h(t), were 
fitted to the Fermi function with the following analytical expression: 
h(t) = R [
1
e(t−τ0−τd)k + 1
]  u(t −τd) 
using a Marquardt-Levenberg nonlinear least square algorithm by letting  k, R 
and  τ0 vary and keeping τd fixed. In the above equation u(t −τd) is the unit 
step function. The  τd accounts for the delay time between the appearance of 
the signal in the LV blood pool and myocardial region of interest (ROI)166.  τ0 
characterizes the width of the shoulder of the Fermi function during which little 
or no contrast agent had left the ROI. R is the index of contrast agent influx 
parameter and k  represents the decay rate of   h(t)  due to contrast agent 
washout. Using the above equation, myocardial blood flow (MBF) estimates are 
calculated as h(t) at t = 0. 
Myocardial perfusion reserve (MPR) was calculated by division of stress 
perfusion rate by rest perfusion rate.  
In addition, voxel-wise MPR results from the epicardial half (outer 50% 
transmural thickness) and from the endocardial half of each segment (inner 50% 
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transmural thickness) were averaged and the endocardial to epicardial CFR 
ratio (endocardial MPR/epicardial MPR) was calculated. 
 
4.4.1.4 Image quality  
A visual score was given for image quality of each dataset using a four-point 
scale: 1—poor, 2—fair, 3—good, and 4— excellent. The severity of respiratory 
artefacts and dark rim artefacts were also scored on a four-point and three-point 
scale respectively.  For respiratory artefacts:  1 – non-diagnostic; 2 – severe 
artefacts but diagnostic; 3 – mild artefacts; 4 – no artefacts.  For dark rim 
artefacts: 1 - circumferential; 2 - segmental; 3 - absent.  
  
4.4.1.5 Statistical analysis  
Data is presented as mean and standard deviation. Group means were 
compared using paired and unpaired Student t test and 1-way ANOVA as 
appropriate. The statistical analyses were performed using PASW software for 
Macintosh (IBM, Chicago, Illinois, version 21).  Mann-Whitney and Chi-squared 
tests were used to test the qualitative measurements for statistical significance, 
with a p value threshold of 0.05. 
 
4.4.2 Results 
A total of 91 subjects were studied.  This included 58 patients with HF (LVEF 
39±10%) and 33 patients with normal LV function (Normal LV group) (LVEF 
64±5%). In the HF group, on the basis of the CMR scan, 30 patients (51.7%) 
had a final diagnosis of ischaemic cardiomyopathy (ICM) and the remaining 28 
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subjects had a final diagnosis of non-ischaemic cardiomyopathy (NICM). 
Demographics and CMR structural findings are given in in Table 2 (shown at 
end of chapter).  
 
4.4.2.1 Visual analysis 
In the ICM group, 25/30 (83%) patients showed evidence of a perfusion 
abnormality. Of these 19/25 (76%) patients showed stress-induced perfusion 
abnormalities, either extending beyond an area of scar or in an area served by a 
separate coronary territory. On segmental analysis, there were 73 segments 
showing stress-induced perfusion abnormalities (4.06±2.05/patient). 90 
segments showed scar-related perfusion abnormalities (4.29±2.13/patient). 
In the NICM group, no visual perfusion abnormalities were reported and 7/28 
patients (for a total of 25 segments) showed late enhancement with a non-
ischaemic-pattern189. 
15/33 (46%) patients in the Normal LV group showed stress-induced perfusion 
abnormalities, with a total number of 105 positive segments (6.4±4.5/ patient). 
No patients from the Normal LV group showed scar on late gadolinium 
enhancement images. 
 
4.4.2.2 Quantitative analysis 
4.4.2.2.1 Stress and rest perfusion estimates 
Detailed results of stress and rest quantitative analysis are reported in Table 3 
(shown at end of chapter).  No significant difference in visually normal segments 
was observed between groups, with an average stress perfusion rate of 
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2.2±1.0ml/g/min in the ICM group, 1.9±0.8ml/g/min in the NICM group and 
2.3±1.3ml/g/min in the Normal LV group (p= 0.18).  
In the ICM group, there was a significant difference in stress perfusion rate 
between visually normal and abnormal non-scarred segments (2.2±1.0ml/g/min 
vs 1.8±0.9ml/g/min, p=0.02).  The presence of ischaemic scar was associated 
with significantly reduced perfusion rate compared to visually normal segments 
(1.5±0.8ml/min vs 2.2±1.0ml/g/min; p=0.005).   
Within the Normal LV group, the difference in stress perfusion rate between 
visually normal and abnormal non-scarred segments was less pronounced and 
not statistically significant (2.3±1.3ml/g/min vs 1.6±0.8ml/g/min, p=0.08).   
There was no significant difference in stress perfusion values between the ICM 
and Normal LV groups in visually abnormal segments (p=0.47).    
Examples of high-resolution, voxel-wise perfusion maps are given in Figure 4.4 










Figure 4.4 - Perfusion images from a heart failure patient 
Images from a heart failure patient with a circumflex artery lesion causing a 
perfusion abnormality extending from base to mid to apex (from top to bottom 
row).  Images in column B show perfusion images, column D shows perfusion 
maps, column C shows the superimposed images.  Column A shows the 
corresponding late gadolinium enhancement images.  Note the respiratory 
artefact (orange arrows).  
 
 
Figure 4.5 - Perfusion images seen from three different heart failure patients 
Perfusion images seen from three different heart failure patients (rows A-C).   
Acquired CMR perfusion image in second column, perfusion map in far right column and 
superimposed images in third column  Corresponding late gadolinium images in far left 
column. Row A shows thinning of the mid inferior wall with matched ischaemia in the 
territory of the RCA, Row B shows a perfusion defect in the LAD territory matched to 
subendocardial scar.  Row C shows homogenous perfusion in a patient with a dilated and 




4.4.2.2.2 Myocardial perfusion reserve 
Detailed results of MPR analysis are also reported in Table 3 (shown at end of 
Chapter).   
No significant difference in visually normal segments was observed between 
groups, with an average MPR of 2.3±0.8 in the ICM group, 2.2±0.9 in the NICM 
group and 2.6±1.1 in the Normal LV group (p= 0.19).   
In the ICM group, there was a significant difference in MPR between visually 
normal and abnormal non-scarred segments (2.3±0.8 vs 1.8±0.9, p=0.04).  The 
presence of ischaemic scar was associated with significantly reduced perfusion 
reserve compared to visually normal segments (1.68±0.08 vs 2.3±0.8, p=0.004).   
Similarly, within the Normal LV group, the difference in MPR between visually 
normal and abnormal non-scarred segments was statistically significant (2.6±1.1 
vs1.7±0.8, p=0.04).   
There was no significant difference in MPR values between the ICM and Normal 
LV groups in visually abnormal segments (p=0.62).    
 
4.4.2.2.3 Endocardial-epicardial CFR ratio 
There was no significant difference in the endo-epi MPR ratio in visually normal 
segments across groups with an endo-epi MPR ratio of 1.05±0.16 in ICM 
patients, 1.02±0.04 in NICM patients and 1.00±0.06 in Normal LV patients 
(p=0.57).    
There was a significant difference in endo-epi CFR ratio between visually 
normal and visually abnormal non-scarred segments in both the ICM and 
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Normal LV groups (ICM group: 1.04±0.09 versus 0.96±0.12 respectively, 
p=0.02; Normal LV group: 1.00±0.05 versus 0.93±0.06 respectively, p=0.02).  
 
4.4.2.3 Coronary angiography 
The results of invasive coronary angiography and perfusion CMR in relation to 
coronary artery territories, including Kappa results, are detailed in Table 4. 
 
4.4.2.4 Image quality  
Detailed results of overall image qualitative assessment, respiratory arterfacts 
and dark rim artefacts are given in Figure 4.7 and in Table 5 below.  No 
significant differences were observed between groups.  The average angular 
extent of dark rim artefact was 27° (range 9-41°). 
 
 
   Figure 4.6 – Figure showing the relative scores for image quality 
Figure showing the relative scores for qualitative image quality, respiratory 





Table 5 - Table showing results of the Chi-squared tests for qualitative 
assessment of image quality according to group 
 
 Chi-square  
 
P value  












4.4.3 Discussion  
This study revealed a number of novel findings. Most importantly, it 
demonstrated the feasibility of quantitative first-pass perfusion analysis in 
patients with heart failure using a combination of high-resolution kt 3T 
acquisition methods and high-resolution voxel-wise quantification. There were 
significant differences of MPR between visually normal and abnormal segments 
in both ICM and Normal LV groups. In the ICM group stress perfusion values 
were also statistically significant between visually normal and abnormal 
segments. This was not the case in the Normal LV group. This could be 
explained by the relatively low number of subjects positive for ischaemia 
included in the study. It is in keeping with previous validation studies that 
compared CMR perfusion and PET, showing good correlation for MPR values 
and weaker correlation for absolute stress perfusion values.  This may relate to 
differences in the methods used for quantification such as the tracer properties, 
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model assumptions, fitting methods and parameter constraints. MPR cancels 
out a degree of variability and this may help explain our results132.  
CMR is now well established for the evaluation of patients with coronary disease 
and heart failure.  Perfusion CMR is increasingly used to determine aetiology of 
heart failure and to plan patient management.  Further, CMR is now well 
established for the evaluation of patients with CAD. The detection of ischaemia 
is rapidly becoming one of the main indications for CMR examination108.  
Studies have also shown that even in non-ischaemic cardiomyopathy the 
presence of ischaemia has implications for the occurrence of adverse 
events191,192. 
As described, perfusion CMR has been previously shown to be at least as 
accurate as nuclear perfusion imaging in patients with angina92,93  and 
quantitative perfusion CMR has been validated against FFR82,167, 
microspheres156, Single Photon Emission Computed Tomography (SPECT)127 
and Positron Emission Tomography (PET) 111-113. 
To our knowledge, there are limited studies using quantitative analysis and no 
previous studies focusing on perfusion in patients with heart failure using CMR. 
Only a few studies, using PET, have been performed specifically exploring 
perfusion abnormalities in patients with HF and these have produced conflicting 
results193-195.  Van Den Heuvel et al. studied a group of NICM patients using 
PET and showed a similar perfusion rate at rest but reduced global myocardial 
perfusion reserve (MPR) versus a group of healthy controls193.  In contrast, 
Neglia et al. showed a reduced MPR at rest as well as during pacing and 
pharmacological stress in patients with NICM195.  The concept that, even in 
NICM, the presence of silent ischaemia may contribute to progressive 
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impairment of LV function was supported by the conclusions of a study by Tio et 
al. Patients with NICM were assessed with PET and dobutamine stress196.  In 
this study, MPR was significantly higher in segments with higher contractile 
reserve and lower in the segments which did not change or deteriorated with 
stress.   Our study reveals a trend towards a lower MPR in normal segments. 
Non-invasive assessment of myocardial perfusion in patients with HF can be 
challenging for a number of reasons.  In cases of advanced HF the LV wall is 
often thinner and remodeled, requiring higher spatial resolution for reliable 
identification of subendocardial areas of stress-induced ischaemia or areas of 
peri-infarct ischaemia. PET is considered the reference standard for in-vivo 
quantitative perfusion assessment. However, it is limited by the intrinsically 
lower spatial resolution and this could be an important limiting factor for the 
assessment of dilated and remodelled ventricles. 
Perfusion CMR, and in particular 3T kt, offers higher spatial resolution and 
arguably is best placed to identify areas of ischaemia in these patients. In 
addition, the advantage of CMR over other techniques to directly visualise scar 
enables more precise assessment of peri-infarct ischaemia. This reduces the 
risk of including scarred areas in segmental averages of perfusion. Perfusion 
rate in areas of scar was found to be reduced and this aspect could result in 
false positive ischaemia results. 
We observed a non-significant trend towards lower perfusion rates in visually 
normal segments of patients with NICM, which would be in keeping with the 
results previously obtained by PET.  This comparison is beyond the scope of the 
study and would merit investigation in future work.  
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Importantly, our results demonstrate a significant endocardial-epicardial CFR 
ratio in ischaemic segments, even in patients with HF who have thinned and 
remodelled ventricles. This is in keeping with findings of a study by Parodi et al. 
where microspheres were injected into the hearts of patients at time of 
transplantation, demonstrating the presence of a transmural gradient of 
perfusion even in the presence of extensive LV remodelling197.  To our 
knowledge, our data is the first to show that non-invasive quantification of 
myocardial perfusion in multiple independent layers of myocardium is feasible 
also in this group of patients. 
The kt sequences used in this study are more vulnerable to respiratory artefact 
than are other perfusion sequences.  We did not observe this effect in our study, 
which may be a reflection of good patient coaching and careful selection of the 
time for the breathhold command. 
 
4.4.4 Study limitations  
1) This was a feasibility study. Visual assessment was the only reference 
standard.  Nevertheless, visual assessment is considered the clinical 
diagnostic standard for perfusion CMR evaluation and extensive 
validation is available against Fractional Flow Reserve (FFR), invasive 
angiography, SPECT and PET. 
2) This study consisted of a small number of patients and in some patients 
the degree of heart failure was mild.  By current criteria many would have 
represented patients within the HFmrEF group.  Our results demonstrate 
that a high resolution quantitative approach is feasible in this cohort but 
this cannot be generalised to patients with more severe LV function.  A 
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study exploring the use of this technique in a larger number of patients 
would be needed to explore this further.   
3) Patients included in this study who had normal LV function were referred 
for a CMR on the basis of symptoms or cardiovascular risk factors – 
some had diabetes or hypertension and therefore could not be 
considered a true control group given recognised abnormalities in 
perfusion seen in these patients.    
4) It is not straightforward to extend our results to other CMR sequences 
and field-strengths, or to standard (segmental) quantitative analysis 
methods.  The quantification process may need to be adjusted for other 
field strengths and perfusion sequences and this could form part of future 
work. 
 
4.5 Conclusion  
In summary, the use of perfusion CMR continues to increase and the quality of 
sequence imaging has advanced in parallel.  There are a number of challenges 
in scanning patients with heart failure, namely thinner LV walls, and breathing 
and respiratory artefacts.  The advances in CMR have enabled high resolution 
imaging quality; alongside this the ability to analyse the data on a voxel level 
can potentially overcome some of these challenges.   
The study described demonstrates that the combination of 3T kt high-resolution 
perfusion CMR with high-resolution voxel-wise quantitative analysis appears 
feasible in heart failure patients.  This approach permits preservation of 
additional information gained from improved spatial resolution, a feature of 
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crucial importance in heart failure in order to be able to appreciate sub-
endocardial perfusion defects.  
Part of this chapter consists of work that has been published:   
Sammut, E., Zarinabad, N., Wesolowski, R., Morton, G., Chen, Z., Sohal, M., Carr-
White, G., Razavi, R., Chiribiri, A. 
‘Feasibility of high-resolution quantitative perfusion analysis in patients with heart 
failure’ 
Journal of Cardiovascular Magnetic Resonance, 2015 (https://doi.org/10.1186/s12968-
015-0124-2) 
Eva Sammut is first author on the publication and was responsible for data collection, 
study design, experimental work and draft/review of the manuscript.  
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Table 2 - Table showing demographic data and structural CMR findings for subjects studied 
 





(NLV) group  
P value  
NICM vs 
ICM group  
P value  
NICM vs 
NLV group 
P value  
ICM vs  






65% 82% 67% - - - - 
Age  
(years+/- SD) 
58±14 63±12 54±18 0.78 0.77 0.08 0.79 
BSA  
(m2+/- SD) 
1.86±0.21 1.96±0.19 1.90±0.19 0.27 1.00 0.70 0.27 
LV EDV  
(ml/m2+/- 
SD) 
102±28 112±33 71±18 0.48 <0.0001* <0.0001* <0.0001* 
LV ESV  
(ml/m2+/- 
SD) 
63±26 73±31 25±8 0.16 <0.0001* <0.0001* <0.0001* 
LVEF  
(%+/- SD) 
39±9 37±10 65±4 0.06 <0.0001* <0.0001* <0.0001* 
LV mass 
(g/m2+/- SD) 
73±18 70±18 55±13 1.00 0.001* 0.006* 0.001* 
RV EDV  
(ml/m2+/- 
SD) 
80±22 74±20 72±18 0.88 0.39 1.00 0.30 
RV ESV  
(ml/m2) 
40±20 35±16 28±10 0.54 0.008* 0.24 0.01* 
        
        
        
        
 136 



















Normal vs  
scarred 
segments 




- 0.08 - 




- - - - 






1.5±0.7 0.02* 0.006* 






- 0.83 - 
Rest perfusion NICM group  
(ml/g/min)  
0.90±0.19  - - - - 




1.0±0.4  0.9±0.4 0.25 0.83 
CFR  
Normal LV group  
2.6±1.1 1.7±0.8 - 0.04* - 
CFR  
NICM group 
2.2±0.8 - - - - 
CFR 
ICM group 
2.3±0.8 1.8±0.9 1.7±0.7 0.04* 0.004* 
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Table 4 – Table showing results of coronary angiography versus perfusion results according to group 
 
Group  LAD territory  Cx territory RCA territory 
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5 Prognostic value of quantitative perfusion CMR  
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5.1 Introduction  
This chapter will describe the shift in focus on the ischaemic burden in the 
management of CAD.  This will conclude with the first published study to 
examine the prognostic value of a quantitative approach compared to visual 
assessment.  As faster, more automated, perfusion CMR analysis becomes 
possible, prognostic data is an important component in driving the impetus to 
translate quantitative perfusion CMR to the clinical setting.  This chapter 
includes a large observational study comparing quantitative and visual perfusion 
analysis in terms of their prognostic value.  We proposed that the use of a 
quantitative approach would provide similar or incremental prognostic value 
compared to visual assessment, and potentially over other recognised risk 
factors, due to its ability to objectively identify ischaemia. Eva Sammut is first 
author on the publication and contributed to the study design, experimental work 
and draft/review of the manuscript.  
 
5.2 Ischaemic burden thresholds according to modality 
The mere presence of ischaemia as identified on visual analysis has been 
shown to relate to prognosis.  In recent years the extent and severity of 
ischaemia, the ischaemic burden, have become a focus. 
On the basis of a number of large nuclear studies, ≥10% ischaemic myocardium 
is considered the risk threshold associated with an increase in adverse events.  
Several studies have demonstrated that in patients with a burden of ischaemia 
above this threshold, there appears to be an advantage of revascularization 
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over medical therapy and that a reduction in ischaemia with treatment appears 
to be associated with lower incidence of adverse events62,63,198-202.  
The thresholds of ischemic burden defined by SPECT have been extrapolated 
to other imaging modalities such as CMR and echocardiography. Evidence 
validating these thresholds for CMR is lacking and different studies have applied 
different thresholds95,203.   A meta-analysis by Shaw et al, proposed that for 
stress perfusion CMR, moderate to severe ischaemia could be defined as  >2/16 
AHA segments, >4/32 segments by perfusion MR (This assumes that the 16 
AHA segments are further subdivided into subendocardial and subepicardial 
halves, which yields a total of 32). Using DSMR this threshold is >3/16 
dysfunctional segments203.  
The quantitative approach also requires consideration of the optimal threshold to 
define ischaemia.  There is no consensus on this and it has remained an 
obstacle to clinical application of quantitative CMR.  In a study by Lockie et al. 
MPR measurements by CMR were compared to fractional flow reserve 
measurements and this suggested an optimal cut off of <1.58 to define 
ischaemia, with a sensitivity of 0.80 and specificity of 0.8982.  A similar cut-off 
(<1.5) was also suggested in an earlier study comparing angiographic severity 
of CAD versus semi-quantitative measurements of MPR by CMR124. 
 
Two important studies are will be key in developing specific indications and 
thresholds to be used for cardiovascular imaging in the setting of CAD.  The 
MR-INFORM (MR Perfusion Imaging to Guide Management of Patients with 
Stable Coronary Disease) trial95 randomized patients to be guided for the need 
of revascularization either by CMR or the FFR and showed that guiding the 
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management of patients with suspected CAD based on CMR result was safe 
and resulted in fewer invasive procedures – the full results are awaited.  The 
ISCHEMIA (International Study of Comparative Health Effectiveness with 
Medical and Invasive Approach) trial67 is a large randomized multi-centre study 
designed to further investigate the benefit of revascularization compared to 
medical therapy in those with moderate to severe ischaemia on stress testing by 
SPECT, echocardiography or CMR. This study is still in the recruitment phase 
but will aim to use contemporary non-invasive ischaemia modalities, medical 
therapy and percutaneous techniques to explore once again the impact of PCI 
over medical therapy in light of the controversies and criticisms of previous 
studies and the persistence of the use of PCI for patients with stable angina.  
 
5.3 The importance of cross-modality validation 
A number of important considerations must be taken into account when 
considering the optimal test to assess ischaemia.   
5.3.1 Target 
A comparison of tests which use either dobutamine or vasodilator stress is likely 
to produce differing results due to their differing targets on the ischaemic 
cascade – as discussed in earlier chapters perfusion abnormalities will be more 
extensive and occur earlier in the ischemic cascade whereas regional wall 
motion abnormalities are associated with more severe stenosis and occur later 
in the cascade36.  
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5.3.2 Spatial resolution 
The extent of ischaemia can be imaged both radially and transmurally although 
it is also important to consider the spatial resolution and endocardial definition of 
each technique. This is substantially lower in nuclear imaging techniques and 
echocardiography by comparison to CMR.  Furthermore, within CMR there have 
been substantial improvements in spatial resolution, and therefore of visually-
determined appreciation of subendocardial perfusion defects.  Studies 
employing direct comparison of ischaemic burden by CMR using a standard and 
high-resolution technique, show that the accuracy of MPR is greater with a high 
resolution technique in patients with angiographic three-vessel disease204.  
High-resolution sequences were also better correlated with semi-quantitative 
angiographic scores than standard resolution205.  More recently, analysis of 
these higher resolution images has also been described on a voxel-wise level 
and has compared favourably with the invasive reference of microspheres in an 
explanted pig heart model140,184.  
5.3.3 Inducible versus non-inducible perfusion defects 
The presence of scar can complicate ischaemia assessment.  Scarred areas are 
not considered ischaemic. Assessment of ischaemia in these areas is either 
‘matched’ and therefore considered non-inducible or extends beyond the scar 
and represents peri-infarct ischaemia.  This relies on direct visualization of scar 
and a high spatial resolution, both possible only in CMR. In the clinical setting 
this is usually achieved by simple visual assessment.  Initial studies are 
available that suggest that combined high-resolution assessment of quantitative 
perfusion and late gadolinium enhancement images by CMR is feasible and 
may further improve the technique206.  
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5.3.4 Whole heart coverage 
In the context of assessment of the ischaemic burden it is important to note that 
nuclear techniques provide whole heart coverage whereas in perfusion CMR, 
only three or four short axis, non-contiguous slices are acquired.  This is the 
standard clinical approach; slices which include basal, mid and apical LV are felt 
to provide a representative picture of the left ventricular myocardium.  
Calculation of the total ischaemic burden is therefore an extrapolation using 
CMR and it can be argued that the assessment of ischaemic burden may be 
incomplete and therefore imprecise.  Substantial work has been directed into 
overcoming the numerous technical challenges involved in the acceleration of 
data acquisition without significant loss in image quality. Newer 3D perfusion 
sequences permit whole heart 3D first pass perfusion with all slices being 
acquired at the same point in the cardiac cycle. Initial reports suggest good 
correlation between semi-quantitative angiographic scores, FFR and ischaemic 
burden calculated by 3D perfusion CMR171,172,207.  Compromise in spatial 
resolution is inevitable – wider coverage is exchanged for inferior resolution - 
and one should compare high resolution 2D approach versus 3D whole heart 
perfusion CMR. A study comprising 27 patients performed direct comparison of 
high-resolution 2D and whole heart 3D perfusion CMR (both visually assessed). 
This delivered promising results with a strong correlation and broad agreement 
between 2D and 3D with regard to calculated ischaemic burden208.   Initial 
studies have also shown that quantitative assessment of 3D perfusion CMR is 
feasible and with high diagnostic accuracy170.  Larger datasets and further 
comparison between these approaches are required to explore this further. 
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5.3.5 Field strength  
In the context of CMR there is some evidence suggesting that perfusion CMR is 
more accurate when performed at higher magnetic field strengths – studies 
have shown that at 3T both sensitivity and specificity are improved compared to 
1.5T perfusion CMR. This is likely to be due to improved signal to noise and 
contrast to noise ratios resulting in better detection of subendocardial perfusion 
and reduced occurrence of dark rim artefacts182.  This study was performed 
using visual assessment and would benefit from revisiting with quantitative 
analysis in due course.   
 
5.4 Calculation of ischaemic burden by perfusion CMR 
In the clinical setting perfusion CMR is assessed visually. Although both visual 
and quantitative analysis can provide data on ischaemic burden, visual analysis 
is subject to variation in reader expertise.  The quantitative approach has been 
shown to be less susceptible to inter-observer variation120.  This is particularly 
an issue in multi-vessel CAD. The appearance of balanced ischaemia where all 
segments are hypoperfused can potentially lead the reader to provide a false 
negative result.  Data is now available suggesting diagnostic superiority of 
quantitative CMR perfusion analysis specifically in the setting of multi-vessel 
coronary disease120.  Patel et al. studied a group of 30 patients who had 
undergone a positive nuclear test and were scheduled for coronary 
angiography.  Patients underwent a stress perfusion CMR, using a dual bolus 
approach; quantification was performed by Fermi deconvolution.  In single 
vessel disease >50% severity, quantitative and visual analysis performed 
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similarly (83% versus 80% respectively). Likewise, for single vessel disease 
>70% severity (77% versus 67% respectively). A stepwise reduction in MPR 
was noted with increasing severity of single vessel CAD and the authors were 
able to define cutoff values according to stenosis severity, yielding an area 
under the curve of 0.82 for the detection of CAD >50% (optimal MPR threshold 
1.85) and 0.77 for CAD >70% (optimal MPR threshold 1.55).  Importantly, 
patients with three vessel CAD had a higher burden of ischaemia as assessed 
by quantitative analysis than those with single vessel disease (60% versus 25%, 
p=0.02) whereas no difference could be detected with visual assessment (31% 
versus 21%, p=0.26).  
 
Figure 5.1 - Bar chart showing differences between visual and quantitative 
analysis when considering single or multi-vessel disease  
In single vessel disease, quantitative and visual analysis performed similarly.  In 
contrast, in patients with multi-vessel CAD there was a significant difference 
between the two approaches, favouring quantitative analysis.  
         Adapted from Patel et al.120  
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5.5 Prognostic value of perfusion CMR 
The following section describes an observational clinical study, performed as 
part of this thesis, which compared the prognostic value of quantitative CMR 
perfusion against visual assessment in a group of unselected patients with 
suspected CAD.  
  
5.5.1 Methods  
5.5.1.1 Study design  
Patients with suspected CAD referred on a clinical basis to the King’s College 
London CMR Service at St Thomas’ Hospital (Guy’s and St Thomas’ NHS Trust) 
between January 2009 and January 2015 were considered for enrolment. 
Consecutive patients who underwent a clinical CMR scan comprising 
assessment of cardiac function, ischaemia testing with high-resolution dual 
bolus adenosine stress and rest perfusion imaging followed by late gadolinium 
enhancement (LGE) imaging were included in the study. Patients in whom 
regadenoson was used were excluded from the study since the half-life of the 
drug has the potential to result in the acquisition of rest perfusion images with a 
degree of residual hyperemia, potentially resulting in the underestimation of 
MPR88,89.    
The study was conducted in accordance with the Declaration of Helsinki (2000) 
and was approved by the National Research Ethics Service. All patients 
provided written informed consent. 
The start of the follow-up was defined as the date of the CMR scan. The primary 
endpoint was as a composite of cardiovascular death (defined as death due to 
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myocardial infarction, heart failure or ventricular arrhythmia), non-fatal 
myocardial infarction (MI defined as clinical acute coronary syndrome with 
associated ECG changes and elevation of serum biomarkers of myocardial 
necrosis to >99th percentile of the assay upper limit of normal209, aborted sudden 
cardiac death (SCD, defined as documented ventricular fibrillation or sustained 
ventricular tachycardia with hemodynamic compromise requiring defibrillation or 
cardioversion not associated with acute myocardial infarction), and late 
revascularisation (percutaneous coronary intervention (PCI) or coronary artery 
bypass grafting (CABG) >90 days after the start of follow-up). In order to avoid 
the potential effect of a positive CMR result leading to early revascularisation, 
we excluded procedures within 90 days of the CMR scan from the endpoint 
definition revascularization59,210.  Patients who did not experience events were 
censored at the point of last follow-up. Where patients experienced more than 
one event, only the first event was considered. 
Follow-up was performed through interrogation of electronic patient records and 
patient notes. All events were adjudicated by consensus of three physicians 
blinded to CMR data. Mortality and cause of death were obtained from the 
Office for National Statistics and through review of medical records, death 
certificates and post-mortem data where available. 
5.5.1.2 Image acquisition 
Patients were asked to refrain from nicotine and caffeine-containing foods and 
beverages for 24 hours prior to the scan. Standard 2, 3 and 4-chamber cine 
images were acquired during breath hold. Contiguous short-axis slices were 
acquired from the base to the apex for calculation of left ventricular (LV) 
volumes, function and mass. Following 4 minutes of adenosine (140mcg/kg/min, 
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increased to 210mcg/kg/min if there was an inadequate response211), stress 
perfusion data were acquired in 3 short-axis slices with a saturation-recovery k-t 
sensitivity encoding [k-t SENSE] accelerated gradient-echo method212,  covering 
16 of the standard myocardial segments (segment 17 was excluded). 
A dual-bolus contrast agent scheme was used to correct for signal saturation of 
the arterial input function as previously described130.  In brief, 0.0075 mmol/kg 
gadobutrol (Gadovist, Bayer, Berlin, Germany) was administered as a pre-bolus 
at peak stress with imaging of the arterial input function. First-pass perfusion 
data were then acquired after the injection of 0.075 mmol/kg gadobutrol at 4 
ml/second followed by a 20 ml saline flush. Rest perfusion imaging was 
performed after a minimum of 15 minutes following the stress acquisition prior to 
acquisition of late gadolinium enhancement imaging according to Society of 
Magnetic Resonance (SCMR) guidelines190.   LGE imaging was performed after 
a further dose of contrast agent, to a total dose of 0.2 mmol/kg gadobutrol. 
5.5.1.3 Image analysis  
Ventricular volumes, atrial size, and left ventricular mass were calculated and 
normalized to body surface area (CVI42, v5.1.1, Circle Cardiovascular Imaging, 
Calgary, Canada). Segmental mass was measured in end-diastole and 
expressed as percentage of total LV mass and was used in the calculation of 
the ischaemic burden. 
Visual assessment was performed using stress and rest perfusion and LGE 
images with consensus of two SCMR level III accredited physicians using the 
standard 16-segment AHA model and standardized reporting criteria. Scans 
were reported visually on a clinical basis and therefore baseline clinical data 
were available to the observers performing visual assessment. 
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A perfusion abnormality was defined visually according to the criteria previously 
described in the MR-INFORM (MR Perfusion Imaging to Guide Management of 
Patients with Stable Coronary Disease) study95 as a delayed wash-in of contrast 
persisting for ≥5 dynamics in 1 or more AHA segment compared with normal 
remote myocardium. Since the spatial resolution of CMR allows for appreciation 
of subendocardial versus transmural perfusion defects, each of the 16 AHA 
segments were subdivided into an endocardial and epicardial half resulting in a 
total of 32 segments to allow more accurate calculation of ischaemic burden. 
Segments in which LGE was present were excluded from ischaemia 
assessment.  
Surface coil intensity correction was performed prior to quantification using pre-
contrast imaging data153.  Time signal-intensity curves were extracted using 
commercially available software (CVI42). 
 
Quantitative analysis was performed blinded to baseline clinical data.   
Quantitative perfusion analysis was performed by Fermi-constrained 
deconvolution according to the methods described by Wilke et al.142 
 and Jerosch-Herold et al.143 where time-signal intensity curves for the tissue 
impulse response function, h(t), were fitted to the Fermi function using a 
Marquardt-Levenberg nonlinear least squares algorithm according to the 
following analytical expression: 
 
by letting k, R and τ0 vary and keeping τd fixed. In the above equation, u(t − τd) 
is the unit step function. The τd accounts for the delay time between the 
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appearance of the signal in the LV blood pool and myocardial region of interest 
(ROI). τ0 characterizes the width of the shoulder of the Fermi function during 
which little or no contrast agent had left the ROI. R is the index of contrast agent 
influx parameter and k represents the decay rate of h(t) due to contrast agent 
washout. Using the above equation, myocardial blood flow (MBF) estimates are 
calculated as h(t) at t=0. Myocardial perfusion reserve (MPR) was calculated as 
the ratio between stress and rest MBF estimates166.    
Ischaemia was defined as segments with MPR<1.5, according to previously 
validated criteria82.  
5.5.1.4 Statistical methods 
The statistical analysis was performed by two of the authors (SS and TI). Data 
for categorical variables are presented as frequencies and percentages. Data 
for continuous variables are presented as mean±standard deviation (SD) or as 
medians and interquartile range (IQR) depending on normality. The study cohort 
was stratified according to the presence or absence of events during follow-up. 
Differences between categorical variables were evaluated using Fisher’s exact 
test. Comparisons between continuous variables were performed with the 
independent samples Student t-test or using the Wilcoxon rank-sum test as 
appropriate. Two-tailed p values <0.05 were considered significant. 
Survival risk classifiers were built using a penalized Cox proportional hazards 
models with L1-(Lasso) penalty. Double-loop cross-validation with 500 re-starts 
was used to obtain robust unbiased estimates of predictive strength as outlined 
by Simon et al.213.  A baseline model was built containing established prognostic 
variables - age, gender and LGE - as un-penalized independent variables. LV 
ejection fraction (LVEF), revascularisation within 90 days and pre-scan 
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revascularization also entered the baseline model and were subject to 
penalization214. None of these penalized variables were found to provide 
predictive information, and therefore were not retained in the final model 
specification. The baseline model was then extended to include the visual 
ischaemic burden or MPR ischaemic burden. The predictive performance of the 
resulting enriched models was evaluated by 10-fold cross-validation with 500 re-
starts213.  Survival probabilities were derived for each patient for the 2-year time 
point. The 2-year time point was chosen on the basis of ≥75% cohort having 
follow-up of 869 days (2.4 years). Cross-validated receiver-operator 
characteristic curves were created for each model at 2 years and the associated 
cross-validated area under the curve (AUC) determined215.  Patients were 
classified into the three categories: low (<1%), intermediate (1-3%) and high 
(>3%) risk as specified by current ACC guidelines216.  Cross-validated 
categorical net reclassification improvement (NRI) and integrated discrimination 
improvement (IDI) reclassification metrics were then computed for the two 
perfusion models in relation to the baseline model217.  
After establishing the independent predictive value of each measure of perfusion 
as a continuous covariate, the perfusion measures were dichotomized using a 
threshold of ≥2 segments for visual ischaemia and ≥10% for ischaemic MPR203.  
Model performance was re-assessed as previously using cross-validated Cox 
regression and reclassification metrics for the 2-year time point. 
Kaplan-Meier-curves were produced for time to the composite endpoint to 
visualize the discriminative power of LGE and perfusion measurements.  
All statistical analysis was performed with R version 3.3.0 (R Core Team 
(2016)). 
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5.5.2 Results 
A total of 434 patients met the inclusion criteria: 24(5.5%) were lost to follow-up 
and 15(3.5%) were excluded due to poor image quality. The baseline clinical 
and CMR characteristics of the final cohort of 395 patients stratified by event 
status are listed in Table 5. Patients tended to be middle-aged (58±13 years), 
mostly male (70%), with the majority having known hypertension (59.5%), 
hypercholesterolemia (54.7%) and approximately one in five had diabetes 
(19.7%). About one third of the patients had had previous revascularisation 
either by PCI or CABG. About one third (34.9%) of the patients had stress-
induced perfusion abnormalities on visual assessment and 35.4% were positive 
for LGE. In total, 40 patients underwent revascularisation within 90 days (7 
CABG, 33 PCI, median 30 and 36 days respectively post CMR) and these 
events were excluded from subsequent analysis. 
The median follow-up was 460 days[IQR 190-869]. Overall, 52 patients met the 
primary endpoint: 39 patients underwent revascularisation after 90 days (23 
elective PCI for stable angina, median 196 days after CMR[IQR 135-240]; 5 
unplanned PCI due to unstable angina, 220 days after CMR[IQR 140-704]; 10 
patients underwent elective CABG, 188 days after CMR[IQR 148-282]), 1 
patient had unplanned CABG due to unstable angina, 190 days after CMR). 
Other events consisted of non-fatal MI in 7 cases, 896 days after CMR[IQR 56-
1160] (leading to unplanned revascularisation in 3 subjects), 4 cardiovascular 
deaths, 508 days after CMR[IQR 186-856] and 2 aborted SCD at 16 and 443 
days after CMR. 
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The baseline cross-validated Cox regression model found the linear predictors 
to be age, gender and LGE as follows: 
~0.025 ∗ age + 2.993 ∗ gender + 0.616 ∗ LGE  
 
The addition of visual ischaemic burden as a continuous covariate yielded a 
linear predictor of: 
~0.028 ∗ age + 3.108 ∗ gender + 0.563 ∗ LGE +  1.423 ∗ visualischaemic burden 
The corresponding model for MPR ischaemic burden as a continuous covariate 
was: 
~0.02 ∗ age + 2.722 ∗ gender + 0.678 ∗ LGE + 2.490 ∗ MPRischaemic burden 
 
 
The addition to the baseline model of dichotomized visual ischaemic burden 
using a threshold of ≥2 segments yielded a model of: 
~0.019 ∗ age + 2.949 ∗ gender + 0.486 ∗ LGE + 1.374 ∗ visual≥2 segments 
The corresponding model for dichotomized MPR ischaemic burden using a 
threshold of ≥10% ischaemic myocardium was: 
~0.016 ∗ age + 2.486 ∗ gender + 0.497 ∗ LGE + 1.761 ∗ MPR≥10% 
 
Ischaemia assessment by visual or quantitative analysis significantly improved 
predictive performance by comparison with the baseline model alone. When 
established clinical thresholds were utilized, there were further significant 
improvements in model performance.   
Figure 5.2 illustrates the ROC curves for 2-year outcome for the continuous and 
dichotomized visual and quantitative perfusion results.  This translated into a 
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significant improvement in risk reclassification (Figure 5.3).  Kaplan-Meier 
curves illustrating survival in patients stratified according to LGE and 
dichotomized visual and quantitative perfusion findings are shown in Figure 5.4. 
 
 
Figure 5.2 - Receiver-operator characteristic curves for 2-year outcome for 
visual and quantitative analysis  
Receiver-operator characteristic curves for 2-year outcome for the baseline cross-validated 
Cox regression model and for the extended models including visual and ischaemic burden 
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Figure 5.3 - Cross-validated categorical net reclassification improvement (NRI) 
and integrated discrimination improvement (IDI) reclassification 
Cross-validated categorical net reclassification improvement (NRI) and integrated 





Figure 5.4 - Kaplan-Meier curves illustrating survival in patients according 
to dichotomized visual and quantitative analysis 
Kaplan-Meier curves illustrating survival in patients stratified according to 
LGE and dichotomized visual (Panel A) and quantitative (Panel B) ischaemic 
burden. 
  156 
On further analysis of the concordance of results obtained from visual and 
quantitative analysis, the incidence of primary events was noted to be highest in 
the context of concordant positive tests (53.9% of the total events) and the 
lowest event rate was observed in patients negative in both tests (9.6%). In the 
case of disagreement, we observed a higher number of patients meeting the 
primary endpoint when classified as positive on quantitative analysis (23.1%) 
compared with those positive only on visual assessment (13.5%). 
 
5.5.3 Discussion 
The described study represents the first to address the prognostic benefit of 
quantitative analysis of stress perfusion CMR. A quantitative approach has 
previously been shown to significantly improve diagnostic performance over 
visual assessment specifically in the setting of multi-vessel coronary artery 
disease120.  Our data demonstrate that a quantitative approach is also superior 
to visual assessment in an unselected group of patients from a prognostic 
perspective. Moreover, our data demonstrate the independent prognostic value 
of ischaemic burden measurements over and above LGE assessment, 
highlighting the strength of CMR as a multi-parametric technique. 
In this study, both visual and quantitative analysis were performed in a high-
volume tertiary centre, and by experts. It is a significant finding that the semi-
automated quantitative analysis performed similarly, if not slightly better, than 
visual assessment performed by expert readers. This is of increasing relevance 
as recent technical advances in image reconstruction and analysis techniques 
are likely to permit the robust full automation of quantitative analysis in coming 
years159,218.  The findings have important implications for facilitating the rapid 
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and more widespread adoption of stress perfusion CMR by less experienced 
centers and readers, and allowing realisation of the full prognostic value of 
perfusion quantification. 
It is encouraging that there were only a small number of non-analyzable cases 
in the study (3.5%).  This was mainly due to respiratory motion, a known 
limitation of the high-resolution k-t accelerated techniques used in this study219.  
The advent of novel motion correction techniques is likely to ameliorate this 
further220.  
We found that the consensus-based threshold of ≥10% ischemic myocardium or 
≥2 abnormal segments can be validly extrapolated from nuclear medicine to 
CMR203.  The use of these thresholds not only improved model predictive 
performance, but also translated into significant reclassification of patient risk 
using established risk categories. This is a reassuring finding since important 
studies such as MR-INFORM and the ISCHEMIA (International Study of 
Comparative Health Effectiveness with Medical and Invasive Approach) Trial are 
employing these criteria67,95.   
In this study, abnormal perfusion was defined by an MPR<1.5. This threshold 
has previously been validated against FFR82 and is very similar to the optimal 
threshold found in some PET studies in patients with angina requiring 
revascularization221. 
 
5.5.4 Study Limitations 
1. This was a single-center study, performed at a tertiary hospital with a 
high-volume CMR service. The single-center design permitted 
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standardization of the pharmacologic stress protocols and of the 
acquisition methods.  
2. This was an observational study which could suffer potential inherent bias 
but nevertheless represents a real-world scenario. Consecutive patients 
fulfilling the entry criteria were included but may have constituted a 
selected group.   
3. A dual-bolus approach was used, justified by the need to minimize signal 
saturation effects in the arterial input function. It is recognized that the 
relative complexity of this approach makes it more difficult for less 
experienced centers to adopt.  The emergence of dual-sequence 
acquisition schemes and other advances may render this less of a barrier 
in the future131,159,160.   
4. Mirroring previous clinical studies where visual CMR results may have 
influenced revascularisation decisions, we excluded early 
revascularisation events (within 90 days) from the primary composite 
endpoint59,210.  All scan reports were issued within 5 days with a median 
time of 36 days between scan to revascularisation in patients undergoing 
early revascularisation. On this basis, we feel that the cut-off of 90 days 
appears to be reasonable in our cohort for minimizing the CMR result 
influencing revascularisation. Furthermore, we would suggest that were it 
present, any bias would have favored a visual analysis approach as this 
was used for clinical decision-making. Although all endpoints were 
adjudicated blind to CMR data and in our modelling, and early 
revascularisation was not a significant predictor of outcome, we cannot 
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exclude the possibility that the impact of ischaemia may have been 
underestimated in the presence of prompt revascularisation. 
5. The presence of severe ischaemia, defined as vasodilator-induced 
systolic dysfunction by CMR, was previously shown to predict poor 
prognosis in a large series of patients and to identify a subgroup of 
patients who benefitted most from revascularisation. A comprehensive 
evaluation of the ischaemic cascade, including induced-systolic 
dysfunction, was not performed in this study.  
6. Finally, this study focuses solely on the use of CMR perfusion and uses 
visual assessment as the clinical reference standard. CMR perfusion was 
not directly compared with other modalities such as PET or SPECT. PET 
remains the non-invasive reference method for quantitative perfusion 
measurements. However, it is not widely used clinically, involves 
significant cost and uses ionising radiation. SPECT is more widely 
available but also uses ionising radiation and has lower spatial resolution 
than CMR. Visual and quantitative CMR analysis have been shown to 
perform similarly or better to these modalities in other studies but a direct 
comparison was not possible in this study. 
 
5.6 Conclusion 
In recent years there has been growing appreciation of the importance not only 
of the presence but also the severity and extent of ischaemia as a prognostic 
marker.  There is a growing body of evidence supporting more widespread use 
of quantitative analysis, which lends itself well to calculation of ischaemic burden 
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both in terms of extent and severity. Quantitative analysis of perfusion CMR has 
now been demonstrated to be robust and reproducible, increasingly automated 
and, importantly advantageous over visual assessment in selected groups of 
patients.  
The study presented here provides further support for the introduction of 
quantitative CMR perfusion analysis to the clinical setting. It supports the use of 
current consensus-based prognostic ischaemic burden thresholds for perfusion 
CMR.  Quantitative perfusion analysis performed similar to, or when using a 
threshold based approach, better than visual assessment.  In this study, the use 
of quantitative analysis provided incremental value over other recognized risk 
factors such as the presence of late gadolinium enhancement in an unselected 
cohort of patients.  
This study should provide a basis to performing larger, multi-centre prospective 
studies to explore the prognostic implications of quantitative CMR perfusion 
analysis. 
 
Part of this chapter consists of work that has been published:   
Sammut, E., Villa, ADM., Di Giovine MD, G., Dancy, L., Bosio, F., Gibbs, T., 
Jeyabraba, S., Schwenke, S., Williams, SE., Marber, M., Alfakih, K., Ismail, TF., Razavi, 
R., Chiribiri, A. 
‘Prognostic value of quantitative perfusion CMR’ 
JACC Imaging, 2017 (https://doi.org/10.1016/j.jcmg.2017.07.022) 
Eva Sammut is first author on the publication and was responsible for data collection, 
image analysis and draft of the manuscript.    
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Table 5 - Baseline clinical and MR characteristics of study cohort  







Age, years 57.6±13.2 63.3±11.8 58.3±13.1   0.019 
Sex, Male (n, %) 226 (65.9) 51 (98.1) 277 (70.1) <0.001 
Body Mass Index, kg/m2 1.95±0.23 2.00±0.20 1.96±0.23 0.612 
Risk Factors (n, %)     
    Diabetes Mellitus 66 (19.2) 12 (23.5) 78 (19.7) 0.575 
    Hypertension 201 (58.6) 34 (66.7) 235 (59.5) 0.368 
    Current Smoker 63 (18.4) 10 (19.2) 73 (18.5) 0.849 
    Ex-Smoker 31 (9.0) 4 (7.7) 35 (8.9) 1.000 
    Hypercholesterolemia 180 (52.5) 36 (72) 216 (54.7) 0.025 
    Previous PCI/CABG 101 (29.2) 34 (65.4) 135 (34.2) <0.001 
    PCI/CABG within 90 days 36 (10.5) 4 (7.7) 40 (10.1) 0.804 
    Atrial Fibrillation 36 (10.5) 10 (19.2) 46 (11.6) 0.100 
CMR Characteristics     
  LVEDV, ml 152[130-183] 156[125-195] 153[129-183] 0.462 
  Indexed LVEDV, ml/m2 78 [67-91] 79 [65-96] 79 [67-91] 0.790 
  LVESV, ml 60 [47-82] 65 [41-97] 60 [46-84] 0.223 
  Indexed LVESV, ml/m2 30 [24-40] 32 [22-47] 31 [24-41] 0.374 
  LVEF, % 60 [53-66] 59 [44-67] 60 [52-66] 0.121 
  LV Mass, g 107 [88-134] 115 [97-134] 109 [90-134] 0.086 
  Indexed LV Mass, g/m2 55 [46-66] 60 [50-67] 56 [47-56] 0.075 
  RVEDV, ml 149[126-174] 143[114-170] 147[124-174] 0.185 
  Indexed RVEDV, ml/m2 75 [64-87] 73 [60-88] 31 [23-38] 0.178 
  RVESV, ml 62 [44-77] 57 [46-78] 61 [44-77] 0.671 
  Indexed RVESV, ml/m2 31 [23-39] 31 [22-38] 31 [23-38] 0.610 
  LA size, cm2 23 [20-26] 22 [18-27] 23 [19-26] 0.944 
  RA size, cm2 20 [17-23] 21 [18-24] 20 [17-23] 0.464 
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  Resting Heart Rate, min-1 71.8±14.2 68.7±13.5 70.8±14.0 0.182 
  Stress Heart Rate, min-1 96.8±17.4 90.9±16.1 95.6±17.6 0.042 
  Rest Systolic BP, mmHg 137.9±22.7 137.4±22.2 137.9±22.4 0.859 
  Rest Diastolic BP, mmHg 79.3±12.5 74.9±10.9 78.6±12.5 0.097 
  Stress Systolic BP, mmHg 132.9±20.6 131.8±19.8 132.8±20.4 0.652 
  Stress Diastolic BP, mmHg 74.5±12.5 74.5±9.8 74.5±12.2 0.763 
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6 Hybrid PET-CMR imaging 
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6.1 Introduction  
This chapter will focus on the use of hybrid imaging to make a more direct 
comparison between PET and MR using a specialized cardiac phantom. 
Nuclear imaging modalities suffer a number of drawbacks: they use ionising 
radiation, they have limited spatial resolution by contrast with CMR, they are 
inferior in terms of assessment of cardiac chamber dimension and functional 
analysis, they cannot directly visualise scarred regions and finally, the 
availability of PET is restricted to large centres with an on-site cyclotron for 
tracer production. These factors make CMR an attractive alternative.  Previous 
studies, described in previous chapters, have suggested that CMR is non-
inferior to SPECT90,92,93,127.  Previous studies comparing quantitative 
measurements of coronary flow reserve using PET and MR have demonstrated 
a good correlation between the modalities when considering coronary flow 
reserve (CFR) 111-113.  There is however a lesser correlation of absolute stress 
and rest estimates and this has been ascribed to specific tracer properties, 
modelling assumptions, fitting methods and parameter constraints132.  Previous 
studies comparing PET and CMR can also been criticised on the basis that the 
MR and PET scans were performed in sequence, in some cases on different 
days.  
Part of this chapter consists of work that has been published - Eva Sammut is 
second author on the publication and contributed to the study design, 
experimental work and draft/review of the manuscript.  The published study 
serves primarily as a feasibility study of the first simultaneous PET-MR 
acquisitions from a dynamic cardiac perfusion phantom but in addition allows 
direct correlation of perfusion quantification between modalities against a true 
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perfusion rate – a situation not possible in-vivo, but providing a basis for future 
in-vivo work.   
 
6.2 PET-CT  
Multi-modal imaging is not a new concept.  Indeed, PET scanners have been 
combined with CT scanners for over a decade222.  The addition of CT allowed 
combination of functional PET data with high-resolution, three-dimensional 
anatomical data, yielding more accurate attenuation correction, and localisation 
of tracer uptake within a single examination.  Studies have demonstrated clear 
advantages to the use of a combined approach223-225.  Initial studies used only a 
low-dose CT scan for attenuation. More recently, the use of full, diagnostic-
quality CT improved yield, at the cost of more radiation to the patient226.  
PET-CT remains a clinically applicable combined tool particularly in the field of 
oncology but does suffer from limitations.  Despite use of the same scanner, the 
PET-CT scans are performed in sequence rather than simultaneously.  This 
increases overall scan time.  Most importantly, this sequential scanning can be 
problematic in terms of attenuation correction and co-registration due to breath-
hold pattern and patient movement.  This can significantly compromise accuracy 
of quantification of radiotracer activity227-230.  
 
6.3 Hybrid PET-MR imaging  
Recent technical developments have led to the development of systems which 
combine PET and MRI imaging.  These systems do allow simultaneous imaging, 
providing temporal correlation of dynamically acquired data from both 
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modalities.  This improves cross-modality validation, reduces scan time relative 
to independent CMR and PET-CT scans, and reduces exposure to ionising 
radiation since the CT component is eliminated231.  MRI also brings the 
advantage of superior tissue characterisation in contrast to CT, an important 
factor in the main applications of PET: oncology and cardiology.  From a cardiac 
perspective the unrivalled ability to acquire high-resolution functional 
information, such as ventricular function and mass, myocardial scar, make it an 
attractive option to examine pathophysiology in more depth.  The use of 
advanced MRI techniques such as phosphorus spectroscopy with MRI 
combined with the functional metabolic information from PET confer the same 
advantages. 
Studies comparing PET-MR with PET-CT within the field of oncology have been 
encouraging232,233.  
 
Over the past decade, both PET and MRI technologies have been developed 
further.  Currently available sequences show a dramatic improvement in spatial 
resolution of MRI and high sensitivity PET allows enables detection of minute 
amounts of radiotracer in-vivo.   
 
6.3.1 Challenges of hybrid PET-MR  
The combination of PET and MR into a single system has also come with 
several challenges.  Commercially viable units are now available in few centres 
in the UK.  
The PET and MRI subsystems have the potential to degrade one another.  The 
PET scanner hardware may disrupt the homogeneity of the magnetic field and 
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produce distortion of the applied gradient field causing a loss of image quality 
and artefacts.  In turn, the magnetic field at the centre of MRI imaging can affect 
the PET scanner by distorting the path of electrons through the photomultiplier 
tubes (PMTs) used in conventional PET scanners.  The role of the PMT is to 
transform the visible light produced in the scintillator into an electric signal 
detectable by PET electronics.  A number of detector design modifications have 
been proposed to address this234.  
Attenuation, traditionally performed using CT, has proved to be a challenge 
using PET-MR and here too a number of techniques have been proposed which 
include CT-based atlas or MR based attenuation235-240.  
Finally, physical restrictions are also a consideration since the size of the bore in 
the MRI scanner is already modest and cardiac coils must also be placed on the 
patient.  One of the main challenges has been to try to incorporate the PET 
component without reducing the size within the bore even further. In practice, 
this is currently achieved by installing a PET insert in a magnet designed to 
equip a wide bore MRI scanner. This allows the system to have a bore with a 
diameter of 60 cm, suitable for most patients. 
 
6.3.2 Challenges specific to cardiac PET-MR 
Cardiac imaging is more challenging than imaging of other organs as it has 
three, rather than one, potential sources of motion – respiration, cardiac 
contraction, and voluntary or involuntary patient movement.  Eliminating the 
effect of cardiac and respiratory motion in PET-MR has been addressed via a 
number approaches241-244.   
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6.3.3 Clinical PET-MR 
The bulk of work to date using hybrid PET-MR has been conducted in animals 
and has yielded encouraging results. In the clinical setting, most work has 
addressed brain or oncologocal imaging which does not carry the same 
variables as cardiac imaging.  The use of clinical hybrid PET-MR in the field of 
cardiology is however steadily increasing.   
The feasibility of using hybrid PET-MR imaging to identify areas of non-viable 
myocardium using [18F]-FDG has been studied.  It has been proposed that the 
mismatch between FDG uptake and scar by late gadolinium enhancement 
(LGE) could be used to define the area at risk if used in patients post acute 
myocardial infarction245-247.  
In chronic myocardial infarction, areas of reduced uptake of [18F]-FDG and LGE 
have been shown to correlate well, including a recent study focusing on viability 
using a hybrid PET-MR system248.  
The use of hybrid PET-MR to assess perfusion is limited.  Initial results appear 
to suggest similar outcomes between PET-CT and PET-MR when comparing 
quantification of myocardial blood flow - a recent study Kero et al. in 10 patients 
with suspected CAD demonstrated a high intra-class correlation coefficient of 
0.98249.  
In a recent study, 12 patients who had undergone SPECT showing rest 
perfusion defects were scanned with PET-MR using [18F]-FDG and LGE, and 
results were compared to SPECT versus CMR methods250.  The hybrid 
approach showed good correlation with the CMR approach for identifying 
normal, scar and ischaemic segments, with poor correlation between SPECT 
and CMR.  Compared to CMR alone there was reclassification of 19.2% 
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segments using a hybrid approach with a significant impact on downstream 
revascularisation. CMR perfusion routinely images only three slices. PET is able 
to take into account three-dimensional whole heart. When both modalities are 
used in combination, more comprehensive imaging is obtained and 
complimentary information is yielded with consequent benefit in assessment. 
PET-MR systems have also been used to image myocarditis, sarcoidosis, 
cardiac tumours, and Takotsubo cardiomyopathy using glucose uptake as a 
surrogate for inflammation or a metabolically active lesion251-254.  Finally, a 
number of studies have used PET-MR to image coronary or carotid plaques 
which may be vulnerable to rupture255,256.  
 
6.4 Feasibility of simultaneous PET-MR perfusion using a novel 
cardiac perfusion phantom 
The background described above formed the basis of the subsequent study 
conducted at King’s College London as part of this.  In brief, the study aimed to 
compare simultaneous perfusion quantification from the two modalities using a 
physiologically validated phantom and hybrid PET-MR scanner. 
 
6.4.1 Methods  
6.4.1.1.1 Phantom 
The custom designed perfusion phantom used in this study was designed and 
built at King’s College London as a prototype149.  It was designed to simulate 
physiological volumes and conditions to provide a reference method for 
quantification techniques using delivery of a known perfusion rate.  The cardiac 
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perfusion phantom has previously been validated to provide data suitable for 
quantitative analysis.  It has been employed in MR quantification141 and in 
comparison with CT perfusion257. In essence:  water is pumped through an MR-
safe myocardial perfusion phantom placed in the scanner. The phantom is 
representative of the large thoracic vessels and of the heart of a 60kg subject. It 
is composed of four cardiac chambers (120 ml each) and associated thoracic 
vessels (aorta, pulmonary artery, pulmonary vein, vena cava). A schematic 
representation detailing the phantom and supporting precision pumping and 




  Figure 6.1 - Basic schematic representation of the cardiac phantom 
Basic schematic representation of the phantom showing the control unit outside the 
scan room and the phantom components inside the PET-MR scanner. VC = vena 
cava, PA/PV-pulmonary artery/vein, RA/LA=right/left atrium, RV/LV-right/left 
ventricle.  
         Adapted from Chiribiri et al.149  
 
Myocardial perfusion is monitored in real time by flow meters which continuously 
sample the flow rate by means of high-precision digital flow meters (Atrato, 
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Titan, Sherborne, United Kingdom) These flow meters also provide adjustment 
of the speed of rotation of roller pumps through a feedback mechanism. 
Perfusion values are obtained by means of measurement of the distribution 
volume for the radioactive tracer and for the Gadolinium-based contrast agent 
(GBCA, Gadovist®, Bayer HealthCare, Berlin, Germany). The flow rate is then 
divided by this value. All pump controls and flow/perfusion rates are handled 
remotely from a custom-written LabVIEW application (LabVIEW Professional 
Development System 2014, National Instruments, Austin TX, USA) controlled 
from a dedicated remote workstation using an iPad application (Dashboard for 
LabVIEW, National Instruments, Austin TX, USA).  
 
In this study, no radiotracer or GBCA re-entered the system after injection. The 
model was non-recirculating and this permitted study of first-pass myocardial 
perfusion data.  
6.4.1.1.2 Scanning parameters 
PET-MR imaging was performed on a 3T Siemens Biograph mMR scanner 
(Siemens Healthcare GmbH, Erlangen, Germany). The MR sequence consisted 
of a clinically utilized imaging protocol, (a 2D TurboFLASH saturation recovery 
gradient echo sequence; TE=1 ms, TR=164 ms, Flip angle=10o, slice 
thickness=6 mm, voxel size=1.875 mm, matrix size 144x192 voxels), with 
temporal resolution of 1 image per cardiac beat. MR data was acquired in a 
single transverse plane identified by markings on the phantom, the locations of 
which corresponded to a known dispersion volume for the GBCA and 
radiotracer. Cardiac output flow rate was set to 3 litres/minute, with true 
myocardial perfusion rates (hereon denoted PT) set to 1, 2, 3, 4 and 5 ml/g/min. 
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A previously validated dual-bolus protocol was used for GBCA injection, with a 
pre-bolus of 0.001 mmol/kg of GBCA injected before a main bolus of 0.01 
mmol/kg, (based on the weight of a 60kg patient)130.  A minimum pause of 30 
seconds was allowed between the pre-bolus and the main bolus of GBCA to 
ensure return to baseline values of signal in the vascular and myocardial 
compartments.  
3D PET data was acquired in a single list-mode file and re-binned into short 
frames during the peak influx and washout phases (60 x 3 seconds) with longer 
frames towards the end of the washout phase (12 x 15 seconds). PET image 
frames were reconstructed using the standard manufacturer-issued filtered 
back-projection (FBP) algorithm available on the scanner (344 x 344 matrix, 
Gaussian smoothing filter of 4 mm.  The resulting PET voxel sizes were 2.086 
mm x 2.086 mm x 2.031 mm). Attenuation correction of PET data was provided 
by the standard dual-point VIBE T1-weighted Dixon sequence available on the 
mMR scanner front end239.  Total attenuation of the phantom was low as there 
was no attenuating material surrounding the phantom.  
A mean of 207.8±9 MBq was injected in order to exclude potentially confounding 
dead-time effects in the PET detectors. After preloading of [18F]F- into the tubing, 
the main bolus of GBCA  and [18F]F- was injected simultaneously via a contrast 
injection system (Spectris Solaris, Bayer AG, Leverkusen, Germany) through 
the vena cava tubing of the phantom. Simultaneous dynamic PET-MR imaging 
was performed for a total of 300 seconds. A single simultaneous PET-MR 
acquisition was performed at each PT step, and each step was repeated in order 
to gauge repeatability of the phantom. Following each scan, water was pumped 
through the myocardial compartments of the phantom for a minimum of 60 
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seconds between experiments to ensure a complete washout of GBCA and 
radiotracer before the next scan.  
6.4.1.1.3 Image Analysis  
Dynamic PET images were analysed in PMOD v 3.7 (PMOD Technologies, 
Zurich, Switzerland) to produce time-activity curves (TACs). 2D MR images 
were analysed in OsiriX (OsiriX 64-bit, version 8.0.2, Pixmeo SARL, Geneva, 
Switzerland) to produce time-intensity curves (TICs). A region of interest (ROI) 
of 1.6 cm (tubing diameter) was placed over the aorta of the phantom, and ROIs 
of 4 cm diameter were placed over the left and right myocardial sections, 
ensuring inclusion of the entire section of the vessel and tissue compartment in 
the segmentation. Positioning of ROIs on the PET image plane corresponding to 
the MR image plane was determined from fusion of the dynamic 3D PET and 2D 
summed dynamic MR images using PMOD. ROIs were placed on PET images 
over the same spatial area as the MR ROIs. The PET volumes of interest (VOIs) 
were 6.093 mm thick (3 PET slices) in the axial-dimension in order to match the 
slice thickness of the MR data (6 mm). All PET data were decay-corrected to the 
scan start time. We obtained a set of TACs and TICs for the aorta and 
myocardial compartments over the range of PT.  
6.4.1.1.4 MR perfusion calculation 
In-house software was used for perfusion quantification (Labview 2014 for Mac, 
National Instruments, Austin, USA). A model-independent deconvolution 
approach was used to calculate the tissue impulse response function, providing 
results in units of 1/second and was not scaled to be in units of ml/g/min. In brief: 
relative perfusion can be calculated based on the central volume principle using 
a signal deconvolution method143.  
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The TIC for the myocardial uptake function, M(t), can be calculated from the TIC 
for the arterial input function, Cin(t), convolved with the tissue impulse response 
function h(t), in which Cout(t) denotes the contrast concentrations in the venous 
out-perfusion: 







We performed this calculation using the pre-bolus curve, Cin(t), as an input 
function, in order to minimize the effect of signal saturation by the main bolus of 
higher GBCA concentration, (an effect which has been noted in previous work) 
and with this phantom at high GBCA dosages130,149.  In the range of 
physiological concentration used in the pre-bolus injection, MR signal intensity is 
proportional to GBCA concentration. The tissue impulse response function h(t) 
has the shape of an exponential decay. MR relative perfusion measurements 
were calculated from the h(t)) when h(t=0), i.e. at the peak point of the 
exponential decay. The delay between the arterial input TIC and the myocardial 
TIC was accounted for in the model144. 
6.4.1.1.5 PET perfusion calculation 
PET data was modelled using a one-tissue compartment model characterized 
by a one blood compartment, one tissue compartment and two rate constants K1 
(uptake rate constant in units of ml/g/min) and k2 (clearance rate from tissue to 
blood constant in units of min-1). For this phantom study, using [18F]F- we 
assume an extraction fraction of 1.0 due to the lack of any metabolic processes, 
and thus the K1 constant is entirely representative of perfusion. In order to 
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eliminate any prospective bias, PET and MR data was analysed independently 
by two authors blinded to the true myocardial perfusion rates, PT.  
The terms ‘flow’ and ‘perfusion’ have been used interchangeably in both PET 
and MR literature. Owing to the fact that rates of liquid through our phantom 
were calibrated in ml/g/min  (i.e. units of perfusion) and K1 values from PET 
kinetic modeling were in the same units, we have opted for consistency in 




6.4.2.1.1 Simultaneous imaging 
As the PET acquisition is fully 3D (25.8 cm field of view), all myocardial 
chambers can be visualized simultaneously. Figure 6.2 illustrates the rapid 
passage of radiotracer from right atrium to ventricle, through the pulmonary 
circulation and into the left atrium and ventricle and exiting through the aorta.   
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  Figure 6.2 - Single coronal PET slice from the 3D phantom acquisition 
Single coronal PET slice from the 3D phantom acquisition at a cardiac output rate of 
3 L/min, showing an example of radiotracer distribution in the myocardial chambers 
at increasing post-injection time points.   All images are shown at the same 
windowing and level.  
(RA/LA=right/left atrium, RV/LV-right/left ventricle) 
 
 
 Figure 6.3 displays a fused transaxial image of the single MR slice with the 
corresponding merged 3 PET slices covering the same axial extent. The inset 
image of  Figure 6.3 shows the passage of MR contrast only, which temporally 
matches the distribution of PET radiotracer. The expected GBCA and PET 
radiotracer distribution through the phantom can be seen at increasing time 
points of the 2D MR imaging sequence and fused PET-MR images detailing the 
first pass dynamics of the phantom.  
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 Figure 6.3 - Example of fused PET-MR images 
Example of fused PET-MR images showing dynamics of GBCA and radiotracer 
transfer through the phantom. (A) – bolus in the VC (t=0 s). (B) – out-perfusion from 
the RV through the PA (t=3 s), (C) – coronary circulation to the PV (t=5 s) and the 
aorta (AO).  
Inset images show the time distribution of GBCA only.  
 
 
Image processing of the ROI/VOIs to produce TACs and TICs enables 
comparison of resulting mean PET kBq/ml to MR signal intensity during transit 
of the GBCA and radiotracer, as shown in    Figure 6.4.  
 
  178 
 
   Figure 6.4 – Comparison of PET mean activity and MR mean signal time 
intensity curves 
Comparison of mean activity concentration (kBq/ml) time activity curves (TAC) and 
mean MR signal (AU) time intensity curves (TIC) acquired from the phantom VOIs 
(PET-top) and ROIs (MR-bottom). Data are presented for simultaneous PET and MR 
acquisitions for a myocardial perfusion rate, PT = 4 ml/g/min and cardiac output of 3 
L/min. Repeat scan data using ROI and VOI in the same positions are also plotted 
and show a high level of repeatability. Error bars are omitted in order to improve 
visual clarity of overlapping traces. 
 
As the repeat injection of [18F]F- and GBCA was performed using the same 
timings and methodology as the first test, the time traces produced by both PET 
and MR data were similar. Although omitted from    Figure 6.4 for clarity, for a 
single PT of 4 ml/g/min, one standard deviation of the mean PET activity 
concentration from the VOI varied over time from ±2 to ±24%, while that of the 
MR mean ROI signal intensity varied over time from ±13% to ±29%. Standard 
deviations were similar for other values of PT.  
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   Figure 6.5 shows a comparison of the input functions from both imaging 
methods normalised by their respective maximum signal intensities: 
- first between the peak of GBCA and the radiotracer (A),  
- second between the MR pre-bolus peak (used for the MR perfusion analysis) 
and a time-shifted PET TAC overlaid to provide comparison (B), and  
- finally a normalized comparison of the functions obtained from the myocardial 
chamber (C). These traces show that the input functions for both PET and MR 
models have similar characteristics but with clear difference in transit time, 
potentially due to higher mass and viscosity of the GBCA. 
 
   Figure 6.5 – Comparison of AIFs derived from PET and MR signal traces  
Comparison of normalized (respective maximum signal intensity) AIFs derived from 
both PET and MR signal traces at a myocardial perfusion rate of 4 ml/g/min and 
cardiac output of 3 l/min. Image (A) represents the input functions from the main MR 
bolus and PET bolus, showing a longer washout of GBCA than radiotracer in the 
main bolus. Image (B) details the MR prebolus with the same PET bolus as (A) but 
time-shifted to provide comparison. Image (C) details the simultaneous curves from 
the myocardial compartment showing a clear difference in transit time, potentially 
due to higher mass and viscosity of the GBCA.  
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6.4.2.1.2 Perfusion calculations 
PET datasets were used to calculate perfusion (ml/g/min) via K1, and MR datasets 
to calculate relative perfusion values via h(t=0) as described above. Resulting K1 
and h(t=0) and are shown in  
Table 6 below.   
 
Table 6 - Results and repeatability of simultaneous quantification by PET or 
MR using cardiac phantom 
 











1 1.14 3.8 0.96 7.83 0.132 4.019 
2 1.93 2 1.62 1.71 0.213 4.141 
3 2.94 1.55 2.44 2.05 0.279 3.346 
4 3.81 2.41 3.20 2.93 0.339 3.834 
5 5.14 1.83 4.43 3.35 0.403 2.985 
REPEAT 
     
 
1 1.18 0.5 0.99 7.68 0.133 3.953 
2 2.07 1.87 1.87 1.74 0.201 3.112 
3 2.98 2.6 2.60 2.06 0.293 4.526 
4 3.98 3.21 3.21 2.16 0.384 4.259 
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Figure 6.6 shows three plots detailing the relationship between K1 and PT, h(t=0) 
and PT and also h(t=0) and K1. The results show that K1 is linearly related to PT 
(R2=0.99), and that h(t=0) is also linearly related to both PT and K1 (R2 values of 
0.99 in both cases).  
 
 
Figure 6.6 – Plots demonstrating linear relationship between true perfusion rate 
(PT), and PET   (K1) and MR (h(t=0) data  
Top - Resulting K1 values from a single compartment model for PET data plotted 
against PT.  
Middle – MR values of h(t=0) from model-independent deconvolution for MR images 
plotted against the range of PT. Bottom - MR values of h(t=0) plotted against the 
range of K1 from PET kinetic modelling.  
 
6.4.3 Discussion 
We performed PET-MR tests using a specialized cardiac phantom allowing 
assessment of myocardial perfusion measurements with both imaging 
modalities from simultaneously acquired data. Both PET and MR are accurate 
tools for the assessment of myocardial ischaemia, but there are drawbacks 
inherent to each technique. For instance, in MR derivation of fully quantitative 
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perfusion units is still a complex process due to the relationship between signal 
intensity and gadolinium contrast and dependence on acquisition sequence258.  
In addition, dynamic imaging favours 2D images. This means that perfusion 
calculations cannot be representative of the entire volume. In PET, the cost of 
the perfusion exam can be prohibitive. The procedure requires access to short-
lived radiotracers and thus access to a cyclotron. There is also a not 
insignificant radiation dose associated with the radiotracer. Although the 
principles of image formation between MR and PET are based on entirely 
different physical principles, we have shown that similar TACs and TICs from 
the arterial and myocardial compartments can be obtained from a single short 
acquisition. Furthermore, it has been possible to show that the results obtained 
with the employed MR and PET models are linearly related to the true 
myocardial perfusion rate, PT.  
The phantom is physiologically faithful and therefore enables exploration of 
some relevant aspects of perfusion dynamics of the human heart.   Figure 6.2 
and  Figure 6.3 demonstrate the distribution of both GBCA and radiotracer 
through the right side of the cardiac chambers followed by the left, with 
perfusion through the myocardial compartments following shortly after. 
Simultaneous traces of PET activity concentration and MR signal intensity seen 
in    Figure 6.4 demonstrates the transit of radiotracer and GBCA through the 
phantom, showing the simultaneity of PET and MR signals that can be achieved 
in this phantom. Our data also confirms that when a dual bolus approach is used 
in MR, linear perfusion estimates to those obtained in PET are achievable. 
In this study, we adopted a dual-bolus injection scheme previously described 
and validated by our group130,150.  The results of this study demonstrate that this 
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approach results in MR input functions which are very similar in shape and 
transit time to the reference standard PET input functions, as demonstrated in    
Figure 6.5. The myocardial compartment TAC and TIC match closely in terms of 
wash-in. Nevertheless, the MR TIC is observed to have a longer transit time 
than the radiotracer.  We propose that this may be due to the higher particle 
mass and viscosity of the GBCA in contrast to the radiotracer. 
One of the main benefits of the phantom model is its reproducibility. Table 6 
demonstrates that repeat acquisitions at the same PT  give similar TAC and TIC.  
Upon calculation of perfusion via PET, K1 values were in the range of 1.2%-
7.5% of each other. A similar repeatability is shown in MR data with a 
repeatability of 0.6%-13% for h(t=0). PET measurements at PT = 1 ml/g/min 
showed an overestimation of PT by 16%. The PT rates of 2, 3, 4 and 5 ml/g/min 
were accurate to K1 values to within a maximum of 2.65%, indicating good 
precision for repeated measurements and also good accuracy to PT values 
above 1 ml/g/min.  Variation in the true measurement of PT = 1 ml/g/min due to 
physical inconsistency of the roller pumps may account for the larger differences 
at this value of PT, and will be investigated in the next generation of the phantom 
currently under development. Although h(t=0) values represent relative 
perfusion measurement and were not scaled to represent absolute perfusion 
units, their relationship to PT and K1 can be clearly observed in Figure 6.6, which 
records the linear relationship found between h(t=0) and K1, as well as h(t=0) 
and PT.  
Total analysis time of each series of PET images was approximately 30 
minutes, and MR images were approximately 5-10 minutes. Owing to the 
geometrical differences between phantom and patient images, semi-automated 
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PET analysis software could not be used. Furthermore, PET images were re-
binned into short frames of 3 seconds because of the rapid transit of the 
radiotracer in water. In a clinical image we expect to have to analyse a lower 
amount of data and frames.  
Attenuation correction is a major issue in clinical PET-MR imaging and the focus 
of much research235-240,259.  In this work, we utilised GBCA for the bolus 
injection, and in clinical studies the concentration would be far higher. Previous 
work by our group has shown that despite large concentrations of GBCA up to 
65 mM (presenting the scenario of GBCA bolus in the left ventricle 
simultaneously with the PET radiotracer), the effect of attenuation of gamma 
photons by GBCA on quantified activity concentration (kBq/ml) in the final 
reconstructed images is less than 5% when compared to no GBCA present260. 
We believe that by providing a standardized setup and known perfusion rates, 
results, claims and hypotheses from clinical studies can be further investigated. 
Previous studies have shown that MPR calculated from independent CMR and 
PET scans have been shown to correlate well.  There was a weak correlation 
between absolute CMR perfusion at stress and rest111. This may indicate that 
errors in quantification have a similar effect on stress and rest perfusion MBF 
values but are cancelled by calculation of the MPR. Future experiments could 
verify this finding by the exclusion of physiological variation. The phantom also 
allows comparison of kinetic models given the known ground truth of perfusion 
rates, and the potential for development of new hybrid kinetic models employing 
both PET and MR data. Another potential advantage of the approach is the 
possibility to address differences in the way images are acquired and modality-
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specific artefacts, such as saturation effects in MR or attenuation correction in 
PET. 
Knowledge of the relationship between PT, K1 and h(t=0) may allow the creation 
of a modality-specific calibration curves. Particularly in the case of perfusion 
MR, this could allow converting the results of the deconvolution operation from 
seconds-1 to ml/g/min of perfusion. This approach could prove of value as a 
substitute for current approaches based on constraining the deconvolution 
operation144,147.  This may lead to an improvement in the correlation between 
absolute MBF values measured with MR and PET. 
 
6.4.4 Study limitations  
1. The use of the phantom in this work for simultaneous PET-MR 
acquisitions as a surrogate for clinical acquisitions presents some 
fundamental limitations. Despite the fact that the TIC and TAC curves are 
similar in appearance for this simplified phantom study, it may not be the 
case for clinical studies in a human cohort due to the mechanism of 
transport of radiotracer (intracellular) and GBCA (extracellular). Therefore 
the phantom study serves to provide preliminary investigation into the 
standardized comparison between PET and MR perfusion values in a 
controlled simulation. The phantom model used in our experiments is not 
able to capture the broad range of body structures and physiological 
states that may be present in a clinical setting and as such represents an 
oversimplification of the cardiovascular system which cannot detail true 
myocardial diffusion or radiotracer uptake.  
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2. Despite a good correlation between PET and MR perfusion, there remain 
fundamental differences between the calculation methodology between 
the MR model-independent deconvolution approach and perfusion as 
calculated from a single compartment PET model. As is the mechanism 
with PET radiotracers, no separate tissue compartment exists, for 
example one with well-defined mechanical properties such as a 
membrane. Therefore true intracellular uptake cannot be simulated. 
Strategies would be required in order to simulate the kinetics of other 
perfusion tracers that undergo metabolic processes such as [13N]NH3 or 
[18F]Flurpiridaz. Efforts will made to create myocardial compartments 
within the phantom, which would allow a more accurate approach to 
kinetic modeling.  
3. We performed only 1 repeat acquisition of each PT in this feasibility study.  
Repeat measurements would allow the calculation of a repeatability 
coefficient for both the PET and MR datasets. 
4. The current phantom model setup is unable to reproduce the multiple 
sources of image artefacts in PET-MR such as the effects of motion due 
to respiration or cardiac contraction. Thus the phantom creates an 
environment free of these potentially confounding effects focusing only on 
the assessment of the perfusion dynamics within the cardiac 
compartments.  Translation of calibrations from the phantom to the 
clinical setting should be treated with caution. Confounding factors from 
clinical data may include the use of respiratory correction via importation 
an average cine CT or using MR-based navigators261 or employing MR 
motion-field based cardiac motion correction employed in PET 
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reconstruction262.  Efforts to apply these techniques specifically to 
quantitative dynamic PET-MR cardiology are in their infancy, although 




The advances in PET and MR technology have paved the way for the 
combination of these modalities and to allow the strengths of each to be 
harnessed simultaneously.  One of the additional benefits is the ability to directly 
compare results of parameters such as perfusion from each without concerns in 
physiological variations which may occur with a time lag between studies.   
Though in its infancy this represents an exciting opportunity and preliminary 
preclinical and clinical results have been encouraging. The experiments 
performed in this study demonstrate similar first-pass dynamics of both the PET 
and MR contrast agents. Importantly, we have also established a correlation 
between perfusion quantification of the PET time-activity traces using a kinetic 
model, relative MR perfusion using a deconvolution model and the true manually 
set myocardial perfusion rate. This work contributes to the growing body of 
knowledge on PET-MR and will inform future clinical studies.   
The phantom used in this study has the potential for improving standardisation 
of perfusion measurements, analysis routines, development of imaging 
protocols and potential calibration of MR perfusion.    
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7 Excitation-contraction coupling and the cardiac 
microarchitecture  
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7.1 Introduction  
Previous chapters have detailed the tightly coordinated vasodilatory capacity 
and the relevance of myocardial ischaemia to cardiac function.  Electrical 
impulse propagation and the cardiac microstructure are also highly coordinated 
to deliver effective cardiac output.  In heart failure, these precisely synchronized 
systems are disrupted. This chapter will discuss heart failure from the 
perspective of excitation-contraction coupling and the cardiac microarchitecture. 
This chapter will describe the highly structured system at cellular and tissue 
level, underlining the need for adequate and continuous ATP supply and an 
efficient supply of oxygen-rich blood.  
The bulk of this chapter will focus on the use of cardiac diffusion tensor imaging, 
an advanced CMR technique for in-vivo imaging of cardiac myofibres.  This will 
include a study which examines myofibre architecture in dilated cardiomyopathy 
and proposes insights into the underlying mechanistic processes using dual 
heart-phase cardiac DTI, 3D tagging and biomechanical modelling. We 
proposed the hypothesis that there would be structural differences at a myofibre 
level that would relate to the reduced cardiac contractility seen patients with 
DCM.  Furthermore, we hypothesised that these changes could adaptive in 
preserving function in DCM. Eva Sammut was joint first author on the 
publication and was responsible for patient recruitment and scanning, and 
involved in analysis and drafting of the manuscript.  
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7.2  Excitation-contraction coupling  
Excitation-contraction coupling is a vast topic which can only be summarised 
here. As suggested by the term, excitation-contraction coupling (ECC) refers to 
the physiological process of conversion of an electrical stimulus to a mechanical 
response. This is central to the heart’s ability to generate adequate contractile 
force.  
In the myocardium the action potential is produced by spontaneous 
depolarisation of the pacemaker cells in the sino-atrial (SA) node (in contrast to 
the skeletal muscle cell where membrane depolarisation is triggered by neuronal 
activity). From the SA node, the electrical impulses excite the right atrium and 
spread to the atrio-ventricular (AV) node.  The impulse then travels through the 
Bundle of His, which has the special quality of rapid electrical transmission, and 
to the left and right bundles, which depolarise the left and right ventricle 
respectively, almost simultaneously. This process is initiated by excitation-
contraction coupling (ECC), a cascade of events which triggers shortening of 
many sarcomeric units - contractile units composed of actin and myosin 
filaments within each myocyte to produce cardiac contraction. Individual 
myocytes are interconnected by intercalcalated discs (made up of three types of 
cell-cell junction - fascia adherens, desmosomes and gap junctions) – the gap 
junctions facilitate electrical communication from one myocyte to the next, 
producing smooth coordinated contraction of the myocardium. The myofibre 
arrangement is also crucial to the maximising the force of contraction and the 
volume of blood ejected from the ventricles in systole.  
On depolarisation, sodium ion influx triggers opening of L-type calcium (Ca2+) 
channels on the myocyte cell membrane. The influx of calcium ions to the cell 
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via L-type channels binds to, and activates, ryanodine R2 (RyR2) channels 
located on the sarcoplasmic reticulum (SR) causing further release of stored 
calcium264,265.  This phenomenon is known as Ca2+ induced-Ca2+ release 
(CICR).  The transient local increase in cytosolic calcium concentration due to 
release of stored Ca2+ from the SR is known as a calcium spark. When one 
RyR receptor is activated this leads to another and another being activated - a 
wave of Ca2+-induced activation, the whole cell CA2+ transient, spreads across 
the cell causing contraction of the sarcomere264.   The majority of calcium 
release into the cytoplasm is from the SR with a ratio of stored versus influx in 
the region of 10:1, with a smaller amount of Ca2+ entering the cell via the 
Ca2+/Na2+ exchanger pump266.  
An increase in cytosolic Ca2+ binds to troponin C which modulates the troponin 
complex on the sarcomere and exposes a binding site on the actin molecule. 
The myosin head binds to ATP using myosin ATPase and attracts the actin 
filaments towards the centre of the sarcomere – the actin and myosin filaments 
slide over one another and shorten myocyte length.    
This is a continuous process which occurs as long as cytosolic calcium 
concentration remains high. Ca2+ is actively removed from the cytosol 
predominantly by the sarcoplasmic reticulum ATP-dependent (SERCA) pump, 
the sodium-calcium exchanger pump (NCX), the sarcolemmal Ca2+ ATPase, 
and via the mitochondria.  The relative proportion of each Ca2+ removal method 
depends on the species studied – in humans, the predominant removal 
mechanism is via the SR Ca2+ ATPase (around 70%), with around 28% related 
to the NCX pump and only around 1% is removed by other methods267. 
  192 
To maintain homeostasis, the Ca2+ released in the cytoplasm must be 
thoroughly removed within each cardiac cycle.  This results in removal of 
calcium ions from the troponin complex, and inhibits the actin-binding site, thus 
restoring the relaxed sarcomere length.   
 
 
Figure 7.1 - Schematic representation of excitation-contraction coupling 
Schematic representation of excitation-contraction coupling.  Ca2+ enters the cell via 
L-type channels which triggers release of stored Ca2+ from the sarcoplasmic 
reticulum (SR) via the ryanodine R2 (RyR2) channels.  Ca2+ also enters the cell via 
the Ca2+/Na+ exchanger pump.  The Ca2+ transient is used for sarcomeric 
shortening (cardiac contraction).  Ca2+ is removed from the cytoplasm via the SR 
SERCA pump, Na2+/Ca (NCX) pump and via the Ca2+ ATP pump.   
         Adapted from Bers et al.267  
 
 
CICR is dependent on tight coupling between the L-type and RyR2 channels, 
primarily achieved by a highly organised dense network of T-tubules, 
invaginations of the sarcoplasmic reticulum which penetrate the cell. This close 
physical proximity of channels facilitates almost instantaneous, synchronous 
excitation of the sarcomeric units within each myocyte.  The other major factor is 
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adequate availability of ATP since ECC requires considerable amounts of 
energy. The main cellular energy consumers are the myosin ATPase of the 
contractile filaments, the NCX pump, and the SR Ca2+ ATPase268.  Even at rest, 
ECC consumes vast amounts of energy - during maximal workload, there is 
turnover of the entire ATP pool each couple of seconds265,269-271.  
 
7.3 Excitation-contraction coupling in heart failure  
It is accepted that lesser and slower contraction of individual cardiomyocytes 
contributes to reduced overall contractility in heart failure272,273.  Fundamental to 
this is a decrease in Ca2+ transients due to a lesser Ca2+ release from the SR 
upon L-type channel activation274,275.  This is related to decreased SR Ca2+ 
content, leakage of the RyR channels, reduced activity and expression of 
SERCA function or increased NCX pump activity276-278.  
Excitation-contraction coupling occurs primarily at the sites of T-tubule/ 
sarcoplasmic reticulum junction.  In heart failure there is reduced density, 
dilatation or abnormal orientation of the T-tubule network.  The loss of T-tubules 
results in dyssynchronous release of sarcolemmal calcium due to a physical 
uncoupling of the L-type and RyR receptors. Loss of T-tubule integrity has been 
linked directly to the progression of heart failure279. 
.  
 
7.4 Cardiac deformation  
The complex muscle structure of the heart is made up of cardiomyocytes which 
contract upon an electrical stimulus.  During contraction, there is motion in three 
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orthogonal directions – longitudinal, circumferential and radial - each myocyte 
thickens in diameter and shortens in length, producing shortening in the 
longitudinal and circumferential direction and concurrent thickening in the radial 
direction. In the healthy heart, using tagging CMR (this will be discussed in more 
detail later in the chapter) the left ventricle has been shown to shorten 15-20% 
in the longitudinal and circumferential direction and thicken 30-40% in the radial 
direction. There is also simultaneous rotation of the heart - when viewed from 
base to apex the base moves in an anti-clockwise direction and the apex in a 
clockwise direction280.   ‘Twist’ is defined as the difference between rotation at 
the base (negative angle) and at the apex (positive angle). This is typically 10-
15 degrees. ‘Torsion’ is twist normalized to long axis length.  More rotation is 
noted at the apex than the base and in the subendocardial layer relative to the 
subepicardium280.  This complex, spiral, motion leads to the stroke volume being 
expelled efficiently from the cavity. The difference between end-diastolic and 
end systolic function, represented as a percentage, equates to the left 
ventricular ejection fraction.    
  
  195 
 
Figure 7.2 - Schematic diagram depicting the three orthogonal components of 
myocardial motion 
The three components of myocardial deformation are longitudinal, circumferential 
and radial strain. During systole, the heart shortens in the longitudinal and 
circumferential directions and increases in the radial direction.  In addition, the heart 
rotates during contraction.   
 
7.4.1 Myocardial strain   
CMR anatomical cine-imaging permits high-resolution appreciation of the 
subendocardial and subepicardial borders which can be manually segmented to 
provide accurate measures of left ventricular volumes and used to calculate 
ejection fraction, left ventricular mass and wall thickness. Global measures do 
not adjust for regional wall motion abnormalities. Furthermore, identification of a 
regional wall motion abnormality does not consider whether a region is actively 
contracting or whether it is passively ‘pulled’ by an adjacent region.  In addition, 
rotation of the heart and through-plane motion can make visual interpretation 
challenging.   
In recent years, there has been significant interest in more detailed, quantitative 
assessment of myocardial deformation, and calculation of strain and strain rate.  
Strain is defined as “a dimensionless quantity produced by the application of a 
stress in terms of a fractional change from the unstressed dimension”.  Put 
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another way, strain, for which the symbol ε is used (with L the length of the 






Strain can be measured invasively using surgically embedded radio-opaque 
markers281-284 or ultrasound crystals (sonomicrometres) 285,286 into the 
myocardium, and plotting their movement in the cardiac tissue using fluoroscopy 
or ultrasound.  This can only be applied to animal models, cannot be applied 
repeatedly and the implants may themselves alter the local tissue dynamics.   
Strain can be assessed non-invasively by echocardiography using Doppler 
imaging or speckle tracking, or using CMR phase contrast imaging287-289 or 
myocardial tagging sequences. 
 
7.4.2 Myocardial tagging  
Myocardial tagging is used to evaluate the dynamic deformation of lines or grids 
superimposed on the myocardium during the cardiac cycle.  First introduced in 
1988 by Zerhouni et al.290, it involves modulation of the tissue magnetization 
using specific radiofrequency prepulses to create visible markers, seen as grids 
or parallel lines, on the myocardium which can be imaged and tracked over 
time. To eliminate influence by respiratory motion this is typically done during a 
breath-hold with a navigator sequence to ensure a similar cardiac position within 
the thorax.   
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A number of different sequences are available for tagging (SPAMM, DENSE, 
DANTE, HARP, CSPAMM, SENC). Each of these has been refined to improve 
resolution, signal-to-noise and scan time.  
In 2D tagging, the tagging lines are applied perpendicular to the imaging plane 
to perturb the longitudinal magnetization at specific locations (creating the grid) 
without affecting the magnetisation of surrounding regions.  These ‘lines’ are 
initially black due to the magnetization saturation and move with the tissue 
producing images through the cardiac cycle. Since tagging lines represent 
alterations in the longitudinal magnetization, they fade with relaxation due to 
exponential decay of T1.  As a result, tagging is better quality at 3-Tesla than at 
1.5-Tesla (longer T1 time at higher field strength) and is better pre-contrast 
(contrast shortens T1 relaxation). 2D tagging is the most commonly used 
tagging method whereby a stack of short axis images is acquired and a 3D 
reconstruction is created by means of data interpolation. The disadvantage of 
2D tagging is its susceptibility to through-plane motion where a point moves out 
of the imaging plane and may be incorrectly assigned to another point. 3D 
tagging involves application of three orthogonally-orientated tagged cine lines to 
cover the entire LV permitting calculation of three-dimensional displacement 
fields free of the issue of through-plane motion.  2D tagging can be assessed 
visually but the significant advantage of tagging is the potential for quantification 
of the three components of myocardial motion – longitudinal, radial and 
circumferential strain – and torsion.  
Normal strain values vary but different groups have reported similar average 
values291,292.  Results from tagging data compare to measurements from 
speckle tracking293 and sonomicrometers294.  There has been much interest in 
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the clinical relevance of strain and this may provide insight into cardiac 
mechanics and also complement standard indices of pump function such as 
ejection fraction. Longitudinal strain has been noted to be abnormal in cases of: 
heart failure with normal ejection fraction295; chemotherapy-related 
cardiotoxicity296; cardiac amyloidosis297; hypertrophic cardiomyopathy298 and 
Takotsubo cardiomyopathy299.  A meta-analysis, pooling 16 studies (5721 
patients) on heart failure, acute MI and valvular heart disease, has shown global 
longitudinal strain to be a stronger predictor of mortality than LV ejection 
fraction300.  The degree of torsion is also a useful and interesting index. A 
number of studies have shown that in dilated cardiomyopathy, rotation of the 
heart has an inverted pattern or is reduced301-304.   
 
7.5 Cardiac microstructure in the healthy heart  
In 1965, Grant et al. stated that “the search for an accurate and detailed picture 
of the muscular architecture of the left ventricle is by no means trivial”305.  The 
myocardium consists of a three-dimensional functional syncytium of branching 
and inter-connecting myocytes embedded in a predominantly collagen matrix.  
Myocytes are clustered into myocyte aggregates which cannot be truly defined 
as distinct fibres but which are separated by collagen sheetlets305-307.  These 
laminar sheetlets (previously called sheets) each consist of a layer of five to ten 
branching myocytes which interconnect with neighbouring layers. The 
connection of myocytes between layers is most prominent at the epicardium and 
decreases significantly through the mid wall and subendocardium with a 
heterogenous extension of sheetlets through the LV wall.  Sheetlets are 
  199 
orientated perpendicular to the local myocyte plane and appear to fall into two 
distinct populations, generally perpendicular to one another308,309 – these are not 
however completely separate and are seen to intersperse in the mid 
myocardium310,311.  
In the left ventricle, the overall direction of myocyte aggregates is found to follow 
a helical arrangement (see Figure 7.3). These run in opposite directions at 
subendo- and subepicardial level.  The helix is right-handed (positive 
angulation) at subendocardium and transitions to being left-handed (negative 
angulation) at the subepicardum with myofibre aggregates in the mid LV layer 
being orientated transversely312.  
The helical arrangement is consistent with the torsion direction noted 
macroscopically in the epicardium because of greater epicardial muscle mass 
and a greater moment arm around the long axis292.  The helical arrangement of 
the myocytes is expressed as the helix angle– this is taken to be the angle 
between the locally defined transverse plane and the angle of the principal 
myofibre direction.    
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Figure 7.3 - Schematic diagram showing helical arrangement of epicardial and 
endocardial myofibres 
Subendocardial and subepicardial myofibres follows a helical arrangement which run 
in opposite directions.  The mid LV myofibres are arranged transversely.   
Myocytes are clustered into myocyte aggregates separated by collagen sheetlets.  
These laminar sheetlets each consist of a layer of five to ten branching myocytes 
which interconnect with neighbouring layers.  
         Adapted from Nielles-Vallespin et al.313  
 
 
7.6 Cardiac contraction 
Individual myocytes have been shown to shorten by only around 15% and 
thicken by around 8% during systole307.  This does not fully account for the 
magnitude of myocardial wall thickening known to be at least 30%313. In order to 
explain this discrepancy, it has been proposed that there is dynamic 
rearrangement of the helical arrangement of the myofibres and, furthermore, 
that the cleavage planes between the myocytes allow for sliding of the sheetlets 
in respect to one another with cardiac contraction314,315.  Indeed, in early work by 
Spotninz et al. the number of myocytes across the ventricular wall was seen to 
increase from end diastole to end systole. This supports the theory of a dynamic 
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rearrangement during cardiac contraction316.  Other studies have used confocal 
micrography to show that there is a reduction in resistance to shear stress 
during contraction which facilitates radial thickening317,318.  Cardiac myofibre 
arrangement has been examined using animal models with hearts arrested in 
systole and diastole.  This demonstrated that in diastole, the myofibre 
aggregates are aligned more tangentially to the epicardial surface and in systole 
they assume a more transverse orientation315,319.  Changes in both the helix 
angle and sheetlet angle during contraction have been observed but it is the 
sheetlet angle that is generally considered to be the principal component 
responsible for macroscopic LV wall thickening (see Figure 7.4).  
  
 
Figure 7.4 -  Schematic diagram showing dynamic alteration in myofibre 
alterations during cardiac contraction 
Myocytes are clustered into myocyte aggregates separated by collagen sheetlets.  
These laminar sheetlets each consist of a layer of five to ten branching myocytes 
which interconnect with neighbouring layers.  
During cardiac contraction, there is shortening of the ventricle from base to apex with 
concurrent wall thickening, related predominantly to a more transverse sheetlet 
angulation in systole.   
         Adapted from Nielles-Vallespin et al.313  
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7.7 Diffusion tensor imaging  
Diffusion tensor imaging (DTI), also known as diffusion tractography, is a CMR 
technique which permits study of tissue microstructure in-vivo.  
In-vivo DTI is well established for imaging of static organs such as neurological 
tracts in the brain320,321.  The base premise of DTI involves the imaging of the 
diffusion of water. When this is not bound to tissue, water will diffuse at the 
same rate in all directions – this can be visualized as a sphere.  In contrast, 
within a tissue, water will diffuse more freely in one direction than in others - this 
is known as the phenomenon of anisotropy.  This produces a different diffusion 
characteristic which will be seen to progress in different directions and this can 
be used to create a map of diffusion.  In can, in turn, be applied to an image of 
the structure of interest - the displacement probability of diffusing water 
molecules within the tissue is measured and the arrangement of the mean 
direction of water diffusion can be reconstructed.   
Cardiac DTI is acquired as a series of 2D short axis slices which can then be 
reconstructed in 3D form. In cardiac DTI, the use of diffusion-sensitising 
sequences permits calculation of a set of three eigenvectors (see Figure 7.5).  
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Figure 7.5 - Schematic showing the three orthogonal eigenvectors used in DTI 
Three orthogonal eigenvectors are used in DTI to create a map of water diffusion in 
a tissue of interest.  In cardiac DTI, the first eigenvector (red arrow) represents the 
mean intravoxel myofibre orientation from which the helix angle can be calculated, 
the second eigenvector (orange arrow) represents the sheetlet orientation from 
which the mean intravoxel sheetlet angle can be calculated and the third eigenvector 
(green arrow) represents the sheet normal direction.   
         Adapted from Tseng et al.322 
 
Water will diffuse more readily along the myofibre and therefore the first, largest 
eigenvector (E1) represents the average local myocyte orientation within the 
voxel. The second, and second largest, eigenvector (E2) corresponds to the 
average local sheetlet direction.  E1A is the angle relative to the local wall 
tangent plane and represents the mean helix angle. E2A is mean intra-voxel 
sheetlet angle.  The third eigenvector is the sheet-normal which is perpendicular 
to the helix and sheet plane (also known as the transverse angle). 
Scalar metrics such as mean diffusivity (MD) and fractional anisotropy (FA) 
permit characterisation of structural integrity by recording the degree of free 
diffusion in a tissue as a general measure- ‘diffusivity’ is the average of the sum 
of eigenvalues; ‘fractional anisotropy’ is an index which reflects the degree of 
anisotropy within a voxel (the difference by which the tissue diffusion compares 
to an idealised sphere).  
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Figure 7.6 – Example of reconstructed 3D whole heart DTI image 
Reconstructed 3D whole heart image representing measured helix angles from in-
vivo cardiac DTI.  Note the change in  colour indicates the helix angle, with variation 
from subendocardium to subepicardium. 
         Adapted from Mekkaoui et al.323  
 
7.7.1 Challenges of cardiac DTI 
The application of DTI to a moving tissue, in particular the heart, is more 
challenging than in a static organ such as the brain.   
The relaxation time of the myocardium is significantly shorter than in the brain. 
This imposes significant restrictions on the echo time that can be used.  
Secondly, inhomogeneity of the B0 field is increased in the thorax, particularly at 
higher field strengths, by comparison with the brain. This leads to higher 
incidence of artefacts which can affect the diffusion-weighted images.  Finally, 
the application of DTI in a beating heart with respiratory motion and 
displacement of the myocardium during cardiac contraction is even more 
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challenging - the diffusion of water is several orders of magnitude smaller than 
bulk motion.   
Until relatively recently, cardiac DTI was only feasible in an ex-vivo model in 
order to counter some of the challenges described above.  These early studies 
showed that cardiac DTI was possible without destruction of the myocardial 
architecture and was validated against histological examination315,324,325.  It was 
demonstrated that the first and second eigenvectors correlated with histological 
findings of the mean orientation of the myofibres and sheetlet direction 
respectively. Other studies have used animal models to explore 
pathophysiology. These studies have used ex-vivo cardiac DTI in experimental 
models of myocardial infarction and myocardial ischaemia323-325.  Most studies 
have been performed in experimental preclinical models and though animals 
can be examined more extensively, there are conflicting reports on similarities 
myofibre architecture between species323,326.  
Ex-vivo cardiac DTI suffers from various limitations related to: the method/ 
duration of fixation of the tissue; the cardiac phase in which the heart was fixed 
(ie in a systolic or diastolic state) and the absence of normal loading conditions.   
This has stimulated the search for ways to overcome the limitations.   
7.7.2 Challenges of in-vivo cardiac DTI 
The sequences used for ex-vivo images (pulsed gradient spin echo/ Stejskal-
Tanner sequences) are highly motion sensitive and therefore would not be 
suitable - the signal relating to diffusion would be overwhelmed by bulk motion.   
A number of other sequences have been proposed. The most commonly used 
approach is the dual-gated stimulated echo acquisition mode (STEAM) 
sequence.  The physics principles related to this sequence are beyond the 
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scope of this thesis.  In essence these involve three excitation pulses applied 
over two successive heartbeats.  This sequence is relatively insensitive to 
cardiac motion but is not robust in arrhythmia, as it requires a regular R-R 
interval and matched cardiac position between the two pulses.  The STEAM 
sequence has been criticised on the grounds that the use of two successive 
heart beats is inefficient in producing a signal and there is loss of signal between 
the two RF pulses.  In addition to respiratory motion, cardiac DTI in the beating 
heart is also affected by cardiac contraction and strain. The need for specific 
correction of strain continues to be a debated issue but there is agreement that 
strain produced by myocardial deformation has an impact on diffusion 
measurements.  An effective in-vivo cardiac DTI sequence would be capable of 
the following:  
Encoding of diffusion in a very short time period so that the myocardium 
is almost immobilized at the time of contraction, and  
Insensitivity to diffusion outside of the time of encoding period so that the 
diffusion measurement will not be affected by motion effects from times 
outside of the diffusion encoding period327.   
This is a particular concern when using the STEAM sequence for in-vivo 
imaging given the relatively long acquisition time.  One proposed approach to 
resolve this is to image at the so-called ‘sweet-spot’ – a time point, individual for 
a subject, where the temporal mean of strain approaches zero thereby 
eliminating the effect of strain318,328.  Typically this is at the mid-systolic or mid-
diastolic phase of the cardiac cycle.  Ex-vivo studies have shown significant 
dynamic rearrangement of myofibre architecture during cardiac contraction and 
recent years have seen growing interest in performing dual-phase in-vivo 
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cardiac DTI where the fibre architecture can be examined in systole and 
diastole.  Some studies have shown that at peak systole the results of diffusion 
DTI, in particular the sheetlet angles, are significantly affected at end-systole 
unless strain is measured and specifically corrected for329.  Other studies have 
shown that the effect of strain compares well to ex-vivo measurements if 
measured at the sweet-spots, where strain is negligible and therefore not a 
factor313,330.  
 
In-vivo cardiac DTI has been used to report normal ranges of helix and sheetlet 
angles in healthy hearts331-334.  Pathological conditions such as myocardial 
infarction, hypertrophic cardiomyopathy and, more recently, dilated 
cardiomyopathy have been investigated with in-vivo cardiac DTI313,330,335-337.  In-
vivo cardiac DTI has been shown to be reproducible in healthy hearts and also 
in patients with hypertrophic cardiomyopathy333,338.   
A number of ex-vivo and in-vivo cardiac DTI studies have shown that there is a 
limited degree of change in helix angle between systole and diastole but a more 
significant change in the sheetlet angle315.  The sheetlet dynamics have been 
shown to be abnormal in ex-vivo experimental canine models of ventricular 
dyssynchrony and rodent models of dystrophy, and more recently in in-vivo work 
of hypertrophic cardiomyopathy and dilated cardiomyopathy313,330,337.  
 
With these studies as background, we performed the following study with the 
specific aim of exploring the use of dual phase in-vivo cardiac DTI alongside 3d 
myocardial tagging for strain correction in a group of patients with dilated 
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cardiomyopathy.   Furthermore, we used biophysical modelling to try to gain 
further insight into the mechanism.   
 
7.8  Dilated cardiomyopathy 
Dilated cardiomyopathy (DCM) is an umbrella term which encompasses a range 
of acquired and hereditary diseases but by definition is unrelated to obstructive 
epicardial coronary disease.  On a macroscopic level, regardless of aetiology, 
DCM results in a cascade of events propagated by ventricular chamber 
enlargement and progressive contractile dysfunction.  Over time, the heart loses 
the ability to compensate for the loss of contractile force and clinical 
manifestations become apparent. In addition, activation of neurohormonal 
pathways exacerbates cardiac haemodynamic abnormalities and leads to 
adverse cardiac remodelling or end organ damage.   The clinical course is 
variable but is progressive and largely irreversible. The decline of cardiac 
function brings a risk of sudden cardiac death from malignant arrhythmias.  
Despite developments in understanding and treatment approaches, the disease 
is not yet fully characterised and prognosis remains poor.  On a cellular level, 
regardless of aetiology, histological findings tend to be non-specific, with 
hypertrophy and elongation of myocytes, reduced density of myofibrils, cellular 
necrosis, and fibrosis339.  An understanding of the structural adaptations and 
maladaptations, and pathophysiological responses of the condition in-vivo 
remains a prime aim of development of new approaches to therapy.   
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7.9  Studying dynamic myofibre reorientation in dilated 
cardiomyopathy  
7.9.1 Methods 
7.9.1.1 Study Protocol  
Patients with non-ischaemic dilated cardiomyopathy were enrolled at St 
Thomas’ Hospital, King’s College London. The criteria for DCM included left 
ventricular ejection fraction (LVEF) below 50%, no myocardial scar on previous 
cardiac MR scan, and a previous invasive coronary angiogram confirming 
unobstructed epicardial coronary arteries. All patients were taking maximally 
tolerated medical therapy at the time of enrolment. Age-matched healthy 
volunteers without a history of cardiac events were enrolled as the control group 
at the University Hospital Zurich. Imaging, at both sites, was performed on 1.5T 
Philips Achieva systems (Philips Healthcare, Best, The Netherlands) equipped 
with 32-channel cardiac receiver arrays. Written informed consent was obtained 
from all subjects prior to imaging, and the study protocol was approved by the 
ethics committees of King’s College London and the Canton of Zurich.  
Prior to diffusion imaging, balanced steady state free precession (bSSFP) cine 
data (spatial resolution 2x2x15 mm3, temporal resolution 30 ms) was acquired in 
two-chamber and short-axis view of the left ventricle (LV). On cine images, 
subject-specific mid-diastolic and peak-systolic time points were visually 
determined. To assess cardiac function, a contiguous stack of short-axis cine 
images from apex to base was acquired (spatial resolutions 1.6x1.6x8 mm3, 
temporal resolution 30 ms). 
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7.9.1.1.1 Diffusion Tensor Imaging 
Diffusion weighted imaging was performed in short-axis view orientation using 
stimulated echo acquisition mode (STEAM) imaging with single shot echo planar 
image (EPI) readout340.  The imaging plane was placed at mid-ventricular level 
and the acquisition was ECG triggered to peak systole and mid diastole. 
Consistent levels of breath holding were ensured by respiratory navigator gating 
(gating window 5 mm). Eight signal averages for each diffusion direction were 
acquired within a single breath hold. A total of ten optimized diffusion directions 
were encoded (25) with a b-value of 350 s/mm2, resulting in 22 breath holds for 
two cardiac phases. Parameters of the diffusion sequence were: field-of-view: 
309×129 mm2, in-plane resolution: 2.5×2.5 mm2, slice thickness: 8 mm, TE/TR 
18 ms/2 R-R intervals, partial Fourier factor 0.65.  
7.9.1.1.2 Motion Imaging 
Tissue motion and strain were quantified using three-dimensional 
complementary spatial modulation of magnetization (CSPAMM) tagged imaging, 
employing a segmented echo planar imaging readout341.  Three tagged cine 
image volumes were acquired in two long and one shot axis plane sequentially, 
covering the whole LV. Data acquisition was navigator gated (acceptance 
window 15 mm) within three consecutive breath holds, each spanning over 18 
heartbeats. Imaging parameters were as follows: field-of-view: 108x108x108 
mm3, spatial resolution: 3.5x7.7x7.7 mm3, tag line distance: 7 mm (EPI factor 7, 
3 excitations per heart phase), temporal resolution: 20 ms. Geometrical stack 
alignment of all tagged volume images was performed by incorporating 
navigator offsets and rigid image registration.  
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7.9.1.1.3 Data Analysis 
Functional Analysis 
Left and right ventricular volumes and ejection fraction, and left ventricular mass 
were calculated by manual drawing of end-diastolic and end-systolic contours 
on short-axis images excluding the papillary muscles (CVI software, Circle 
Cardiovascular Imaging Inc., Canada). Left ventricular wall thickness was 
measured at end diastole and end systole in the mid LV, at the level of the 
papillary muscles.  
 
Diffusion Tensor Analysis 
Upon image registration, systolic and diastolic diffusion tensors were determined 
taking into account diffusion weighting of the “b=0 s/mm2” image342. Systolic 
diffusion tensors were corrected for myocardial strain, as previously reported329.  
Upon tensor calculation, helix, transverse and sheet angles were computed as 
described in the supplemental material.  
For each diffusion tensor, a locally normalized transmural position was 
calculated. Helix angles (HA) were binned along ten equidistant transmural 
positions, followed by linear regression to determine the slope of the transmural 
HA course. To avoid partial voluming effects at the endo- and epicardial 
boundaries, data points from 80% of the inner myocardium were used for data 
fitting. HA ranges were computed as differences between maximum 
(endocardial) and minimum (epicardial) HA values within the 80% transmural 
interval. MD, FA, HA slope and transverse angles (TA) were evaluated in the 
whole left ventricle for each cardiac phase and reported as median and 
interquartile ranges across both groups. Radial and axial diffusivities were 
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computed similarly and are reported in the supplemental material. Sheetlet 
angles were evaluated in the anterior-septal region in the proximity of the 
surface coils to reduce the impact of noise as a confounding factor. Sheetlet 
angles are reported as histograms for both cohorts (see Figure 10.10). 
 
Motion and Strain Analysis 
On the 3D tagging data, endo- and epicardial contours of the LV were manually 
defined while excluding papillary muscles. Longitudinal and circumferential 
strain were determined by contour tracking utilizing the SinMod algorithm 
(TagTrack, GyroTools LLC, Zurich, Switzerland)343.  Radial strain was evaluated 
by the Harmonic Phase algorithm344. Cardiac torsion was normalized to long-
axis length as described previously345.  Circumferential and radial strains are 
given in the mid ventricular region. Longitudinal strain was computed across the 
whole LV.   
 
Biomechanical Modelling 
Two idealised geometric models of the LV truncated at the base were created 
using the average measurements (end-diastolic long and short-axis lengths, wall 
thickness and cavity volumes). The two models represent an average of the 
control and DCM populations. Fibre distributions were chosen to match the 
average end-diastolic HA slopes observed in the respective cohorts.     Figure 
7.7 shows both models as well as the HA maps in short-axis view.  
Sheet angle (E2A) distributions were chosen to match the frequencies observed 
in the data at end diastole, with idealised transmural variation based on previous 
studies (6,31) changing from 0° to 90° between endocardium and midwall, and 
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from -90° to 0° between midwall and epicardium. Passive inflation and active 
contraction of the ventricle were simulated using computational biomechanical 
models346.  The impact of dilatation and increased sphericity on the changes of 
HA slopes was explored and compared between the groups. Additionally, strain 
and torsion were measured in both models with varying HA slopes to investigate 
whether the changes in fibre orientation were in part responsible for the 
differences seen in these parameters.    
 
  
   Figure 7.7 - Idealised LV models used for biomechanical modelling 
A - Idealised LV models used for biomechanical modelling of healthy and DCM 
hearts.  
B - Idealised helix angle maps based on average end-diastolic measurements in 
controls and DCM patients. 
 
7.9.1.1.4 Statistical Analysis  
Differences between diastolic/systolic parameters and DCM patients/controls 
were determined by a Wilcoxon signed-rank and Wilcoxon rank-sum test, 
respectively. A p-value below 0.05 was considered statistically significant.  
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7.9.2 Results 
A total of 15 patients and 10 healthy subjects were recruited. Nine patients and 
nine healthy volunteers were scanned successfully and comprised the final 
cohort. Datasets were rejected due to either technical issues or breathing 
motion related signal loss in the diffusion weighted images.  
Demographics and clinical characteristics are given in Table 7 (shown at end of 
chapter).  The DTI data are summarized in Table 8 (shown at end of chapter). 
7.9.2.1.1 Helix angles  
Figure 7.8 shows example helix (E1A) and sheetlet (E2A) angle maps for a 
control subject and DCM patient in diastole and systole. Histograms of HA 
distributions for both cohorts are displayed in Figure 7.9.  A change towards 
steeper HAs during contraction is seen in the controls, whereas inconsistent 
dynamic change between heart phases is observed in the patients. Bin counts 
of diastolic HAs close to zero degrees were reduced in DCM relative to healthy 
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Figure 7.8 - Comparison of helix angle and sheetlet maps acquired in diastole and 
systole  
Example of helix (E1A) angle and sheetlet (E2A) maps acquired in diastole and systole 




Figure 7.9 - Histograms of diastolic and systolic helix angles for controls and 
DCM patients  
Histograms of diastolic and systolic helix angles for controls (a) and DCM patients 
(b). While a shift towards steeper helix angles is seen in the systolic healthy heart, 
systolic and diastolic distributions are similar in the DCM case. Error bars indicate 
interquartile ranges across the subjects. c) Corresponding transmural helix angle 
slopes in diastole versus systole for the control and DCM groups. d) Diastolic and 
systolic helix angles for control and DCM modelling as compared to the data. 
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In diastole, the HA slope was significantly steeper in the patients when 
compared to controls (-1.02±0.53°/% depth versus -0.78±0.22°/% depth, 
p<0.01).  
In systole, there was a significant increase in maximum endo- and epicardial HA 
in the controls suggesting a more longitudinal alignment of myofibre aggregates 
with cardiac contraction. This resulted in a significant increase in HA slope in the 
control group from diastole to systole (-0.78±0.22°/% depth to -1.06±0.23°/% 
depth, p<0.01). In contrast, there was no significant change in HA slope from 
diastole to systole in the DCM patients (-1.02±0.53°/% depth to -1.01±0.59°/% 
depth, p=0.89).  
7.9.2.1.2 Sheetlet angles  
Histograms of E2A sheet angle distributions for controls and DCM patients are 
shown in Figure 7.10 .  A change in E2A angles towards a broader distribution 
during contraction is seen in the control group, whereas reduced dynamic 
change between diastole and systole is observed in the DCM patients. Bin 
counts of diastolic sheetlet angles close to zero degrees are reduced in DCM 
relative to healthy controls. 
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Figure 7.10 - Histograms of diastolic and systolic E2A sheetlet angles for controls 
and DCM patients  
Histograms of diastolic and systolic E2A sheet angles for controls (a) and DCM 
patients (b). The sheet angle distribution is broader in the systolic healthy heart 
compared to diastole, whereas systolic and diastolic distributions are similar in the 
DCM case. Histograms of change between diastolic and systolic E2A distributions 
for controls (c) and DCM patients (d). Controls exhibit a marked change in E2A as 
opposed to little change in DCM patients. Model results follow a similar trend. Error 
bars indicate interquartile ranges across the subjects. 
 
7.9.2.1.3 Transverse angles  
Transverse angles are distributed around zero degrees indicating the expected 
circumferential alignment of the fibre aggregates (shown in Table  at end of 
chapter).  
 
7.9.2.1.4 Mean diffusivity (MD) and fractional anisotropy (FA) 
In both diastole and systole, there was lower FA in the DCM group than in the 
controls (diastole 0.56±0.07 versus 0.63±0.05 respectively, p<0.04; systole 
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0.58±0.08 versus 0.62±0.07 respectively, p=0.56). There were no significant 
differences in FA between cardiac phases in either group.  
There was a trend towards higher MD in the DCM group relative to controls 
(diastole 1.17±0.22x10-3mm2/s versus 1.09±0.12x10-3mm2/s, p=0.23; systole 
1.23±0.34x10-3mm2/s versus 1.09±0.27x10-3mm2/s, p=0.27). There were no 
significant differences in MD between cardiac phases in either group.     
 
7.9.2.1.5 Torsion and strain  
Table 8 reports maximum torsion and strain for both groups.  Figure 7.11 shows 
the median torsional deformation and cardiac strain parameters over the cardiac 
cycle. Longitudinal, circumferential and radial strains were all significantly 
reduced in the DCM group compared to the controls.  Table 9 shows the torsion 
and strain values according to group.  
 
 
Figure 7.11 – Torsion and strain over cardiac cycle for both groups 
Time course of myocardial torsion (a), radial (b), circumferential (c) and longitudinal 
(d) strain for DCM and control.  Error bars indicate interquartile ranges across the 
subjects. 
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Table 9 – Table showing maximum torsion and strain for both groups  
 
 DCM group (N=9) Control group 
(N=9) 
P value (DCM 
vs Control) 
Max torsion (°/mm) 0.17±0.19 0.28±0.09 <0.02* 
Max radial strain  0.11±0.02 0.25±0.04 <0.01* 
Min circumferential 
strain  
-0.12±0.07 -0.17±0.04 <0.01* 




Mean (systolic and diastolic) HA slope was correlated against maximum torsion, 
LVEF and longitudinal strain. The correlations were found to be limited in both 
groups (Figure 7.12). In the patient group there was a trend towards reduced 
torsion and longitudinal strain with increased HA slope compared to controls. 
LVEF was found to remain on a constant 40% for HA slopes of about 1.0°/% 
transmural depth. This decreased to 15% with increased HA slope.  
In the control group, values for peak torsion were spread by approximately 15% 
around 0.30°/mm and the values for longitudinal strain were in the range of 
0.15-0.19 for the controls compared to 0.07-0.17 for the DCM patients. LVEF 
values in controls were densely distributed around 58±7%.  
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Figure 7.12 – Helix angle in relation to torsion, LV ejection fraction and 
longitudinal strain 
Peak torsion (a), left-ventricular ejection fraction (LVEF) (b) and (negative) 
longitudinal strain (c) as a function of normalized helix angle (HA) slope. A trend 
towards lower torsion (a), LVEF (b) and longitudinal strain (c) with increasing helix 
angle slope is seen in the DCM group.  
 
7.9.2.1.6 Biomechanical Modelling 
The active contraction phase was simulated for the healthy and the DCM 
models in order to understand the differences in the HA changes between end-
diastolic and end-systolic states. Both models were progressively activated at 
respective end-systolic volumes, and the change in HA slopes at the endo- and 
epicardial surfaces was recorded. Figure 7.9 shows the results for the two 
models. The model supports the observation from the data, the slope change is 
higher in controls in contrast to that in DCM patients  
The change in E2A distributions between diastole and systole is illustrated in 
Figure 7.10 . A significant change is observed in controls (up to 0.13/0.06 in 
data/model), whereas the distribution for DCM patients remains largely 
unchanged (up to 0.03/0.03 in data/model), reflecting the trend seen in the data. 
The next modelling objective addressed a possible explanation of the observed 
changes in HAs by the dilatation and remodelling seen in DCM hearts. To this 
end, the control LV was inflated from its reference volume to the DCM model 
reference volume. The measured HAs at the larger volume was steeper, but the 
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change was too low to explain the difference between the measured control and 
DCM HA slopes (0.03°/%depth, see Figure 7.13).  
 
 
Figure 7.13 – Comparison of change in helix angle between actual and modelled 
data  
Change in helix angle slope caused by passive inflation of the control LV model to 
DCM model cavity volume as compared to measured difference in control and DCM 
helix angle slopes. Volume change alone does not explain observed differences 
between the two cohorts. 
 
When repeated for the DCM LV, a more spherical geometry, and inflated to 
twice the cavity volume, a larger change in HA was observed (0.1°/%depth). 
Nevertheless, the DCM modelled result was still significantly lower than the 
values observed in the data (0.36°/%depth difference calculated between 
control and DCM DTI data). This suggests that LV size and shape do not appear 
to be entirely responsible for the steepening of HAs seen in DCM patients in 
comparison with controls.   
Finally, we aimed to investigate whether the change in HA was contributing to 
the reduced torsion and strain or was a compensatory factor in preserving 
cardiac function (see Table 10). Strain and torsion were evaluated in each 
model with both control and DCM HA distributions. The results are shown in 
Table 9. These results show that in the DCM group, when simulating with 
steeper angles, torsion was reduced and strain values were unchanged. A 
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similar pattern was demonstrated in the control group. This suggests that 
steeper angles do not play a compensatory role in aiding cardiac contraction 
and that torsion impairment is exacerbated with steeper angles in hearts of 
either geometry. It is worth noting that the values of strain and torsion do not 
directly compare to those from the data though there are clearly similar trends 
and this likely reflects the use of an idealised non-patient specific model. 
 
Table 10 - Biomechanical modelling torsion and strain results according to 
shape and helix angles 
 
 Control shape/  





DCM shape/  
Control helix  
angles 
DCM shape/ 
DCM helix  
angles 
Max torsion (°/mm) 0.24 0.19 0.13 0.10 
Max radial strain  0.41 0.43 0.23 0.23 
Min circumferential 
strain  
-0.18 -0.18 -0.11 0-.10 





In this study, the dynamic change of myofibre aggregate orientation in DCM 
patients and healthy controls was investigated using in-vivo dual phase cardiac 
DTI. A statistically significant change of myocyte orientation between diastole 
and systole was found in the control group. The longitudinal fibre alignment 
during contraction is assumed to optimize cardiac pumping efficiency and has 
been described previously using in-vivo and ex-vivo DTI data and 
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histology315,318,329,347.  In contrast to healthy controls, the change in HA from 
diastole to systole was found to be far less pronounced in DCM patients and 
was not statistically different between both heart phases. On average, diastolic 
myofibre aggregate orientation had a more longitudinal orientation in DCM 
patients relative to healthy controls. Seven out of nine DCM patients showed 
comparable systolic HA configurations relative to healthy controls. In the two 
remaining patients, clearly increased HA slopes in both cardiac phases were 
recorded. One might speculate that this elevated longitudinal myocyte 
orientation could result from advanced remodelling as these two patients were 
considerably older (76 and 77 years) when compared to the mean age of the 
patient population (60±14 years), and had the poorest LVEF. Accordingly, this 
could be due to successive elongation of myocytes and reduced contractility. 
Similar reorientation was previously described by Tseng et al.336 in hypertrophic 
hearts, but this has not been confirmed by more recent data330. 
In addition, we demonstrated that there are differences in sheet angle pattern 
between the groups. In the controls, sheet angle distribution changes 
dynamically between systole and diastole with a broader distribution in systole. 
The systolic and diastolic distributions in the DCM patients are, however, similar 
between the two cardiac phases.  
In general, cardiac pumping performance in the DCM patients was significantly 
reduced compared to the controls as quantified by a number of parameters: 
LVEF, maximum torsion, longitudinal, radial and circumferential strain. 
Particularly low values for LVEF, torsion and strain values were recorded for the 
two patients with elevated HA slopes. Our data on maximum torsion in DCM 
patients and controls is in good agreement with literature values302.   
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As well as the clinical and gross structural changes seen in DCM, the effects of 
myofibre aggregate reorientation must be considered alongside well-recognised 
subcellular changes such as microarchitecture disarray. Histologically, heart 
failure is characterised by myocyte elongation, reduced myocyte density and 
fibrosis. These changes have been correlated with ex-vivo DTI results in 
previous studies348,349. The observed trend towards increased MD and 
decreased FA supports the presence of reduced myofibril density and cellular 
necrosis.  
Using biomechanical modelling we were able to reproduce similar trends 
between the model and the data. There were differences of changes in HA 
when activating the model relative to the in-vivo findings prompting for further 
work including patient-specific geometries and myofibre aggregate data as well 
as myocyte modelling at the microscale. The use of biomechanical modelling 
was twofold.  First, an attempt to understand whether the size and/or shape of 
the ventricle could be responsible for the altered steep angle of the myofibre 
aggregates in diastole. Second, an investigation of the implications of fibre 
alterations were investigated, in particular whether these are beneficial or 
detrimental to efficient cardiac contraction. Initial tests showed that even 
pronounced dilatation of the heart is not sufficient to produce the observed 
differences in HA between the groups. We noted however that the correlation 
between simulated and actually measured myofibre aggregate orientation 
improves, when simulating a dilated, more spherical heart. Furthermore, the 
biomechanical simulations show that the reduction in torsion appears to be 
exacerbated by steeper HAs with no improvement or deterioration in strain. This 
was found in both LV models and suggested that this factor is independent of 
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the changes to LV size and shape. Even in a dilated and remodelled heart the 
steeper angles are not beneficial to maintaining longitudinal, radial or 
circumferential strain or torsion. The exacerbated deterioration in strain and 
torsion observed in the DCM group may thus reflect underlying subcellular 
changes that were beyond the scope of this study.  
There is little correlation with any of the single parameters tested against the 
change in HA slope in the subjects studied. This suggests that a composite of 
factors such as dilatation, poor systolic function and the recognised subcellular 
alterations seen in DCM may be responsible for this structural rearrangement. 
Further studies would be needed to confirm this.    
In summary, this study demonstrates that there are changes in diastolic myocyte 
orientations and, importantly, that there is reduced and inconsistent dynamic 
reorientation during cardiac contraction in DCM patients relative to healthy 
hearts. We have been able to show that the change in left ventricular shape 
does not entirely explain the difference seen in HA slope between DCM patients 
and controls. We have also demonstrated findings that suggest that steeper 
HAs do not confer a compensatory adaptation in terms of cardiac contraction. 
Overall, our findings provide new insight into the structural alterations within the 
living heart in DCM and underline the importance of MR diffusion tensor imaging 
to gain deeper understanding of cardiac disease.   
7.9.4 Study Limitations 
1. The DCM patient cohort in this study was small and though all had a 
diagnosis of non-ischaemic cardiomyopathy the aetiology may be 
heterogeneous. Clinical, morphological and functional data were variable 
and, accordingly, a large variation of HA distribution was recorded.  
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2. Overall the patients studied present a form of milder DCM and therefore 
our results cannot provide a complete picture of changes in myofibre 
aggregate architecture in all stages of DCM. Similarly, the impact of 
medical therapy cannot be appraised due to the small sample size but 
this would be an interesting avenue of future work. In addition some of 
the measurements were taken only in specific regions of the myocardium 
to reduce low signal-to-noise effects and therefore may not be 
representative of the entire myocardium should there be heterogeneous 
changes.   
3. Because of scan time constraints, the imaging resolution of cardiac DTI 
was relatively coarse (2.5x2.5x8 mm3) and partial voluming effects were 
inherent at the endo- and epicardial borders. To reduce the impact of this 
effect, edge voxels were excluded from the analysis.  
4. The limitations in time scan, and patient cooperation also meant that only 
one slice could be acquired using cardiac DTI (taking approximately 1 
hour per patient) and that all patients were not successfully scanned.  
The time taken to perform the scans makes cardiac DTI unfeasible 
currently in routine clinical use.  Faster acquisition is likely to change this 
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A paper since the publication of the study above deserves specific mention313.   
This elaborate study had two components – first: in-vivo cardiac DTI was 
performed in porcine models at six to nine time points in the cardiac cycle; 
second continuous cardiac DTI was performed in-situ after cardiac arrest by 
either potassium chloride (which arrested the heart in a diastolic configuration) 
or barium chloride (which arrested the heart in diastole initially then underwent a 
single slow cardiac contraction and remained contracted).  
A number of important findings were reported.   
As suggested by others previously, the study showed that, in normal hearts, the 
major change in myocardial wall thickening was an increase in the sheetlet 
angle (E2A) – this was seen in both the in-vivo group and in the potassium 
chloride versus barium chloride arrested ex-vivo group, with similar values. This 
correlated with histological analysis of sheetlet angles.  The slowly contracting 
barium chloride arrested group was compared to the in-vivo group in order to 
examine the changes in wall thickness and the effect of strain. The estimated 
effect of strain was in the order of 17%.  These workers were reassured by the 
finding that sheetlet angle change was similar in both the arrested and the in-
vivo hearts. This suggested a small effect of strain on measured E2A values.  
On histological examination, the previously described helical pattern of fibre 
orientation was shown to change little from systole to diastole in both in-vivo and 
ex-vivo hearts.   
In parallel to this study, in-vivo dual-phase cardiac DTI was performed on a 
group of volunteers, on patients with hypertrophic cardiomyopathy and on 
dilated cardiomyopathy with particularly interesting findings.  The findings in 
healthy subjects reflected those seen in the porcine work with significant change 
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in sheetlet angle from diastole to systole.  In hypertrophic cardiomyopathy, the 
sheetlet angle was higher than controls in diastole with similar values in systole.  
In contrast, in dilated cardiomyopathy, there was a similar sheetlet angle in 
diastole but lower sheetlet angle change in systole.  Importantly the study 
showed similar reductions in longitudinal, radial and circumferential strain in 
both disease groups compared to controls and the changes in sheetlet angle 
exceeded the estimate of the effect of strain.  This suggests that hypertrophic 
cardiomyopathy represents a form of disease whereby the hearts are 
permanently in a more systolic, contracted state whereas in dilated 
cardiomyopathy the hearts are permanently in a more diastolic state.  This may 
account for the predominant diastolic impairment seen in hypertrophic 
cardiomyopathy as opposed to the predominant systolic impairment seen in 
dilated cardiomyopathy.  
 
7.10  Conclusion 
The arrangement of the cardiac microstructure is complex, highly organized and 
fundamental to cardiac function. The arrangement of the myocardial myofibres 
and sheets contributes significantly to efficient ventricular function and in recent 
years, there has been increasing interest in characterising differences between 
normal and diseased or injured hearts.  This can be assessed non-invasively 
with diffusion tensor imaging (DTI) which relies on the anisotropy of the 
myocytes and the diffusion of water.  The development of in-vivo cardiac DTI 
has presented a number of challenges but has also provided new insights into 
the nature of dynamic alterations of myocyte architecture in vivo in health and 
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disease. This study adds to the body of literature on this topic and shows a loss 
of dynamic helix and sheetlet reorientation. Using biophysical modeling we have 
been able to suggest that in part it is the altered geometry which causes these 
changes and that furthermore, this altered structural arrangement and dynamic 
rearrangement appears to be maladaptive and exacerbates reduced contractile 
parameters.  This is an area for future work using patient specific models.  
 
Part of this chapter consists of work that has been published:   
Von Deuster, C., Sammut, E., Asner, L., Nordsletten, D., Lamata, P., Stoeck, C.T, 
Kozerke, S., Razavi, R. 
‘Studying dynamic myofiber aggregate reorientation in dilated cardiomyopathy using  
in-vivo magnetic resonance diffusion tensor imaging’  
Circulation Cardiovascular Imaging, 2016 (http:// 
doi:  10.1161/CIRCIMAGING.116.005018) 
Eva Sammut is joint first author on the publication and was responsible for data 
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Control group (N=9) 
 
P value  
(DCM vs 
Control)  
Male 7 7 - 
Age (years) 61±24  51±11 0.052 
Heart rate (beats/min) 66±16 62±13 0.38 
BSA (m2) 1.8±0.2 1.8±0.5 0.75 
iLV EDV (ml/m2) 84±48 83±18 0.48  
iLV ESV (ml/m2) 57±47 31±10 <0.01* 
LVEF (%) 41±11 58±7 <0.01* 
iLV mass (g/m2) 78±22 53±17 <0.02* 
iRV EDV (ml/m2) 72±38 82±28 0.40 
iRV ESV (ml/m2) 36±18 32±9 0.40 
RVEF  (%) 55±13 61±7 0.063 
LV diastolic wall 
thickness  (mm) 
9±1 9±1 0.96 
LV systolic wall 
thickness  (mm) 
10±2 12±4 0.054 
    
 
* denotes significance  
BSA: Body Surface Area, iLV EDV: indexed Left Ventricular End Diastolic Volume, iLV ESV: 
indexed Left Ventricular End Systolic Volume, LVEF: Left Ventricular Ejection Fraction, iLV 
mass: indexed Left Ventricular mass, iRV EDV: indexed Right Ventricular End Diastolic Volume, 
iRV ESV: indexed Right Ventricular End Systolic Volume, RVEF: Right Ventricular Ejection 
Fraction, LV: Left Ventricle. Reported values are median±interquartile range. 
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Table 8 – Diffusion tensor data according to group 
 











vs systole)  
DCM vs 
controls  
Diastolic HA slope [°/Trans. 
depth] 
-1.02±0.53 -0.78±0.22 0.89 <0.01* <0.01* 
Systolic HA slope [°/Trans. 
depth] 
-1.01±0.59 -1.06±0.23 - - 0.90 
Diastolic HA range [°] 74±44 54±16 0.82 <0.01* <0.02* 
Systolic HA range [°] 76±45 77±14 - - 0.97 
Diastolic TA [°] 0±25 -2±17 0.82 0.43 0.40 
Systolic TA [°] 0±30 -1±24 - - 0.63 
Diastolic MD [x10-3mm2/s] 1.17±0.22 1.09±0.12 0.43 0.50 0.23 
Systolic MD [x10-3mm2/s] 1.23±0.34 1.09±0.27 - - 0.27 
Diastolic FA  0.56±0.07 0.63±0.05 0.36 0.30 <0.04* 
Systolic FA 0.58±0.08 0.62±0.07 - - 0.56 
     
 
* denotes significance  
HA: Helix Angle, TA: Transverse Angle, MD: Mean Diffusivity, FA: Fractional Anisotropy. 
Reported values are median±interquartile range. 
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8 Conclusion  
 
  
  233 
In conclusion, this thesis presents a number of original studies which have 
explored the use of quantitative perfusion, CMR and cardiac DTI.  
We have been able to show that quantitative assessment with high resolution 
quantitative CMR is feasible and reproducible in patients with heart failure.  
Given the prevalence of HF and increasing reliance on CMR to evaluate 
patients, this small study is the first to test this specific hypothesis and these 
initial results are encouraging. 
Quantitative analysis is not a new technique but, despite multiple validation 
studies, has resisted attempts to move it out of the research arena and into the 
clinical setting.  The thesis also presents a large observational study which has 
conducted the first assessment of the prognostic use of quantitative perfusion 
CMR.  This study has shown that this performs at least as well as visual 
assessment by expert readers. The study establishes a significant base for 
larger randomised studies. The increasingly prevalent automatisation of the 
analysis pipeline, combined with prognostic data should enable translation to the 
clinical setting.  
PET remains the non-invasive reference standard of assessment of perfusion. 
Nevertheless the improved tissue characterisation, and the structural and 
functional information provided by MRI has increased the attraction of MRI for 
perfusion assessment in particular for patients with coronary disease.  
Previous studies have suggested an imperfect correlation between PET and 
MR. We have explored this correlation using a specialized cardiac phantom 
which simulates perfusion (with known true perfusion rates) and a hybrid MR-
PET scanner. Despite differing methods of analysis, we have demonstrated 
excellent correlation between MR, PET and known true perfusion values.  
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This thesis also presents work on the use of cardiac diffusion tensor imaging in 
dilated cardiomyopathy. This used a dual-phase, in-vivo cardiac DTI approach, 
biomechanical modelling and strain data from 3D tagging CMR. We were able to 
demonstrate and document significant differences in fibre architecture between 
subjects and controls. This has shed light on the interplay between cardiac 
structure and function in health and disease and is the basis for further 
exploration of therapeutic targets or biomarkers. Time constraints and issues of 
patient cooperation prevent this being available for clinical use for the present, 
but there is scope for developing this further.  
In conclusion, this work has presented a number of studies focusing on 
quantitative perfusion analysis and cardiac DTI.  All research is incremental, 
building on the work of others and in turn serving as a platform for further 
advance. Our work has provided much scope for further exploration of the 
clinical applicability of these techniques.  
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